<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">57761</article-id><article-id pub-id-type="doi">10.7554/eLife.57761</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-183441"><name><surname>Chai</surname><given-names>Annie Wai Yeeng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8015-6050</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-183442"><name><surname>Yee</surname><given-names>Pei San</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-94732"><name><surname>Price</surname><given-names>Stacey</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183443"><name><surname>Yee</surname><given-names>Shi Mun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183444"><name><surname>Lee</surname><given-names>Hui Mei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183445"><name><surname>Tiong</surname><given-names>Vivian KH</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183446"><name><surname>Gonçalves</surname><given-names>Emanuel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9967-5205</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183447"><name><surname>Behan</surname><given-names>Fiona M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183448"><name><surname>Bateson</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183449"><name><surname>Gilbert</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183450"><name><surname>Tan</surname><given-names>Aik Choon</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183451"><name><surname>McDermott</surname><given-names>Ultan</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-168327"><name><surname>Garnett</surname><given-names>Mathew J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-182818"><name><surname>Cheong</surname><given-names>Sok Ching</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6765-9542</contrib-id><email>sokching.cheong@cancerresearch.my</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Head and Neck Cancer Research Team, Cancer Research Malaysia, Head and Neck Cancer Research Team</institution><addr-line><named-content content-type="city">Subang Jaya, Selangor</named-content></addr-line><country>Malaysia</country></aff><aff id="aff2"><label>2</label><institution>Wellcome Sanger Institute, Wellcome Genome Campus</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution>Department of Biostatistics and Bioinformatics, Moffitt Cancer Center</institution><addr-line><named-content content-type="city">Tampa</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Oncology R&amp;D AstraZeneca, CRUK Cambridge Institute</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution>Department of Oral &amp; Maxillofacial Clinical Sciences, Faculty of Dentistry, University of Malaya</institution><addr-line><named-content content-type="city">Kuala Lumpur</named-content></addr-line><country>Malaysia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Reviewing Editor</role><aff><institution>Fox Chase Cancer Center</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ojala</surname><given-names>Päivi M</given-names></name><role>Senior Editor</role><aff><institution>University of Helsinki</institution><country>Finland</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>29</day><month>09</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e57761</elocation-id><history><date date-type="received" iso-8601-date="2020-04-10"><day>10</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-09-28"><day>28</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Chai et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Chai et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-57761-v2.pdf"/><abstract><p>New therapeutic targets for oral squamous cell carcinoma (OSCC) are urgently needed. We conducted genome-wide CRISPR-Cas9 screens in 21 OSCC cell lines, primarily derived from Asians, to identify genetic vulnerabilities that can be explored as therapeutic targets. We identify known and novel fitness genes and demonstrate that many previously identified OSCC-related cancer genes are non-essential and could have limited therapeutic value, while other fitness genes warrant further investigation for their potential as therapeutic targets. We validate a distinctive dependency on YAP1 and WWTR1 of the Hippo pathway, where the lost-of-fitness effect of one paralog can be compensated only in a subset of lines. We also discover that OSCCs with WWTR1 dependency signature are significantly associated with biomarkers of favorable response toward immunotherapy. In summary, we have delineated the genetic vulnerabilities of OSCC, enabling the prioritization of therapeutic targets for further exploration, including the targeting of YAP1 and WWTR1.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Many types of cancer now have 'targeted treatments', which specifically home in on genes cancer cells rely on for survival. But there are very few of these treatments available for the most common type of mouth cancer, oral squamous cell carcinoma, which around 350,000 people are diagnosed with each year.</p><p>Designing targeted treatments relies on detailed knowledge of the genetic makeup of the cancer cells. But, little is known about which genes drive oral squamous cell carcinoma, especially among patients living in Asia, which is where over half of yearly cases are diagnosed. One way to resolve this is to use gene editing technology to find the genes that the cancer cells need to survive.</p><p>Now, Chai et al. have used a gene editing tool known as CRISPR to examine 21 cell lines from patients diagnosed with oral squamous cell carcinoma. Most of these lines were from Asian patients, some of whom had a history of chewing betel quid which increases the risk of mouth cancer. By individually inactivating genes in these cell lines one by one, Chai et al. were able to identify 918 genes linked to the survival of the cancer cells. Some of these genes have already been associated with the spread of other types of cancer, whereas others are completely unique to oral squamous cell carcinoma. The screen also discovered that some cell lines could not survive without genes involved in a signalling pathway called Hippo, which is known to contribute to the progression of many other types of cancer.</p><p>Uncovering the genes associated with oral squamous cell carcinoma opens the way for the development of new targeted treatments. Targeted therapies already exist for some of the genes identified in this study, and it may be possible to repurpose them as a treatment for this widespread mouth cancer. But, given that different cell lines relied on different genes to survive, the next step will be to identify which genes to inactivate in each patient.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>CRISPR screen</kwd><kwd>oral squamous cell carcinoma</kwd><kwd>Hippo pathway</kwd><kwd>fitness genes</kwd><kwd>therapeutic targets</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Newton-Ungku Omar Fund and Medical Research Council, United Kingdom</institution></institution-wrap></funding-source><award-id>MR/P013457/1</award-id><principal-award-recipient><name><surname>McDermott</surname><given-names>Ultan</given-names></name><name><surname>Garnett</surname><given-names>Mathew J</given-names></name><name><surname>Cheong</surname><given-names>Sok Ching</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>206194</award-id><principal-award-recipient><name><surname>Price</surname><given-names>Stacey</given-names></name><name><surname>Gonçalves</surname><given-names>Emanuel</given-names></name><name><surname>Behan</surname><given-names>Fiona M</given-names></name><name><surname>Bateson</surname><given-names>Jessica</given-names></name><name><surname>Gilbert</surname><given-names>James</given-names></name><name><surname>Garnett</surname><given-names>Mathew J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Cancer Research Malaysia</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Chai</surname><given-names>Annie Wai Yeeng</given-names></name><name><surname>Yee</surname><given-names>Pei San</given-names></name><name><surname>Yee</surname><given-names>Shi Mun</given-names></name><name><surname>Lee</surname><given-names>Hui Mei</given-names></name><name><surname>Tiong</surname><given-names>Vivian KH</given-names></name><name><surname>Cheong</surname><given-names>Sok Ching</given-names></name></principal-award-recipient></award-group><funding-statement>This work was directly supported by the Newton-Ungku Omar Fund and the Medical Research Council, United Kingdom (MR/P013457/1). Authors in SCC's group were supported by sponsors of Cancer Research Malaysia; Authors in MJG's group were supported by Wellcome. Other funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genome-wide CRISPR/Cas9 screens enable the identification of actionable vulnerabilities of oral squamous cell carcinoma, and their unique dependencies on YAP1 and WWTR1 of the Hippo pathway.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous tumor arising from the mucosal surfaces lining the upper aerodigestive tract. The commonest subtype, oral squamous cell carcinoma (OSCC) is especially prevalent among Asian countries (<xref ref-type="bibr" rid="bib8">Bray et al., 2018</xref>). OSCC has been associated with distinct risk habits such as betel quid chewing, tobacco smoking and alcohol consumption (<xref ref-type="bibr" rid="bib78">Shield et al., 2017</xref>). The 5-year survival rate for OSCC is about 50% (<xref ref-type="bibr" rid="bib48">Kumar et al., 2016</xref>) and surgery remains the mainstay of treatment. Cetuximab, an inhibitor of the epidermal growth factor receptor (EGFR), is used in combination with platinum-based chemotherapy for the treatment of advanced OSCC (<xref ref-type="bibr" rid="bib87">Vermorken et al., 2008</xref>). However, the improvement in survival remains marginal (<xref ref-type="bibr" rid="bib87">Vermorken et al., 2008</xref>). More recently, immune checkpoint inhibitors have been approved for the treatment of advanced and metastatic OSCC (<xref ref-type="bibr" rid="bib17">Cohen et al., 2019</xref>). Although an improvement in patients’ outcome is anticipated with the advancement of immunotherapy, clinical trial outcomes showed an average objective response rate of only 13–36% (<xref ref-type="bibr" rid="bib5">Bauml et al., 2017</xref>; <xref ref-type="bibr" rid="bib10">Burtness et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Ferris et al., 2016</xref>), and the factors determining response towards checkpoint inhibitors are still largely unknown. This underscores the need to identify further therapeutic targets for OSCC.</p><p>Genomic sequencing technology has enabled the delineation of the comprehensive mutational and transcriptomic landscape of cancers, including OSCC (<xref ref-type="bibr" rid="bib83">The Cancer Genome Atlas Network, 2015</xref>; <xref ref-type="bibr" rid="bib68">Pickering et al., 2013</xref>). However, the functional significance of most of these genetic alterations remains unclear and little is known about their value as therapeutic targets for OSCC. Identifying the genetic dependencies of OSCC will, therefore, be critical for the development of novel therapies. Genome-scale functional genetic screens allow the high-throughput identification of genes that govern cell survival (<xref ref-type="bibr" rid="bib28">Gerhards and Rottenberg, 2018</xref>). Previously, such genes were identified using RNA interference (RNAi) technology (<xref ref-type="bibr" rid="bib58">McDonald et al., 2017</xref>; <xref ref-type="bibr" rid="bib85">Tsherniak et al., 2017</xref>). More recently, essential genes have been identified through the use of CRISPR-Cas9 technology due to its high specificity and efficiency compared to RNAi (<xref ref-type="bibr" rid="bib28">Gerhards and Rottenberg, 2018</xref>). Several studies using genome-wide CRISPR-Cas9 screen have already shown promising outcome in identifying novel cancer-specific vulnerabilities that are useful drug targets (<xref ref-type="bibr" rid="bib80">Steinhart et al., 2017</xref>; <xref ref-type="bibr" rid="bib88">Wang et al., 2017</xref>), as well as improving the understanding of drug mechanism of action (<xref ref-type="bibr" rid="bib3">Barazas et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Hou et al., 2017</xref>).</p><p>The Cancer Dependency Map project (a consortium effort by the Wellcome Sanger Institute and the Broad Institute) have conducted CRISPR-Cas9 screen on a large number of cell lines including some OSCC models (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Meyers et al., 2017</xref>). However, there is a lack of representation of Asians OSCC, such as those associated with betel quid chewing habit, one of the major risk factors of OSCC in many Asian countries (<xref ref-type="bibr" rid="bib78">Shield et al., 2017</xref>). Further, the comparison of genomics data across different populations has revealed distinctive features in the different populations (<xref ref-type="bibr" rid="bib13">Chai et al., 2020</xref>).</p><p>To identify genetic vulnerabilities in OSCC, we performed genome-wide CRISPR-Cas9 screens on 21 highly annotated OSCC cell lines, most of which are unique models derived from Asian patients (<xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>). Our study contributes to approximately one-third of the OSCC functional genetic screens currently available globally, expanding the representation of this heterogeneous disease (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Meyers et al., 2017</xref>). In addition to finding known genetic vulnerabilities, we also uncover novel candidate genes essential for OSCC survival that can facilitate the development of new targeted therapies for OSCC. We validated the essentiality of Yes-associated protein 1 (<italic>YAP1</italic>) and WW domain-containing transcription regulator protein 1 (<italic>WWTR1</italic>) and revealed mutually exclusive dependency and compensable functions of these paralogs in different subsets of OSCC models. We identified OSCC tumors with a gene expression signature similar to cell lines with validated dependencies. Among which, OSCC resembling the WWTR1-dependent cell lines showed significant enrichment of immune-related pathways and are associated with biomarkers of response towards checkpoint inhibitors. In summary, our study demonstrated the robustness of genome-wide CRISPR-Cas9 screen in identifying genetic vulnerabilities in diverse OSCC models, offering new molecular insights into this disease.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Genome-wide CRISPR screens in 21 OSCC cell lines</title><p>In order to identify genetic vulnerabilities of OSCC, particularly those that are more relevant to tumors of Asian origin, we conducted genome-wide CRISPR-Cas9 knockout screens (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). We screened a unique set of 14 well-characterized OSCC cell lines termed the ORL-series [ORL-48, –115, −136, –150, −153, –156, −166, –174, −188, –195, −204, –207, -214, –215]. These were established from the tumors of Malaysian OSCC patients (<xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>) and are comprehensively annotated with whole-exome sequencing (WES) and RNA sequencing data. In addition, we screened a further seven OSCC cell lines [BICR10, Ho-1-u-1, HSC-2, HSC-4, PE/CA-PJ15, SAS and SCC-9] sourced from commercial cell line repositories. Demographic details of the patients from whom the 21 OSCC cell lines were derived are shown in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. The presence of mutations and copy number alterations in the top five significantly mutated genes are indicated. Overall, we find that our selection of cell lines represents the diversity of mutated driver genes observed in OSCC.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Genome-wide CRISPR-Cas9 screen on 21 OSCC cell lines.</title><p>(<bold>A</bold>) Demographic details and genomic profile of the patients of which the 21 OSCC cell lines were derived from, with bar charts depicting the number of essential genes identified by MAGeCK. The presence of mutations/copy number alterations in the top five mutated genes in OSCC is shown. Numbers in first column indicated frequency of mutations (%) among OSCC tumors from TCGA (<xref ref-type="bibr" rid="bib83">The Cancer Genome Atlas Network, 2015</xref>) while second column indicated frequency of mutation (%) among 21 OSCC cell lines. Bar charts in the lower panel shows the number of significant fitness genes (those with MAGeCK FDR less than or equal to 5%), with the orange bars representing the number of non-core fitness genes. <italic>Abbreviations: Ind – Indian; Chi – Chinese, Mal – Malay; Jap – Japanese, Cau – Caucasian; F – Female; M – Male; G – Gingiva; T – Tongue; BM – Buccal Mucosa; FOM – Floor of Mouth; LN – derived from lymph node metastasis.</italic> (<bold>B</bold>) Pie charts showing the proportion of fitness genes among the 18,010 genes screened. 918 non-core fitness genes were shortlisted after filtering out the core fitness genes. (<bold>C</bold>) Bar chart depicting the number of non-core fitness genes that are found in 1 to 21 dependent cell lines.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Analysis result from the genome-wide CRISPR-Cas9 screens.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Genome-wide CRISPR-Cas9 screen.</title><p>(<bold>A</bold>) Schematic of the genome-wide CRISPR-Cas9 screening on 21 OSCC cell lines. (<bold>B</bold>) Workflow of CRISPR data processing and analysis pipeline, from raw sgRNA counts to the list of fitness genes that are significantly depleted during the genome-wide CRISPR screening and quantile normalized, batch corrected, scaled CRISPR score, using various bioinformatic tools/algorithms including CRISPRcleanR, MAGeCK and ComBat (indicated in Red font). For details, please refer to the Materials and methods section.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Identification of core and context-specific fitness genes</title><p>Fitness genes were identified after an unsupervised computational correction with CRISPRcleanR (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Iorio et al., 2018</xref>), followed by mean-variance modeling and systematic ranking of significantly depleted genes using MAGeCK (<xref ref-type="bibr" rid="bib51">Li et al., 2014</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). At a false discovery rate (FDR) of 5%, the number of significantly depleted genes ranged from 525 genes in ORL-156 to 1399 genes in ORL-215 (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p><p>As we aimed to identify genetic vulnerabilities of OSCC that can be safely targeted therapeutically, we filtered the significantly depleted genes to exclude previously defined core fitness genes (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Hart et al., 2014</xref>; <xref ref-type="bibr" rid="bib33">Hart et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Meyers et al., 2017</xref>), that were found to be essential across the many cell lines from different lineages, and are likely toxic to the cells when targeted. In general, more than 80% of all the MAGeCK hits were found to be core fitness genes and were filtered out (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Overall, among the 18,010 genes screened, 2539 (14%) were found to be significant MAGeCK hits in at least one cell line and following the removal of core fitness genes (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), 918 context-specific fitness genes were shortlisted for further prioritization (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). About 40% (366 genes) were uniquely essential in a single cell line, while the remaining 60% (552 genes) were essential in at least two cell lines, hence are recurrent context-specific essentialities (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p></sec><sec id="s2-3"><title>Capturing of known HNSCC cancer genes and pathways</title><p>Pathway enrichment analyses on the 918 context-specific fitness genes was conducted on each individual cell line (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Consistent with the highly heterogeneous nature of OSCC, diverse pathways were enriched across these cell lines. Pathways enriched among the 918 genes revealed several cancer-related pathways, potentially comprising important cancer-specific targets (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref> and <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3A-B</xref>). Whilst pathways such as ubiquitin-mediated proteolysis and cellular senescence are common across all cell lines, pathways such as NF-kappa B and MAPK signaling pathways are selectively enriched only in subsets of cell lines.</p><p>Next, we sought to determine which components of the common oncogenic pathways altered in HNSCC (<xref ref-type="bibr" rid="bib83">The Cancer Genome Atlas Network, 2015</xref>) were required for cancer cell fitness and annotated the genes with the frequency of dependency (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Notably, most of the fitness genes are either existing drug targets or deemed clinically actionable. For example, drugs targeting <italic>PIK3CA</italic> and <italic>CDK6</italic> are already in clinical trials for HNSCC treatment [NCT01816984, NCT02537223, NCT03356223, NCT03356587]. We also examined the dependency profile of 44 cancer genes with driver mutations known to be associated with HNSCC (<xref ref-type="bibr" rid="bib2">Bailey et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Martincorena et al., 2018</xref>; <xref ref-type="fig" rid="fig2">Figure 2B</xref>) and found that more than half of these cancer genes were dispensable for OSCC survival. Oncogene addiction has been the promising source of finding the Achilles heel for successful molecular targeted therapy (<xref ref-type="bibr" rid="bib90">Weinstein and Joe, 2008</xref>). Based on the WES data of the 21 OSCC cell lines, we found 43 genes with driver mutations in at least one cell line and plotted the CRISPR score (measure of sgRNA depletion in the CRISPR screen) to examine if there is any differential dependency associated with the mutations (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Dependencies on mutated <italic>PIK3CA</italic> were observed in four OSCC cell lines with a hotspot mutation in E545K (BICR10), Q546R (ORL-150) and H1047R (HSC-2), and to a lesser extent, in ORL-115 with H1047L mutation. Intriguingly, HSC-4, which harbors the same E545K mutation as BICR10, did not show any dependency on the mutated <italic>PIK3CA</italic>, this is consistent with findings from Project Score (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>). A splice site driver mutation in <italic>PTEN</italic> co-occurred in HSC-4 and may have counteracted the oncogene addiction effect on the mutated <italic>PIK3CA</italic>, as suggested previously in breast cancer (<xref ref-type="bibr" rid="bib49">Lazaridis et al., 2019</xref>). Dependency on NFE2L2 was observed in Ho-1-u-1 and BICR10 however the mechanism of activating this oxidative pathway differed between these two cell lines. Oncogene addiction is observed for Ho-1-u-1 with a hotspot mutation (E82D) in <italic>NFE2L2</italic>, that has been shown to enhance its transcriptional activity and promoting cell proliferation (<xref ref-type="bibr" rid="bib77">Shibata et al., 2008</xref>). On the other hand, BICR10 harbors an inactivating mutation on <italic>KEAP1</italic> (R320Q) a negative regulator of <italic>NFE2L2.</italic> The R320Q mutation has been reported to stabilize NRF2 (encoded by <italic>NFE2L2</italic>) and enhances cell fitness as reported previously in lung cancer (<xref ref-type="bibr" rid="bib34">Hast et al., 2014</xref>). Finally, the only cell line that shows dependency on HRAS is ORL-214 which carries a mutation in <italic>HRAS</italic> (G12C). Another gene, encoding ZFP36L1 with truncating mutation at S324 in ORL-48 also showed preferential dependency, suggesting that the effect of this mutation should be studied further.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Identification and analysis of targetable genes and pathways in OSCC.</title><p>(<bold>A</bold>) Common oncogenic pathways altered among HNSCC samples of TCGA were annotated with frequency of dependency. Non-core fitness genes are indicated in red and the percentage of OSCC cell lines that were dependent on the genes are shown. The Drug Gene Interaction database (DGIdb) (<ext-link ext-link-type="uri" xlink:href="http://www.dgidb.org/">http://www.dgidb.org/</ext-link>) was used to determine if the gene is clinically actionable while the availability of drugs were determined using Open Targets Platform (<ext-link ext-link-type="uri" xlink:href="https://www.targetvalidation.org/">https://www.targetvalidation.org/</ext-link>). (<bold>B</bold>) Heatmap of gene essentiality of the 44 HNSCC cancer genes in the 21 OSCC lines. These are consensus cancer genes for HNSCC curated from <xref ref-type="bibr" rid="bib2">Bailey et al., 2018</xref> and <xref ref-type="bibr" rid="bib57">Martincorena et al., 2018</xref>. (<bold>C</bold>) CRISPR scores of genes with driver mutations in at least one of the 21 OSCC cell lines. Cell lines labeled in green with mutation are examples of those showing oncogene addiction on mutated genes, for example on <italic>PIK3CA</italic> (ORL-150, BICR10, and HSC-2) and <italic>NFE2L2</italic> (Ho-1-u-1). (<bold>D</bold>) Pathway enrichment analysis for fitness genes that are differentially enriched among the seven betel-quid associated OSCC. (<bold>E</bold>) Distribution of the 918 fitness genes based on their small molecule inhibitors tractability assessment. Tractability is defined as detailed in <xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref> where: tractability group one included targets with approved drugs (Bucket 1) or drugs in clinical/pre-clinical development (Bucket 2, 3); tractability group two included targets with evidence supporting tractability albeit no drugs are available yet; while the least tractable group three included targets that lacks evidence informing tractability.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Analysis results of targetable genes and pathways in OSCC.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Pathway level enrichment analysis and tractability assessment of fitness genes.</title><p>(<bold>A</bold>) Significantly enriched KEGG pathway based on non-core fitness genes of individual cell lines. Binary heatmap of top 50 most common KEGG pathways enriched by respective non-core fitness genes in the 21 OSCC cell lines. Those with p-values less than 0.05 are indicated in red. (<bold>B</bold>) KEGG pathway enrichment analysis of the 918 non-core fitness genes shows significant enrichment for cancer-related pathways, potentially harboring more targetable cancer-specific genes. (<bold>C</bold>) Functional classification of 918 non-core fitness genes using PANTHER protein class database, separated based on their tractability group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Identification of unique dependencies in betel-quid-associated OSCC</title><p>Studies on the genomic landscape of Asian and Caucasian OSCC have revealed distinct molecular differences, suggesting that some population-specific risk habits might have contributed to these differences (<xref ref-type="bibr" rid="bib83">The Cancer Genome Atlas Network, 2015</xref>; <xref ref-type="bibr" rid="bib13">Chai et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Hsieh et al., 2001</xref>; <xref ref-type="bibr" rid="bib40">India Project Team of the International Cancer Genome Consortium, 2013</xref>; <xref ref-type="bibr" rid="bib93">Zanaruddin et al., 2013</xref>). Betel quid chewing is frequently associated with OSCC in Asia (<xref ref-type="bibr" rid="bib29">Guha et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">India Project Team of the International Cancer Genome Consortium, 2013</xref>; <xref ref-type="bibr" rid="bib76">Shah et al., 2012</xref>). In this study, several Asian-derived OSCC models that were associated with betel-quid chewing were included, and we had the opportunity to determine if there are differences in genetic dependencies between these OSCC (ORL-115, ORL-136, ORL-174, ORL-195, ORL-204, ORL-207, ORL-214) (n = 7), with those that are not associated with betel quid chewing (n = 14) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Of the 110 fitness genes uniquely seen in betel-quid-associated OSCC, the NF-kB signaling pathway stands out as one of the significantly enriched pathway. The fitness genes from this pathway that are unique to the betel quid-associated OSCC include <italic>NFKB2</italic>, <italic>TNFAIP3</italic>, <italic>CSNK2A1</italic>, and <italic>TRIM25</italic>. When cross checking with the DepMap and Project Score data, three out of four (75%) of these genes (<italic>NFKB2</italic>, <italic>TNFAIP3</italic>, and <italic>TRIM25)</italic> were not found among the screened OSCC models, which were mostly derived from Caucasians, or from Asians not known to chew betel quid. Interestingly, our findings are coherent with previous studies from Taiwan and India, where betel quid chewing is common, which have demonstrated that extract from the areca nut of betel quid can directly activate the NF-kB signaling pathway, favoring OSCC cells survival (<xref ref-type="bibr" rid="bib15">Chiang et al., 2008</xref>; <xref ref-type="bibr" rid="bib43">Islam et al., 2019</xref>; <xref ref-type="bibr" rid="bib54">Lin et al., 2005</xref>).</p></sec><sec id="s2-5"><title>Tractability of the identified fitness genes</title><p>Given that many of the reported HNSCC-related cancer genes do not appear to be fitness genes, we sought to determine which of the 918 genes could potentially be tractable using previously defined frameworks (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="bibr" rid="bib9">Brown et al., 2018</xref>; <xref ref-type="fig" rid="fig2">Figure 2E</xref> and <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). From the 918 genes, 45 genes fall into the tractability group 1, some examples of genes in this group include <italic>EGFR</italic>, <italic>PIK3CA</italic>, <italic>CDK4</italic>, and <italic>CDK6</italic>, where anticancer drugs targeting these genes are already approved or clinical trials for the treatment of HNSCC are on-going, demonstrating the robustness of our results. When classified based on protein function using PANTHER (<xref ref-type="bibr" rid="bib60">Mi et al., 2013</xref>), most of those in tractable group 1, are transferase (kinases) (32%) and oxidoreductase (30%), including genes like <italic>CDK4</italic>, <italic>CDK6</italic> and <italic>PIK3CA;</italic> and several genes in the family of NADH:ubiquinone oxidoreductase such as <italic>NDUFB9</italic> and <italic>NDUFC2</italic> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Interestingly, emerging oncology and non-oncology drugs such as the HDAC inhibitors (<xref ref-type="bibr" rid="bib91">Yoon and Eom, 2016</xref>) and miglustat, an approved drug for Gaucher’s disease (<xref ref-type="bibr" rid="bib4">Barth et al., 2013</xref>), were amongst potential drug repurposing candidates that target fitness genes in tractability group 1 (targeting <italic>HDAC2</italic> and <italic>UGCG</italic> respectively). The only transcription factor that falls within tractability group one is the <italic>ESR2</italic>, with several antagonists available owing to its well-studied ligands and structure (<xref ref-type="bibr" rid="bib36">Ho, 2004</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). A further 210 genes (23%) belong to tractability group 2, which harbors novel targets that have evidence supporting their tractability. Albeit no drugs are currently in clinical trials, these may hold potential for future drug development. For example, several companies are developing drugs that could target YAP1, SLC2A1 and PTPN11 which are in tractability group 2. However, about 70% of the 918 genes belong to tractability group 3 (least tractable or lacking evidence) where significant efforts in understanding their structure and function would be necessary to evaluate their tractability. Consistent with previous reports (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>), the least tractable group comprises mainly of nucleic acid-binding proteins and transcription factors, such as the Kruppel-like factors (KLF) gene families (<italic>KLF4</italic> and <italic>KLF5</italic>) and zinc finger proteins (<italic>ZNF148</italic> and <italic>ZNF236</italic>) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>).</p></sec><sec id="s2-6"><title>Fitness genes in copy number amplified regions</title><p>HNSCC belongs to the ‘C class’ tumor, where the landscsape of genomic alterations is dominated by copy number alterations including recurrent chromosomal gains and losses (<xref ref-type="bibr" rid="bib16">Ciriello et al., 2013</xref>). The most frequently reported copy number gains occurr in chromosomes 3q, 5 p, 7 p, 8q, and 11q (<xref ref-type="bibr" rid="bib83">The Cancer Genome Atlas Network, 2015</xref>; <xref ref-type="bibr" rid="bib73">Salahshourifar et al., 2014</xref>). To identify putative oncogenes that are essential for OSCC within these amplified regions, we evaluated the number of candidate fitness genes before and after CRISPRcleanR correction for copy number bias (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). After correction, no enrichment/bias was found in the frequently amplified chromosome, demonstrating effective correction of copy number bias (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). KEGG pathway analysis of the 152 genes from the five amplified regions showed enrichment of several oncogenic signaling pathways such as the small cell lung cancer, Hippo signaling pathway and ErbB signaling pathway (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). We focused our analysis on the Hippo signaling pathway (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>), which has recently been implicated for major oncogenesis role in squamous cell carcinoma, including OSCC (<xref ref-type="bibr" rid="bib12">Campbell et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Ge et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Hiemer et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Wang et al., 2018</xref>). Furthermore, <italic>YAP1</italic> or <italic>WWTR1</italic> amplifications occur in approximately 19% of HNSCC (<italic>YAP1</italic>–5.5%, <italic>WWTR1</italic>–14.3%), which puts it among the top five cancers with the highest amplification of these genes amongst 33 cancer types (<xref ref-type="bibr" rid="bib89">Wang et al., 2018</xref>).</p></sec><sec id="s2-7"><title>Differential dependency pattern on YAP1 and WWTR1</title><p>YAP1 and WWTR1 (also known as TAZ) are transcription co-activators, which are the major effectors of the Hippo pathway (<xref ref-type="bibr" rid="bib30">Guo and Teng, 2015</xref>; <xref ref-type="bibr" rid="bib89">Wang et al., 2018</xref>). YAP1 and WWTR1 are paralogs with ~46–60% similarity in their amino acid sequence (<xref ref-type="bibr" rid="bib30">Guo and Teng, 2015</xref>). They were shown to have both overlapping and distinct roles in different contexts (<xref ref-type="bibr" rid="bib30">Guo and Teng, 2015</xref>; <xref ref-type="bibr" rid="bib69">Plouffe et al., 2018</xref>). In OSCC, overexpression of YAP1 and WWTR1 has been shown to increase proliferation, survival and migration, mainly via interaction with the transcriptional enhanced associate domain (TEAD) transcription factors (<xref ref-type="bibr" rid="bib35">Hiemer et al., 2015</xref>).</p><p>Interestingly, across the 21 OSCC cell lines, there is a subset of lines that show significant dependency on only one of the paralogs, while another subset of lines does not exhibit significant dependency on either <italic>YAP1</italic> or <italic>WWTR1</italic> (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). With the exception of two cell lines, ORL-153 and ORL-215, YAP1-dependent lines and WWTR1-dependent lines are mutually exclusive. There were seven lines that were highly dependent on YAP1 (ORL-48, ORL-136, ORL-156, ORL-204, ORL-207, SAS, SCC-9), four highly dependent on WWTR1 (ORL-174, ORL-188, ORL-214, PE/CA-PJ15), while the other eight were not dependent on either (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Notably, <italic>WWTR1</italic> gene locus (3q25) is at close proximity to the locus of <italic>PIK3CA</italic>, <italic>SOX2</italic> and <italic>TP63</italic> at 3q26-28, whereby their focal amplification is frequently reported in HNSCC (<xref ref-type="bibr" rid="bib83">The Cancer Genome Atlas Network, 2015</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>). The majority of the WWTR1-dependent cell lines have copy number amplification for these genes on 3q25-28 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), but only WWTR1 CRISPR scores are significantly different between those with and without copy number amplification (p&lt;0.001) (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D</xref>). Only two of nine cell lines with PIK3CA copy number amplification are dependent on PIK3CA itself. This suggests that copy number amplification of WWTR1 may constitute to a functional oncogenic role of WWTR1 in OSCC, instead of being a passenger gene that is co-amplified with the canonical HNSCC oncogene, <italic>PIK3CA</italic>. Notably, we also observed an enrichment of <italic>PIK3CA</italic> mutations (p=0.0003) among cell lines that are neither dependent on YAP1 or WWTR1, whereby five out of six such lines have PIK3CA hotspot mutations (BICR10, HSC-2, HSC-4, ORL-115, and ORL-150) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>YAP1 and WWTR1 of the Hippo pathway are selectively essential in a distinct subset of OSCC cell lines.</title><p>(<bold>A</bold>) Essentiality profile (depicted with CRISPR scores heatmap) of YAP1, WWTR1, PIK3CA, TP63 and SOX2 across 21 OSCC cell lines derived from the CRISPR/Cas9 screen. Dependency on these genes were depicted as grey box in the bottom panel, according to the MAGeCK definition of significant depletion at FDR ≤ 0.05. No cell lines were dependent on TP63 or SOX2. The degree of essentiality differs across the lines. Some subsets of the cell lines are only dependent on either YAP1 or WWTR1, while neither gene appears to be essential in another subset of cell lines. <italic>PIK3CA, TP63</italic> and <italic>SOX2</italic> are genes implicated in HNSCC carcinogenesis that are often co-amplified with WWTR1, located on chromosome 3q25-28. All WWTR1-dependent cell lines had copy number amplification on these genes while all PIK3CA mutated cell lines are not dependent on either YAP1 or WWTR1. (<bold>B</bold>) Western blot images showing the protein level of YAP1 and WWTR1 on day 4 upon transducing the Cas-9 expressing cell lines with lentivirus carrying gene-specific sgRNA. Two sgRNAs were used per target gene. (<bold>C</bold>) Co-competition assay was used to validate the essentiality of YAP1 and WWTR1 on the selected cell lines. The growth of the BFP-positive transduced population was compared to the non-transduced population throughout the 18 days assay. The percentage of BFP-positive cells obtained at different time points were normalized to the day 4 readings for respective sgRNA (except ORL-204 which had time points normalized to the day 6 readings for respective sgRNA). PLK1 is a core essential gene included as a positive control. Negative controls include CHAT which is a non-essential gene across the panel of cell lines, and NT serves as a non-targeting control. Data are shown as mean ± SD (n = 2 biological repeats). (<bold>D</bold>) qPCR results show suppression of downstream targets of YAP1 and WWTR1 only when the respective fitness gene is being knocked-out. Down-regulation of CTGF and CYR61 gene expression was observed when YAP1 is knocked-out in the YAP1-dependent cell lines (ORL-48 and ORL-204). In the WWTR1-dependent cell lines (ORL-214, PE/CA-PJ15), CTGF and CYR61 expression is only suppressed when WWTR1 is knocked-out. Data are shown as mean ± SD (n = 2 independent experiments with technical triplicates).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>All raw data related to <xref ref-type="fig" rid="fig3">Figure 3</xref> and its figure supplements on analysis result of YAP1 and WWTR1 as fitness genes for OSCC.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Fitness genes and copy number amplification.</title><p>(<bold>A</bold>) Barcharts showing proportion of screened genes identified by MAGeCK as fitness genes, before and after CRISPRcleanR correction, for those that mapped onto chromosomal region with frequent copy number amplification. (<bold>B</bold>) Distribution of MAGeCK fitness genes across all chromosomes. As expected, Y chromosome have the least percentage of genes being essential. For the rest of the chromosomes, proportion of MAGeCK fitness genes among screened genes ranged from 12 to 19%. Chromosome with frequent copy number amplification did not show significantly higher number of fitness genes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>YAP1 and WWTR1 from the Hippo signaling pathway are fitness genes for OSCC.</title><p>(<bold>A</bold>) KEGG pathway analysis of essential genes found on copy number amplified chromosome shows enrichment of pro-tumorigenic pathway including the Hippo signaling pathway. (<bold>B</bold>) The Hippo signaling pathway and annotation of genes that are OSCC fitness genes. (<bold>C</bold>) Oncoprint downloaded from cBioportal showing the copy number alterations of YAP1, WWTR1, PIK3CA, TP63, and SOX2 in the HNSCC samples (n = 295) (TCGA<sup>1</sup>). Co-amplification of WWTR1 with PIK3CA can be seen in majority of the cases, whereby 40/59 (68%) tumors with PIK3CA amplification also have WWTR1 amplification. (<bold>D</bold>) Boxplots of CRISPR scores for the five genes, classified into two groups with (n = 11) or without (n = 10) copy number amplification of genes on chromosome 3q25-28. OSCC with copy number amplification showed significantly more negative CRISPR score for WWTR1, i.e. more dependent on WWTR1. This correlation was not found for PIK3CA. TP63 and SOX2 were not essential in any of the 21 OSCC cell lines. Whiskers of boxplot show minimum and maximum values, lines representing median. Unpaired two-tailed t-test was used for calculating statistical difference between two groups. (<bold>E</bold>) Baseline mRNA expressions of YAP1 and WWTR1 in selected OSCC cell lines were quantified by qPCR. YAP1-dependent ORL-48 and ORL-204 showed upregulation of YAP1 expression. While in other OSCC cell lines, the extend of WWTR1 overexpression is higher than YAP1. OKF6/htert1, an immortalized normal oral epithelial cell line is used as reference control for calculation of relative fold difference of gene expression. Data are shown as mean ± SD (n = 3 technical repeats). (<bold>F</bold>) Baseline protein expression of YAP1 and WWTR1 protein in selected OSCC cell lines. Actin was probed as a loading control.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Correlation of gene essentiality and gene expression for YAP1/WWTR1.</title><p>(<bold>A</bold>) Plot of differential essentiality between <italic>YAP1</italic> and <italic>WWTR1</italic> reveal correlation of essentiality with gene expression. Gene expression and CRISPR score of <italic>YAP1</italic> and <italic>WWTR1</italic> from Project Score on 273 cancer cell lines were extracted. Those lines that are more dependent on <italic>YAP1</italic> over <italic>WWTR1</italic> (negative differential CRISPR score) are mostly with high <italic>YAP1</italic> (blue) and low <italic>WWTR1</italic> (red) expression; On the other hand, cell lines that are more dependent on <italic>WWTR1</italic> are among those with overexpression of <italic>WWTR1</italic> (red). (<bold>B</bold>) Significant negative correlation between <italic>WWTR1</italic> gene expression and gene essentiality was evident in the 273 cancer cell lines screened in Project Score. Those cell lines that are dependent on <italic>WWTR1</italic> (negative CRISPR score) tend to have higher <italic>WWTR1</italic> expression. (<bold>C</bold>) WWTR1 gene expression and gene essentiality also showed non-significant negative correlation among the 21 OSCC lines screened. (<bold>D</bold>) Other cancer types showing significant negative correlation between <italic>WWTR1</italic> gene expression and gene essentiality include non-small cell lung carcinoma, squamous cell lung carcinoma, glioblastoma, breast carcinoma, and lung adenocarcinoma (data from Project Score).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Clonogenic assay of representative lines and validation of YAP1 dependency in SAS.</title><p>(<bold>A</bold>) Clonogenic assay showing inhibitory effect upon knocking out respective fitness genes in YAP1- and WWTR1-dependent lines. In BICR10 and HSC-2 knocking out of either YAP1 or WWTR1 with sgRNAs did not have any impact on clonogenicity. Experiment is performed in technical triplicate and repeated twice. Representative image of one technical repeat is shown. (<bold>B</bold>) sgRNA level log fold change from triplicate CRISPR screens of SAS. Depletion were seen only in sgRNAs targeting exon 1–4 of YAP1, which were present in YAP1-MAML2 fusion protein, but not seen in sgRNA 6–6 which targets exon 6. Data are shown as mean ± SD (n = 3 biological repeats). (<bold>C</bold>) Western blot to check efficacy of target protein knockout using CRISPR/Cas9 on SAS. Y1K is one of the sgRNA from the KY library v1, targeting exon 4, while Y2B is an independent sgRNA targeting exon 1 of YAP1. (<bold>D</bold>) Co-competition assay results for SAS, validating its dependency on YAP1. Previous work by <xref ref-type="bibr" rid="bib67">Picco et al., 2019</xref><sup>2</sup> revealed oncogenic fusion of YAP1 with MAML2 in SAS, rendering the cells to be dependent on the fusion protein. Both our genome-wide screening data and validation data have also confirmed the preferential dependency of SAS on YAP1, over its paralog, WWTR1. (<bold>E</bold>) Clonogenicity assay confirmed preferential dependency of SAS on YAP1. (<bold>F</bold>) qPCR of downstream target genes showed relatively stronger suppression when the fitness gene, YAP1 is depleted with sgRNA Y1K or Y2B. Data are shown as mean ± SD (n = 2 independent experiments with technical triplicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig3-figsupp4-v2.tif"/></fig></fig-group><p>Intriguingly, mutually exclusive copy number gains of chromosome 3q and 11q22 (where YAP1 is mapped to) have been reported in squamous cell carcinoma (<xref ref-type="bibr" rid="bib12">Campbell et al., 2018</xref>) and consistently, YAP1 and WWTR1 amplification were also found to be mutually exclusive in HNSCC (<xref ref-type="bibr" rid="bib89">Wang et al., 2018</xref>). In our study, despite having cell lines dependent on YAP1, none of the 21 OSCC cell lines shows copy number amplification of YAP1 or neighbouring genes on the chromosome 11q22. This suggests that other non-genomic mechanisms could likely be in place to activate YAP1.</p><p>To investigate if expression of <italic>YAP1</italic> and <italic>WWTR1</italic> is associated with the dependency, we examined baseline mRNA and protein expression of YAP1 and WWTR1 in representative OSCC lines (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2E–F</xref>). Among the YAP1-dependent lines (ORL-48, ORL-204), overexpression of YAP1 mRNA and protein levels were observed. Further, these lines have low protein expression of WWTR1. The mRNA and protein expression of WWTR1 are relatively higher than YAP1 among the WWTR1-dependent cell lines (ORL-214 and PE/CA-PJ15), and those that were not affected when either YAP1 or WWTR1 is knocked-out (‘non-dependent’). To determine if the association between dependency and gene expression is exclusive to OSCC, we computed the differential dependency score of <italic>YAP1</italic> and <italic>WWTR1</italic> and their gene expression for 273 cancer cell lines from Project Score (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A</xref>). Generally, cell lines that are dependent on YAP1 have higher YAP1 expression, and similarly, WWTR1-dependent lines have higher expression of WWTR1 compared to YAP1. WWTR1 gene expression showed significant negative correlation with its dependency in these 273 cancer cell lines (Pearson R = −0.570, p-value=3e-25) and showed non-significant negative correlation among our 21 OSCC lines screened (Pearson R = −0.354, p-value=0.116) (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3B–C</xref>). In other words, the higher dependency on <italic>WWTR1</italic> gene is associated with higher <italic>WWTR1</italic> gene expression. Interestingly, this observation was also seen in other cancer types, including non-small cell lung carcinoma, squamous cell lung carcinoma, glioblastoma, breast carcinoma, and lung adenocarcinoma (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3D</xref>), based on the Project Score data. Among these cancers, non-small cell lung carcinoma showed the highest percentage of WWTR1-dependency (30%), with the strongest correlation (Pearson’s R = −0.934, p-value=0.0021).</p><p>To validate the differential dependency for YAP1 and WWTR1, we performed single-gene knockout using two sgRNAs per gene and investigated the growth inhibition effect of gene knockout using co-competition assay, as previously reported (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>). Two cell lines each from the YAP1-dependent (ORL-48 and ORL-204), WWTR1-dependent (ORL-214 and PE/CA-PJ15) and YAP1/WWTR1 non- dependent (BICR10, HSC-2) groups were used. The efficacy of protein knockout using individual sgRNAs was assayed with western blotting (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><p>The results obtained from the co-competition assay corroborated our CRISPR screen data (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). More than half of the transduced cell population was depleted following YAP1-knockout in ORL-48 and ORL-204 cells, but not when WWTR1 was knocked-out. Likewise, the growth inhibition in ORL-214 and PE/CA-PJ15 was only seen following WWTR1-knockout, but not upon YAP1-knockout. On the other hand, the fraction of transduced cells in BICR10 and HSC-2 did not show any prominent changes upon knockout of either YAP1 or WWTR1. These experiments were validated using clonogenicity assays (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4A</xref>). Together, these results support the differential dependency pattern on <italic>YAP1</italic> and <italic>WWTR1</italic>. Besides, another YAP1-dependent line, SAS has recently been reported to harbor a fusion protein of YAP1 and MAML2 (<xref ref-type="bibr" rid="bib67">Picco et al., 2019</xref>). Our co-competition assay also confirms the dependency on YAP1 in these cells and the differential depletion of sgRNA targeting early and late exons of YAP1 suggested that this oncogenic fusion protein provided a survival advantage (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4B–E</xref>). In OSCC, <italic>CTGF</italic>, and <italic>CYR61</italic> are two canonical transcriptional targets of YAP1 and WWTR1 (<xref ref-type="bibr" rid="bib35">Hiemer et al., 2015</xref>). Consistent with their known pro-survival properties, more substantial reduction of <italic>CTGF</italic> and <italic>CYR61</italic> gene expression were seen only when the respective upstream fitness genes were knocked-out, as measured by qPCR (<xref ref-type="fig" rid="fig3">Figure 3D</xref> and <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4F</xref>).</p><p>Since YAP1/WWTR1 were both known to regulate proliferation and apoptosis, we next investigated whether the depletion of YAP1 and WWTR1 affects cell proliferation or apoptosis in the selected OSCC cells. Consistently, YAP1 depletion in ORL-48 resulted in significant reduction in viable cells, to a level comparable to the depletion of PLK1 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), and this was reflected in the increase in apoptotic cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Further, WWTR1 depletion in ORL-214 showed significantly lower percentage of viable cells when compared with the control, as well as significant increase in apoptotic cells (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). Overall, these results confirm the dependency on either YAP1 or WWTR1 for survival, whereby depletion of the respective fitness genes resulted in increased apoptosis. By contrast, depletion of either YAP1 or WWTR1 did not affect the survival of HSC-2, as confirmed by the apoptotic assay (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>YAP1/WWTR1 knockout impairs proliferation and induces apoptosis in dependent cells.</title><p>(<bold>A</bold>) Knocking out YAP1 or WWTR1 significantly inhibited cell proliferation in the respective dependent cell lines. Cell viability of HSC-2 (a YAP1- and WWTR1-non-dependent cell line) was not affected by depletion of either YAP1 or WWTR1. Experiments are repeated twice in technical triplicates. (n = 3 technical repeats for two biological repeats). Data shown as mean ± SD. *p&lt;0.01; **p&lt;0.001. (<bold>B</bold>) Apoptosis assay revealed that YAP1 depletion in YAP1-dependent ORL-48 resulted in significant increase in apoptotic cells while WWTR1 depletion in WWTR1-dependent ORL-214 resulted in an increase in apoptotic cells. No significant changes in apoptotic cells were observed in HSC-2 when either YAP1 or WWTR1 was depleted. Experiments are repeated twice in technical triplicates. Data of one experiment are shown as mean ± SD (n = 3 technical repeats). *p&lt;0.01; **p&lt;0.001.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Data for cell viability and apoptosis assays.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig4-v2.tif"/></fig></sec><sec id="s2-8"><title>YAP1 and WWTR1 shows compensatory roles in OSCC cell lines</title><p>The lack of dependency on either YAP1 or WWTR1 in the non-dependent lines is intriguing, given the importance of these genes in most OSCC cancer cells. As YAP1 and WWTR1 share high structural homology and have common downstream targets, we hypothesized that YAP1 and WWTR1 could provide compensatory functions to maintain the survival of BICR10 and HSC-2 cell lines when either one of the genes was knocked-out.</p><p>To confirm our hypothesis, we knocked-out both YAP1 and WWTR1 simultaneously by co-transducing the cell lines with lentivirus carrying blue fluorescence protein (BFP)-tagged YAP1 sgRNA and mCherry-tagged WWTR1 sgRNA (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The co-competition assays showed that the population of BICR10 and HSC-2 with the double knockout of both YAP1 and WWTR1 depleted drastically (<xref ref-type="fig" rid="fig5">Figure 5B</xref>) compared to when each gene was knocked-out individually (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). This suggests that in this YAP1/WWTR1 compensable subset of cell lines, the paralogs can compensate for the function of one another to activate the downstream mechanisms required to maintain cell fitness. This was substantiated by quantitative-PCR (qPCR) of downstream targets CTGF and CYR61 where substantial down-regulation in double knockout cells were observed compared to when each gene is knocked-out individually (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Simultaneous depletion of YAP1 and WWTR1 on BICR10 and HSC-2 inhibited cell growth, suggesting compensatory role of YAP1 and WWTR1.</title><p>(<bold>A</bold>) Western blot showing the protein level of YAP1 and WWTR1 in BICR10 and HSC-2 Cas9 cell lines upon different combinations of YAP1 and WWTR1 sgRNA co-transduction. sgRNAs that targeted YAP1 were tagged with BFP marker and WWTR1 sgRNAs were tagged with mCherry marker respectively, they were simultaneously transduced into the Cas9-expressing cell lines to achieve double knockout of YAP1 and WWTR1. (<bold>B</bold>) YAP1 and WWTR1 double knockout cells show inhibited growth in co-competitive assay. Simultaneous knockout of YAP1 and WWTR1 in Cas9-expressing BICR10 and HSC-2 resulted in the depletion of sgRNAs-transduced populations, which was not observed upon the depletion of either gene alone. Results shown were normalized to day 4. Data are shown as mean ± SD (n = 2 independent experiments with technical triplicates). (<bold>C</bold>) qPCR results revealed that strong suppression of <italic>CTGF</italic> and <italic>CYR61</italic> gene expression in BICR10 and HSC-2 is only seen when YAP1 and WWTR1 are simultaneously knocked-out. qPCR was performed in technical triplicates. Data are shown as mean ± SD (n = 3 technical repeats).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Data for co-competitive assay and qPCR.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig5-v2.tif"/></fig></sec><sec id="s2-9"><title>YAP1/WWTR1-dependency associated gene signatures in OSCC</title><p>Next, we sought to determine whether the differential dependency on YAP1 and WWTR1 is also relevant in OSCC tumors. We first derived the gene expression signatures representing the three groups using differentially expressed gene (DEG) analysis based on the OSCC cell lines with validated dependency (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A–B</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). Using the ‘YAP1 dependency signature score’, ‘WWTR1 dependency signature score’ and ‘Compensable signature score’ [see materials and methods], OSCC cell lines were clustered into three broad groups based on their dependency on YAP1, or WWTR1 (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Using the same algorithm, we then computed the dependency signature score for each of the 315 OSCC tumors from the TCGA HNSCC cohort. From the heatmap and clustering analysis based on their dependency signatures, the three groups were also observed among the OSCC tumors (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). To define representative ‘core’ samples, we found 41 OSCC tumors (13%) with high YAP1 dependency signature score (&gt;0.5); 30 OSCC (9.5%) with high WWTR1 dependency signature score (&gt;0.5) and 34 OSCC (11%) with high Compensable signature score (&gt;0.5). Using these core OSCC samples and cell lines with validated dependency, we then used GSEA to identify hallmark pathways that are enriched in each of these groups (<xref ref-type="fig" rid="fig6">Figure 6C</xref> and <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). YAP1-dependent cell lines and tumors showed enrichment in hallmarks related to cell cycle, such as the E2F targets, G2M checkpoint, MYC targets, and DNA repair pathways (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). This is consistent with previous reports that have demonstrated that the transcription factors E2F and MYC are critical downstream regulators of YAP/TEAD-mediated activation of cell cycle genes (<xref ref-type="bibr" rid="bib47">Kapoor et al., 2014</xref>; <xref ref-type="bibr" rid="bib66">Pattschull et al., 2019</xref>). While OSCC with high WWTR1 dependency signature score showed high expression of genes in several hallmarks related to immunity, such as the interferon responses, inflammatory responses and the complement pathway. This association is aligned with the recent findings that WWTR1 may play a role in immunity by upregulating PD-L1 expression (<xref ref-type="bibr" rid="bib44">Janse van Rensburg et al., 2018</xref>). On the other hand, cell lines and tumors with high Compensable signature score showed enrichment in several metabolism-related hallmarks, such as fatty acid metabolism and xenobiotic metabolism. Notably, all three YAP1/WWTR1 compensable cell lines (BICR10, HSC-2 and HSC-4) harbor <italic>PIK3CA</italic> mutation, and that alterations in the PI3K signaling pathway have been linked to multiple metabolic dysregulations in cancer (<xref ref-type="bibr" rid="bib31">Hao et al., 2016</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Identification of YAP1/WWTR1 dependency associated gene signatures in OSCC tumors samples.</title><p>(<bold>A</bold>) Heatmap with hierarchical clustering using the computed signature scores showed clustering of the OSCC cell lines into three groups, based on their validated dependency. (<bold>B</bold>) Heatmap with hierarchical clustering of OSCC tumors using the computed signature scores. The three clusters found from cell lines were also present among the OSCC tumors. For labeling convenience, OSCC with high YAP1 dependency signature score is referred as ‘YAP1-dependent’; ‘WWTR1-dependent’ – high WWTR1 dependency signature score; ‘Compensable’ – high compensable signature score. (<bold>C</bold>) GSEA of the OSCC cell lines and those OSCC tumors with similar gene signatures showed overlapping hallmarks enrichment, while distinct hallmarks were associated with each of the three groups. Only common hallmarks (between cell lines and tumors) with positive normalized enrichment score (NES) of &gt;0.5 were shown. Full GSEA results can be found in <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>. (<bold>D</bold>) OSCC with high WWTR1 dependency signature score showed significantly lower stromal infiltration, but higher immune infiltration compared to the other two groups. (<bold>E</bold>) By comparing the immune expression signatures from <xref ref-type="bibr" rid="bib84">Thorsson et al., 2018</xref>, OSCCs with high WWTR1 dependency signature score are associated with significantly higher IFN-gamma response and cytolytic CD8 T-cells and lower TGF-beta response. (<bold>F</bold>) mRNA expression of PD-L1 (CD274) were significantly elevated among OSCC tumors with high WWTR1 dependency signature score. (<bold>G</bold>) OSCC with high WWTR1 dependency signature score showed significantly higher enrichment score for the 18-gene T-cell inflamed GEP, which is a clinically validated biomarker of response towards checkpoint blockade. For panels D-G, unpaired Welch’s t-test with Welch’s correction was used due to unequal sample size (n = 43, 31, 30, respectively).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Analysis workflow for computing dependency score and heatmap of gene expression for the differentially expressed genes.</title><p>(<bold>A</bold>) Analysis workflow for using differentially expressed gene (DEG) signature derived from cell lines to compute dependency score and to identify OSCC samples with similar gene signature and predicted dependency on YAP1 and WWTR1. Three representative OSCC cell lines with validated dependency patterns on YAP1 and WWTR1 were selected and used to generate a list of DEGs. Next, gene expression data for 315 OSCC samples (TCGA) were downloaded and for each sample, Z-score was generated for all the DEGs. Z-score for the upregulated genes were averaged, subtracted with the average of all Z-score for the downregulated genes, to derive the respective ‘dependency signature score’/”Compensable signature score’. Samples with YAP1 dependency signature score &gt;0.5 were considered as core samples predicted to be YAP1-dependent; Samples with WWTR1 dependency signature score &gt;0.5 were core samples for WWTR1-dependent; while samples with compensable signature score &gt;0.5 were considered core samples for which YAP1 and WWTR1 can compensate for one another. (<bold>B</bold>) Heatmap of the gene expression of all DEGs (supervised clustering), used to derive the ‘YAP1 dependency signature score’, ‘WWTR1 dependency signature score’ and ‘Compensable signature score’, from the nine representative OSCC cell lines.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Comparison of lymphocytes score, immune expression signature and tumor mutational burden.</title><p>(<bold>A</bold>) Lymphocytes score of core OSCC samples were derived from <xref ref-type="bibr" rid="bib84">Thorsson et al., 2018</xref>. OSCC with high WWTR1 dependency signature score have significantly higher lymphocyte infiltration when compared to the other two groups. (<bold>B</bold>) T-cells immune expression signatures (<xref ref-type="bibr" rid="bib84">Thorsson et al., 2018</xref>) of OSCC with high WWTR1 dependency signature score varied from the other two groups. Generally, they had significantly lower CD4 resting memory T-cells and higher CD8 T-cells than the other two groups. (<bold>C</bold>) Tumor mutational burden (number of nonsynonymous mutation/30 Mb) (TMB) of the core OSCC samples. OSCC with high WWTR1 dependency signature score had elevated TMB when compared to the other two groups. All error bars are shown as mean ± SD. Unpaired t-test with Welch’s correction was used for p-values calculation, due to unequal sample size (n = 43, 31, 30, respectively).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig6-figsupp2-v2.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Association with the immune-related gene <italic>PD-L1</italic> is specific to <italic>WWTR1</italic> but not other co-amplified genes in chromosome 3q25-28.</title><p>(<bold>A</bold>) To demonstrate that the association between WWTR1 dependency signatures with the immune-related gene <italic>PD-L1</italic> is specific to <italic>WWTR1</italic> but not due to the transcriptional activity of other co-amplified genes, we used sgRNA to deplete <italic>WWTR1, PIK3CA, TP63</italic>, and <italic>SOX2</italic> in the Cas9-expressing, WWTR1-dependent model ORL-214. Two distinct sgRNAs were used for each gene (1K and 2B). qPCR results revealed the strongest suppression of <italic>PD-L1</italic> gene expression upon WWTR1 knockout, but the expression remain largely unchanged when the other genes were knockout (<italic>PIK3CA, TP63,</italic> and <italic>SOX2</italic>). qPCR was performed in technical triplicates. Data are shown as mean ± SD (n = 3 technical repeats). (<bold>B</bold>) Global gene expression data measured by microarray of SCC2 cells transfected with control siRNA (siCTRL), or siRNA targeting <italic>YAP1</italic> (siYAP) and/or <italic>WWTR1</italic> (siTAZ) were retrieved from <xref ref-type="bibr" rid="bib35">Hiemer et al., 2015</xref> (GSE66949). Gene expression of <italic>PD-L1</italic> was used to correlate with that of <italic>WWTR1, PIK3CA, TP63</italic>, and <italic>SOX2</italic>. Only <italic>WWTR1</italic> gene expression showed significant positive correlation with that of <italic>PD-L1,</italic> despite the fact that <italic>PIK3CA, TP63</italic>, and <italic>SOX2</italic> were often co-amplified with <italic>WWTR1</italic> in OSCC.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57761-fig6-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-10"><title>OSCC with WWTR1 dependency signature and immune biomarkers</title><p>Among the plethora of diverse functions for YAP1 and WWTR1 evidence for their critical roles in mediating immune response have recently emerged (<xref ref-type="bibr" rid="bib27">Geng et al., 2017</xref>; <xref ref-type="bibr" rid="bib44">Janse van Rensburg et al., 2018</xref>; <xref ref-type="bibr" rid="bib65">Pan et al., 2019</xref>). Specifically, WWTR1 but not YAP1 was shown to be essential for T<sub>H</sub>17 cell differentiation (<xref ref-type="bibr" rid="bib27">Geng et al., 2017</xref>), and constitutively active WWTR1 (TAZ-S89A) was shown to induce PD-L1 expression to a much greater extent than YAP1 (YAP1-S127A) (<xref ref-type="bibr" rid="bib44">Janse van Rensburg et al., 2018</xref>). Consistently, the results from the enrichment analysis of WWTR1-dependent OSCC were dominated by immune-related hallmarks. To investigate the association of YAP1/WWTR1 dependency with the immunity of OSCC, we mined the previously defined immune landscape of core samples from TCGA for comparison. Using the stromal and immune signature defined previously (<xref ref-type="bibr" rid="bib92">Yoshihara et al., 2013</xref>), ssGSEA enrichment scores revealed that OSCC with high WWTR1 dependency signature score showed significantly lower stromal signature, but higher immune signature, when compared with OSCC of high YAP1 dependency or Compensable signature scores (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). This suggests an enrichment of immune cell infiltration among OSCC with high WWTR1 dependency signature score. Next, we also assessed the other immune-related scores from previous work (<xref ref-type="bibr" rid="bib84">Thorsson et al., 2018</xref>) and confirmed that these OSCC were associated with significantly enriched interferon-gamma (IFNγ) response signatures and reduced transforming growth factor-beta (TGFβ) response (<xref ref-type="fig" rid="fig6">Figure 6E</xref> and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A–B</xref>). Consistent with that, they also possess significantly higher cytolytic T cells (CD8) score than the other two groups (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). This interesting observation led us to postulate that OSCC cancers with a gene expression signature associated with WWTR1 dependency might be more vulnerable to checkpoint blockade. To extend this hypothesis, we examined the level of several predictive biomarkers for immune checkpoint inhibitor response that had been tested and validated in the clinical setting (<xref ref-type="bibr" rid="bib1">Ayers et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Cristescu et al., 2018</xref>). Interestingly, the PD-L1 mRNA expression and the 18-gene T-cell inflamed gene expression profile (GEP) enrichment scores of the OSCC with high WWTR1 dependency signature score were significantly higher than the other two groups (<xref ref-type="fig" rid="fig6">Figure 6F–G</xref>). They were also associated with higher tumor mutational burden (TMB) albeit not statistically significant when compared with the other two groups (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2C</xref>). To ensure that the association with immune signatures seen is specific to WWTR1 but not caused by other co-amplified genes in 3q25-28 (such as <italic>PIK3CA</italic>, <italic>TP63</italic>, and <italic>SOX2</italic>), we examined the changes in gene expression level of <italic>PD-L1</italic> upon depletion of <italic>WWTR1</italic> and other co-amplified genes. qPCR results revealed strongest suppression of <italic>PD-L1</italic> gene expression upon <italic>WWTR1</italic> knockout, but remain largely unchanged when the other genes were knockout (<italic>PIK3CA</italic>, <italic>TP63</italic>, and <italic>SOX2</italic>) (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3A</xref>). We also examined a microarray dataset from <xref ref-type="bibr" rid="bib35">Hiemer et al., 2015</xref> and showed that a significant correlation of <italic>WWTR1</italic> gene expression with <italic>PD-L1</italic> expression was observed, but no correlation in gene expression was seen between <italic>PIK3CA</italic>, <italic>TP63</italic> or <italic>SOX2</italic> and <italic>PD-L1</italic> (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3B</xref>). Together, these results suggested that OSCC resembling the gene signature with WWTR1-dependent cell lines may be associated with better respond to immunotherapy.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>New therapeutic targets are urgently needed for the development of OSCC treatment. However, genomics studies have shown that oncogenic mutations in OSCC are largely limited to <italic>PIK3CA</italic> and <italic>HRAS</italic> and even in these, mutations are only found in a small subset of patients. Therefore, determining the oncogenic pathways and specific therapeutic targets have not been straight forward for this disease. We performed genome-wide CRISPR-Cas9 screens in a unique collection of OSCC cell lines derived from patients with diverse risk habits to identify genetic vulnerabilities that can serve as a basis for further therapeutic development for OSCC. Adding to existing genomics datasets in OSCC, this approach identifies fitness genes required for the survival of cancer cells where targeting these will result in the killing of these cells. The majority of the cell lines used in this study were from Asian patients where OSCC is more prevalent, and where causative factors include betel quid chewing in addition to smoking that is more often found in Caucasian patients (<xref ref-type="bibr" rid="bib14">Cheong et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Kumar et al., 2016</xref>). The molecular drivers of these patients are under-characterized as genomics data on Asian patients remain limited (<xref ref-type="bibr" rid="bib40">India Project Team of the International Cancer Genome Consortium, 2013</xref>; <xref ref-type="bibr" rid="bib81">Su et al., 2017</xref>).</p><p>Here, we identified 918 fitness genes in OSCC. Pathway enrichment analysis revealed that these genes were highly associated with diverse cancers pathways, confirming the robustness of our screen and pipeline in identifying targetable genetic dependencies. These included known candidate genes that are already being investigated in clinical trials for OSCC or other cancers such as <italic>CDK6</italic>, <italic>PIK3CA</italic>, and <italic>FGFR1</italic>, as well as novel genes that are yet to be explored as therapeutic targets, including those within the oxidative stress pathway (<italic>KEAP1</italic>, <italic>NFE2L2).</italic> Notably, we showed that about 5% (45/918) of these genes are highly tractable with approved drugs, or have drugs that are in late-stage of clinical testing, demonstrating that these screens could help to prioritize drugs that could be repurposed for OSCC treatment. We compared our screens with previous genome-wide RNAi screens and found that candidate genes such as those relating to the cell cycle (<italic>CKAP5, KPNB1, RAN, TPX2</italic>, and <italic>KIF11)</italic> were also identified in our dataset (<xref ref-type="bibr" rid="bib55">Martens-de Kemp et al., 2013</xref>). However, due to stringent filtering of core-fitness genes (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Hart et al., 2014</xref>; <xref ref-type="bibr" rid="bib33">Hart et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Meyers et al., 2017</xref>), these were no longer within the list of OSCC non-core fitness genes.</p><p>Notably, the unique inclusion of several Asian OSCC models known to be associated with betel-quid chewing in our screen enabled us to identify that the NF-kB signaling pathway is among one of the most significantly enriched dependencies among betel-quid associated OSCC compared to cancers not associated with this risk habit. This finding is in line with the past studies reporting direct activation of the NF-kB signaling, upon treatment of OSCC cell lines with the extract of areca nut which is the main component in the betel quid (<xref ref-type="bibr" rid="bib15">Chiang et al., 2008</xref>; <xref ref-type="bibr" rid="bib54">Lin et al., 2005</xref>). By contrast, members of this signaling pathway (<italic>TRIM25, NFKB2, TNFAIP3</italic>) did not seem to be fitness genes in the other cell lines not associated with betel quid chewing, nor those from the Project Score or DepMap (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Meyers et al., 2017</xref>). Members of the NF-kB signaling pathways have been proposed as therapeutic targets for inflammatory diseases and cancers, with various types of inhibitors being developed. In the event of the development of NF-kB inhibitosr with promising clinical utililty in the future, it would be of interest to investigate if increase efficacy of this inhibitor would be seen among the betel-quid-associated OSCC. Appreciating this differences in dependencies in Asian OSCC that remains undiscovered in existing large genetic screens could have significant implications, especially when employing precision medicine in the different populations. We acknowledge, however, that further in-depth investigations including a larger sample size and further representative models, are needed in order to confirm our findings and to inform the basis of developing potential targeted therapy against the unique vulnerabilities among the Asian OSCC.</p><p>Driver mutations are often expected to be robust biomarkers in precision medicine. However, upon analysing the dependency profiles on cancer genes that are commonly mutated in HNSCC and those with driver mutations among our 21 OSCC cell lines, we show that with the exception of some genes with driver mutations leading to oncogene addiction (<italic>PIK3CA</italic>, <italic>HRAS</italic> and <italic>NFE2L2</italic>), most other driver mutations did not confer preferential gene dependency and their value as a drug target remains unclear.</p><p>Given the propensity of copy number alterations in driving OSCC, a ‘C’ class tumor (<xref ref-type="bibr" rid="bib83">The Cancer Genome Atlas Network, 2015</xref>; <xref ref-type="bibr" rid="bib16">Ciriello et al., 2013</xref>), we investigated the commonly amplified genomic regions to look for functionally important candidate genes. One of the pathways that was significantly enriched was the Hippo pathway. Within this pathway, we focused our analyses on <italic>YAP1</italic> and <italic>WWTR1</italic>, two paralogs that show differential dependency pattern in our 21 OSCC cell lines. Copy number amplifications of 11q22 and 3q25 (where YAP1 and WWTR1 are located, respectively) are common events reported in OSCC, often in mutual exclusive manner (<xref ref-type="bibr" rid="bib12">Campbell et al., 2018</xref>; <xref ref-type="bibr" rid="bib89">Wang et al., 2018</xref>). These two genes are the major effectors negatively regulated by the Hippo pathway that is increasingly reported to play multiple roles in carcinogenesis, as reviewed comprehensively in recent years (<xref ref-type="bibr" rid="bib19">Dey et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Santos-de-Frutos et al., 2019</xref>). However, the majority of the studies focused on either one of the paralogs or had assumed similar functions between paralogs (<xref ref-type="bibr" rid="bib75">Santos-de-Frutos et al., 2019</xref>; <xref ref-type="bibr" rid="bib94">Zanconato et al., 2016</xref>). Emerging evidence demonstrate that YAP1 and WWTR1 have distinct roles where they partner with different transcription factors, drive different downstream effectors and also modulate the tumor microenvironment distinctively (<xref ref-type="bibr" rid="bib11">Callus et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Janse van Rensburg et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Kaan et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Plouffe et al., 2018</xref>). Our study revealed the intricate dominance of dependency on either one of the paralogs, despite the other not being deleted or loss. More intriguingly, the subset of lines thought not to be dependent on either YAP1 or WWTR1, were actually lines where the remaining paralog is able to compensate for the lost paralog, therefore, enabling the cells to continue surviving.</p><p>In the context of OSCC/HNSCC, studies demonstrating the distinct roles and regulatory mechanism of YAP1 and WWTR1 are emerging. Analysis of genome-wide transcriptional changes upon knockdown of YAP1 or WWTR1 in OSCC showed that YAP1 had a more prominent role in transcriptional regulation (<xref ref-type="bibr" rid="bib35">Hiemer et al., 2015</xref>). Using a tongue orthotopic mouse model with the deletion of MOB1A/B, <xref ref-type="bibr" rid="bib64">Omori et al., 2020</xref> provided strong evidence that YAP1 acted as a strong driver in OSCC tumor initiation and progression, whereby WWTR1 did not seems to play an equivalent role (<xref ref-type="bibr" rid="bib64">Omori et al., 2020</xref>). The differences between YAP1 and WWTR1 can also be further exemplified in terms of their interaction with upstream/downstream pathways, that would involve other frequently co-amplified genes such as <italic>PIK3CA, TP63</italic>, and <italic>SOX2</italic>. The co-occurrence of amplifications in these genes that are part of the extended signaling network of the Hippo pathway underscores the critical role of the Hippo pathway in driving the OSCC tumorigenesis. Overexpression of PIK3CA was shown to be correlated with YAP1 activation and associated with poor clinical outcome (<xref ref-type="bibr" rid="bib25">García-Escudero et al., 2018</xref>). Further, the activation of the PI3K through mitogenic signaling inhibits the Hippo pathway leading to YAP1 activation and cell growth (<xref ref-type="bibr" rid="bib22">Fan et al., 2013</xref>). On the other hand, WWTR1 was shown to act upstream of SOX2, facilitating stemnesses in HNSCC (<xref ref-type="bibr" rid="bib52">Li et al., 2019</xref>). Intriguingly, while WWTR1 knockdown led to reduction of SOX2 mRNA and protein expression, this was not seen when YAP1 was knockdown in the HNSCC cells (Cal27 and Fadu) (<xref ref-type="bibr" rid="bib52">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Huang et al., 2017</xref>). In support of that, an inverse relationship between the expression levels of YAP1 and ΔNp63 were reported in lung SCC tumor samples (<xref ref-type="bibr" rid="bib39">Huang et al., 2017</xref>). However, this was not seen in HNSCC tumor samples and cell lines (<xref ref-type="bibr" rid="bib26">Ge et al., 2011</xref>), suggesting a cancer/context-specific regulatory mechanism might be in place. Consistent with the oncogenic roles of YAP1 reported in OSCC (<xref ref-type="bibr" rid="bib35">Hiemer et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Omori et al., 2020</xref>), another study showed that p63, together with the co-expressing chromotin remodeling factor, ACTL6A, can drive YAP1 activation, suppressing differentiation and promoting cell proliferation in HNSCC (<xref ref-type="bibr" rid="bib72">Saladi et al., 2017</xref>). Similar observations between WWTR1 and TP63 have not been reported thus far. Hence, understanding the context in which the OSCC lines can be either YAP1-dependent/WWTR1-dependent or having compensable YAP1/WWTR1 is important, as YAP1 and WWTR1-dependency appear to be associated with the enrichment of distinct pathways. Current inhibitors of YAP1 such as verteporfin and CA3 that blocks its interactions with the TEAD transcription factors also targets WWTR1 (<xref ref-type="bibr" rid="bib79">Song et al., 2018</xref>; <xref ref-type="bibr" rid="bib95">Zhang et al., 2015</xref>); therefore, this data underscores the need to develop more specific inhibitors to prevent the targeting of many different downstream pathways. Intriguingly, we also observed enrichment of PIK3CA mutant (p=0.0003) among OSCC lines that are compensable for YAP1 or WWTR1. As recent studies have provided evidence that YAP1 and WWTR1 could mediate mutant PIK3CA-induced tumorigenesis (<xref ref-type="bibr" rid="bib96">Zhao et al., 2018</xref>) andother studies also suggested crosstalk between these Hippo pathway effectors with the PI3K-Akt pathway (<xref ref-type="bibr" rid="bib25">García-Escudero et al., 2018</xref>), confirmatory and mechanistic studies will be needed to delineate why YAP1 and WWTR1 function can be compensated in these <italic>PIK3CA</italic>-mutated cell lines, while distinct dependencies on either paralog are observed in <italic>PIK3CA</italic> wild-type lines. The functional loss of mutated <italic>FAT1</italic> has also been reported to be associated with YAP1 activation in head and neck cancer (<xref ref-type="bibr" rid="bib56">Martin et al., 2018</xref>), however, no enrichment of <italic>FAT1</italic> mutation was seen among the YAP1-dependent nor WWTR1-dependent models in this study.</p><p>We also provided tissue-relevant insights of our findings by including analysis of the OSCC tumors from TCGA. Since <italic>YAP1</italic> and <italic>WWTR1</italic> are transcription co-factors that could regulate a plethora of gene transcriptions, we devised an analysis workflow utilizing the DEGs among the three subsets of OSCC models. We have identified 105 OSCC tumors that show highly similar gene expression signature as the cell lines, which are predicted to share the same dependency pattern. Similarly, comparison of the OSCC tumors based on their gene signatures revealed significant differences in terms of their enriched gene sets and immune signatures. As checkpoint blockade is approved for the treatment of recurrent and metastatic OSCC, understanding how YAP1 and WWTR1 influence the immune microenvironment could provide clues on the combination therapies that could increase the subset of patients responding checkpoint inhibitors. In particular, OSCC with high WWTR1 dependency signature score are significantly associated with various biomarkers that were predicted to show good response toward checkpoint inhibitors. This finding is consistent with the recent discovery that constitutively active WWTR1 induces PD-L1 expression, to a greater extent than YAP1 (<xref ref-type="bibr" rid="bib44">Janse van Rensburg et al., 2018</xref>), and that tumors with YAP1 amplifications have low T-cell infiltration (<xref ref-type="bibr" rid="bib74">Saloura et al., 2019</xref>). These observations have clinical implication as anti-PD1 is an approved therapy for HNSCC and therefore, further investigation and validation will be needed to confirm this observation and its clinical impact. While many companies are developing novel inhibitors targeting YAP1-TEAD transcriptional activity, which should be effective against all other OSCC, combination with checkpoint inhibitor could be considered for those OSCC with WWTR1 dependency signatures. We acknowledge, however, that whilst the dependency observed in cell lines could be recapitulated in OSCC, OSCC tissues would be much more heterogenous and could harbor specific genetic abrogations that could be the dominant driver of tumorigenesis. Therefore, further validation of the association between WWTR1-dependency signature and response to checkpoint inhibitors should be validated particularly in the context of clinical trials involving checkpoint inhibitors.</p><p>The roles of the Hippo signaling pathway and its effectors YAP1 and WWTR1 in cancer immunity remains unclear. The inactivation of the Hippo pathway through the loss of LATS1/2 was reported to cause the induction of anti-tumor immune response and inhibition of HNSCC tumor growth, via the hyperactivation of YAP1/WWTR1 (<xref ref-type="bibr" rid="bib4">Barth et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Moroishi et al., 2016</xref>). This demonstrates that components of the Hippo signaling pathway could also modulate the host tumor microenvironment in addition to what we have demonstrsated in cancer cells. The design and models used in our study have not been set up to examine this where the inherent limitation of using cell lines do not consider the components of the tumor microenvironment in the in vitro screening. Nonetheless, our findings provided a novel insight linking the intricate dependency on YAP1 and WWTR1 with differential state of the immune microenvironment in OSCC which warrants further investigation with the use of immune-competent mouse models, before further clinical evaluation can be made.</p><p>In summary, our study is the first large-scale CRISPR-Cas9 screen and focused analysis conducted on large panels of Asian derived OSCC cell lines and provided a cancer-specific overview of the fitness genes landscape, affording opportunities for further therapeutic targets development. The ability to scrutinize the functional genomics of these fitness genes/pathways to a greater detail was also exemplified in this study.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell lines</title><p>Fourteen OSCC cell lines (referred to as the ORL- series) were derived spontaneously from surgically resected OSCC tissue specimens in Cancer Research Malaysia. Briefly, tissues were collected in α-MEM containing 20% (v/v) FBS, 200 iu/l penicillin, 200 μg/ml streptomycin and 0.1 μg/ml of fungizone. Subsequently, tissues were washed in absolute ethanol for 20–30 s and then washed twice with phosphate-buffered saline (PBS) under sterile conditions. Tissues were minced, washed twice in culture media and re-suspended in α-MEM containing 20% (v/v) FBS, 200 iu/l penicillin, 200 μg/ml streptomycin, 0.4 ng/ml EGF, 2 μg/ml hydrocortisone and 2 mM L-glutamine, and seeded into tissue culture dishes. Cultures were continuously maintained for more than 100 population doublings (<xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>). HSC-2, HSC-4, and SCC-9 were isolated from squamous cell carcinoma of various oral regions, by which the surgically excised tumors were minced and disaggregated to single cells. Epithelial cells proliferated from the explants were then sub-cultured continuously (<xref ref-type="bibr" rid="bib62">Momose et al., 1989</xref>; <xref ref-type="bibr" rid="bib71">Rheinwald and Beckett, 1981</xref>). No special immortalization methods were detailed for BICR10, PE/CA-PJ15, Ho-1-U-1 and SAS (<xref ref-type="bibr" rid="bib20">Edington et al., 1995</xref>, <xref ref-type="bibr" rid="bib7">Berndt et al., 1997</xref>, <xref ref-type="bibr" rid="bib61">Miyauchi et al., 1985</xref>, <xref ref-type="bibr" rid="bib82">Takahashi et al., 1989</xref>) nor for all other cell lines used in this study. All these OSCC cells lines were maintained in Dulbecco’s Modified Eagle’s Medium(DMEM)/Nutrient Mixture F-12 medium (Gibco) supplemented with 10% (v/v) heat inactivated fetal bovine serum (Gibco), and 100 IU Penicillin/Streptomycin (Gibco). All lines were incubated in a humidified atmosphere of 5% CO2 at 37°C. The lines were authenticated by STR profiling using Promega PowerPlex16HS Assay (Promega, Wisconsin, United States), with the data giving more than 80% match to the respective donor or reference as deposited in the databases of cell line resources (such as ATCC, DSMZ, JCRB). Cell lines were routinely tested for the presence of mycoplasma with MycoAlert mycoplasma detection kit (Lonza, Basel, Switzerland). Only mycoplasma-free cell lines were used in all experimentation.</p></sec><sec id="s4-2"><title>Plasmid transfection and virus transduction</title><p>HEK293 cells were transfected using jetPRIME transfection reagent (Polyplus Transfection) according to the manufacturer’s instructions. Briefly, transfection complex consisting of jetPRIME buffer, jetPRIME reagent, vector of interest, pMD2.G and psPAX2 were prepared and mixed with Opti-MEM (Gibco). Next, the transfection complex medium was added to HEK293 cells with 90% confluency. After overnight incubation at 37°C, 5% CO<sub>2</sub>, transfection complex medium was replaced with fresh DMEM high glucose (Gibco) complete medium. Medium containing virus was collected at 48- and 72 hr post-transfection and filtered using PVDF 0.45 μm syringe filter.</p><p>To perform virus transduction, selected cell lines were transduced with lentivirus containing the vector of interest, in the presence of 8 μg/ml polybrene. After overnight incubation, medium containing lentivirus was replaced with fresh DMEM/F12 complete medium. Cells were incubated for 48 hr and harvested to evaluate the transduction efficiency via flow cytometry analysis with BD LSR Fortessa X-20 cell analyser (BD Biosciences). Gating strategy for flow cytometry analysis of transduced cells carrying fluorescence marker is exemplified in <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>.</p></sec><sec id="s4-3"><title>Generation of Cas9-expressing cell lines</title><p>Selected cell lines were transduced with lentivirus containing the pKLV2-EF1α-Cas9Bsd-W (Addgene plasmid # 68343, gift from Kosuke Yusa). Cells stably expressing Cas9 enzyme was established via blasticidin selection 3 days post-transduction. Cas9 enzyme cutting efficiency was routinely checked via lentivirus transduction of the reporter plasmid pKLV2-U6gRNA5(gGFP)-PGKmCherry2AGFP-W (Addgene plasmid # 67982, gift from Kosuke Yusa). The efficiency of Cas9 cutting activity was accessed using a reporter plasmid and analyzed using flow cytometry analysis. The screening will only be conducted on those cell lines with &gt;80% Cas9 cutting activity, as indicated by the efficiency of GFP knockout in cell lines transduced with the reporter plasmid.</p></sec><sec id="s4-4"><title>Genome-wide CRISPR-Cas9 knockout screening</title><p>The Human Improved Genome-wide Knockout CRISPR Library v1 (Addgene plasmid #67989, gift from Kosuke Yusa) containing 90,709 gRNAs targeting a total number of 18,010 protein-coding genes was used in the genome-wide CRISPR-Cas9 screening (<xref ref-type="bibr" rid="bib86">Tzelepis et al., 2016</xref>). For each of the OSCC cell lines, a total of 60 million Cas9-expressing cells were transduced with the CRISPR library lentivirus at a multiplicity of infection (MOI) of 0.3. Polybrene at 8 μg/ml was added to increase transduction efficiency. All screenings were performed in triplicates. Library representation was evaluated by the percentage of BFP-expressing cells, determined using flow cytometry on day 4 post-transduction. The library representation was minimally kept at 100X coverage of the library, equivalent to 30 million cells total, or 10 million cells expressing BFP before proceeding to puromycin selection (2.0 μg/ml) for 3–4 days, to select for successfully transduced cells. Following complete selection with puromycin, a minimum of 75 million cells were maintained throughout the 18 days screen. BFP expression was monitored to ensure selection was adequate. On day 18 post-transduction, 60 million cells were pelleted down for genomic DNA extraction.</p></sec><sec id="s4-5"><title>Genomic DNA extraction of post-CRISPR screened cells</title><p>Genomic DNA was extracted from 60 million post-CRISPR screened cells using QIAGEN blood and cell culture DNA Maxi kit (Qiagen), according to manufacturer’s instruction. Extracted DNA was quantified using Qubit 2.0 fluorometer (Thermo Fisher Scientific).</p></sec><sec id="s4-6"><title>Library preparation of genomic DNA</title><p>To prepare and generate Illumina libraries for deep sequencing, amplification of sgRNA was performed using Q5 Hot Start High-Fidelity 2 × Master Mix and forward/reverse primers pair (gLibrary-HiSeq_50bp-SE-U1 F and R) in 50 μl reaction, as previously described<sup>4</sup>. For the CRISPR library v1 plasmid, 10 independent PCR reactions were set up using 2.0 μg of the plasmid. While for the CRISPR-screen cell lines, 2.0 μg of genomic DNA harvested from day-18 post-transduction was used in each of the 36 independent PCR reactions. The PCR conditions were as follows: 98°C for 30 s, 26–28 cycles of 98°C for 10 s, 61°C for 15 s and 72°C for 20 s, and the final extension, 72°C for 2 min. The PCR products were analyzed on 2% agarose gel and additional PCR cycles were added if necessary.</p><p>About 5 μl of PCR products were pooled from all 36 reactions and QIAquick PCR purification kit (QIAGEN) was used to purify the amplified gRNA. Concentration of purified PCR products were quantified with Qubit dsDNA broad-range (BR) assay kit (Thermo Fisher Scientific), using the Qubit 2.0 fluorometer (Thermo Fisher Scientific). PCR enrichment was then carried out using 200 pg of purified PCR products with 2x KAPA HotStart ReadyMix. 1 μl of forward P5 fusion primer (PE 1.0 p5 Top_PE_C) and 1 μl of different reverse primers (indexed iPCRTags) were used. The PCR conditions were as follows: 98°C for 30 s, 10–12 cycles of 98°C for 10 s, 66°C for 15 s and 72°C for 20 s, and the final extension, 72°C for 5 min. Finally, SPRISelect beads (Beckman Coulter) were used to purify the PCR products at a PCR-product-to-bead ratio of 1:0.8. Purified libraries were dissolved in 30 μl nuclease-free water and quantified using Agilent High Sensitivity DNA kit (Agilent Technologies) on Agilent 2100 Bioanalyzer (Agilent Technologies).</p></sec><sec id="s4-7"><title>Deep sequencing of post-CRISPR screen libraries</title><p>Purified libraries of the triplicate screens tagged with different iPCR tags were pooled and sequenced at about 300x coverage on Illumina HiSeq 2500 with 19 bp single-end (SE) deep sequencing at the Wellcome Sanger Institute (WSI). About 30–40 million reads were obtained for each of the three replicates. Sequences of the Read one sequencing primer (U6-Illumina-seq2) and index sequencing primer can be found in <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>.</p></sec><sec id="s4-8"><title>CRISPR data processing</title><p>sgRNA raw counts in each triplicate of the CRISPR screen were generated using the in-house script developed at WSI, as previously described (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Iorio et al., 2018</xref>). The CRISPRcleanR tool was downloaded as an R package (<ext-link ext-link-type="uri" xlink:href="https://github.com/francescojm/CRISPRcleanR">https://github.com/francescojm/CRISPRcleanR</ext-link>) and used for pre-processing of the sgRNA raw counts (<xref ref-type="bibr" rid="bib42">Iorio et al., 2018</xref>). This tool allows for an unsupervised correction for copy number amplification bias and other gene-independent responses when subjected to CRISPR-Cas9 targeting, hence reducing false-positive call for essential genes (<xref ref-type="bibr" rid="bib42">Iorio et al., 2018</xref>). Briefly, the <italic>ccr.NormfoldChanges</italic> function was used to compute the median-ratio normalization of raw counts and log2 fold-changes for all sgRNAs, averaging from triplicates. The built-in KY_library_v1.0 was used for library annotation and sgRNAs with read counts less than 30 in the plasmid were excluded. Then, the <italic>ccr.logFCs2chromPos</italic> and <italic>ccr.GWclean</italic> function of the CRISPRcleanR were used to perform genome mapping and sorting of the sgRNAs, followed by the correction of the gene-independent responses to compute corrected log-fold changes. As part of the quality assessment, Pearson correlation test was used to compare sgRNA raw counts between replicates of the same cell line, while precision-recall was assessed as previously described, using sets of known essential and non-essential genes (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>).</p><p>The corrected gene-level log-fold changes were quantile normalized and corrected for batch effect using ComBat (<xref ref-type="bibr" rid="bib50">Leek et al., 2012</xref>), we refer this CRISPRcleanR corrected, quantile normalized and ComBat corrected log-fold changes as the ‘CRISPR score’, with a negative value indicating the extent of depletion of sgRNA counts targeting the gene when compared with the initial plasmid library.</p><p>The function <italic>ccr.correctCounts</italic> used inverse-transformation method to generate CRISPRcleanR-corrected counts, which is used as input files for MAGeCK analysis (<xref ref-type="bibr" rid="bib42">Iorio et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Li et al., 2014</xref>). For each of the 21 OSCC cell lines, MAGeCK analysis was performed using default parameters, except that normalization is set to ‘none’, as the input corrected counts had already been normalized using CRISPRcleanR. A false discovery rate cut-off of 5% (FDR ≤ 0.05) was applied to identify the significantly depleted genes in each cell line, defined here as MAGeCK hits.</p><p>To remove potential false-positive hits, RNA-seq expression data of each of the 21 cell lines were utilized to filter out MAGeCK hits with negligibly low or no reported reads (Fragments Per Kilobase of transcript per Million mapped reads (FPKM) &lt;0.5).</p><p>Next, in order to identify and prioritize genes that can be safely targeted for the treatment of OSCC, we curated a list of core fitness essential genes from four different sources and used it to further filter the list of MAGeCK hits from each cell line. The first two sources were the core essential genes (CEG) list, published by <xref ref-type="bibr" rid="bib32">Hart et al., 2014</xref> and the subsequent updated CEG2 list, published in 2017 (<xref ref-type="bibr" rid="bib33">Hart et al., 2017</xref>). The third source is the ‘common-essential genes’, downloaded from Broad’s Institute Cancer Dependency Map database (18Q3 release) (<xref ref-type="bibr" rid="bib59">Meyers et al., 2017</xref>). We also utilized the list of pan-cancer core-fitness genes compiled by Project Score of Cancer Dependency Map at WSI (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>). The full list of all genes from these four sources was tabulated in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></sec><sec id="s4-9"><title>WES and identification of driver mutation</title><p>All 21 OSCC cell lines were subjected to WES at the WSI using HiSeq2500. WES data were processed using an established pipeline as previously described to identify driver mutations (<xref ref-type="bibr" rid="bib41">Iorio et al., 2016</xref>). A total of 43 genes with driver mutation in at least one cell line were identified (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>).</p></sec><sec id="s4-10"><title>Pathway enrichment analysis</title><p>KEGG pathway enrichment analysis was performed using the over-representation analysis function at the ConsensusPathDB (<ext-link ext-link-type="uri" xlink:href="http://ConsensusPathDB.org">http://ConsensusPathDB.org</ext-link>) (<xref ref-type="bibr" rid="bib46">Kamburov et al., 2013</xref>). A threshold of minimum two genes overlapping with the gene set of a given pathway and p-value cut-off of 0.05 were applied. Enriched pathways were ranked by q-value.</p></sec><sec id="s4-11"><title>Differential fitness genes analysis for betel-quid-associated OSCCs</title><p>OSCC models with known betel quid chewing as the only risk habit were included in this analysis – (n = 7; ORL-115, ORL-136, ORL-174, ORL-195, ORL-204, ORL-207 and ORL-214), to compare with the other OSCCs not associated with betel quid chewing (n = 14; ORL-48, ORL-150, ORL-153, ORL-156, ORL-166, ORL-188, ORL-215, BICR10, Ho-1-u-1, HSC-2, HSC-4, SAS, SCC-9, PE/CA-PJ15). Venn diagram was used to depict the number of unique and overlapping fitness genes that are found between those OSCCs with or without association with betel quid chewing.</p></sec><sec id="s4-12"><title>Functional classification and tractability assessment</title><p>To assess the tractability of the 918 non-core fitness genes, we utilized the genome-wide target tractability assessment pipeline as previously described (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="bibr" rid="bib9">Brown et al., 2018</xref>). Based on assessment for small molecules tractability, essential genes were assigned into tractability bucket 1 to 10, with decreasing tractability. Next, essential genes in each tractability group were further classified into protein classes using the PANTHER database online tool (<ext-link ext-link-type="uri" xlink:href="http://www.pantherdb.org/">http://www.pantherdb.org/</ext-link>) (<xref ref-type="bibr" rid="bib60">Mi et al., 2013</xref>).</p></sec><sec id="s4-13"><title>Validation sgRNA design and cloning</title><p>To validate the results obtained from the screen, individual targeted genetic knockouts were generated using CRISPR/Cas9 and plasmid expressing sgRNAs targeting the gene of interest. Two sgRNA sequences were used for each target gene, one was selected from the CRISPR library v1 while another sequence was designed using the Genetic Perturbation Platform (GPP) web portal (<ext-link ext-link-type="uri" xlink:href="https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design">https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design</ext-link>). List of sgRNA used and their sequences can be found in <xref ref-type="supplementary-material" rid="supp11">Supplementary file 11</xref>. pKLV2-U6gRNA5(BbsI)-PGKpuro2ABFP-W and pKLV2-U6gRNA5(BbsI) PGKpuro2AmCherry-W were linearized using <italic>BbsI</italic> enzyme (NEB R0539S) and the concentration was adjusted to 20 ng/μL. Target oligos were phosphorylated and annealed using T4 PNK (NEB M0201). The thermocycler condition used are as follows: 37°C for 30 min, 95°C for 5 min, followed by a ramp down to 25°C at 0.1°C /s. The annealed oligos were next diluted twice for prior to ligation: 1st dilution = 139 μL EB buffer + 2 μL of 10 μM double-stranded oligos; 2nd dilution = 57 μL EB buffer + 3 μL of 1st dilution. Following that, overnight ligation at 4°C was carried out using T4 ligase (NEB M0202S) and 10X ligase buffer (NEB M0202S). The ligation products were then transformed into DH5α chemically- generated competent cells and plated onto Luria Broth (LB) agar plates containing 100 μg/ml Ampicillin. The plasmids were then extracted using QIAprep Spin Miniprep Kit (QIAGEN) and the sgRNA sequences were verified by Sanger sequencing prior to use.</p></sec><sec id="s4-14"><title>Co-competition assay</title><p>The relative growth rate of sgRNA-transduced and non-transduced cells was compared using co-competiton assay, as described previously (<xref ref-type="bibr" rid="bib6">Behan et al., 2019</xref>; <xref ref-type="bibr" rid="bib86">Tzelepis et al., 2016</xref>). Briefly, in order to achieve single gene-specific knockout, the Cas9-expressing cell lines were transduced at 30–70% transduction efficiency, with lentivirus carrying gene-specific sgRNA in pKLV2-U6gRNA5(BbsI)-PGKpuro2ABFP-W. Using flow cytometry, the percentage of BFP-positive sgRNA-transduced cells was measured between day 4 and day 18 post-transduction. The results obtained from days 8, 11, 15 to 18 were normalized to the percentage of BFP-positive transduced cells on day 4 or 6 to investigate the relative growth changes of the transduced population following gene depletion. For each target gene (<italic>YAP1</italic> and <italic>WWTR1</italic>), two different sgRNA were used, one from the Kosuke Yusa’s CRISPR Library v1 (‘Y1K’ – sgRNA targeting YAP1; ‘W1K – sgRNA targeting WWTR1’) and another independently designed sgRNA using Broad’s sgRNA-designer tool (‘Y2B’ – sgRNA targeting YAP1; ‘W2B’ – sgRNA targeting WWTR1). sgRNA targeting a core fitness gene, Polo-like kinase 1 (<italic>PLK1</italic>) was included as a positive control, choline acetyltransferase (<italic>CHAT</italic>)-targeting sgRNA was used as a non-fitness gene negative control and a non-targeting (NT) sgRNA w also included.</p><p>To achieve double gene knockout, sgRNAs targeting two different genes were cloned into either one of the plasmids tagged with BFP or mCherry (pKLV2-U6gRNA5(BbsI)-PGKpuro2ABFP-W or pKLV2-U6gRNA5(BbsI)-PGKpuro2AmCherry-W). Thereafter, the changes in the BFP- and mCherry double-positive cell population was measured as mentioned above.</p></sec><sec id="s4-15"><title>Lysates preparation and western blotting</title><p>To determine the baseline protein expression level, OSCC parental cell lines were seeded in 100 mm<sup>3</sup> dish and cultured until they reached 70–80% confluency. To assess the differential expression of the protein of interest after gene knockdown, Cas9-expressing cells were transduced with the target sgRNA at above 90% transduction efficiency. Next day, transduced cells were selected using 2 μg/ml of Puromycin. Day four post-transduction, percentage of BFP-expressing cells were determined using flow cytometry and total cell lysates (TCL) were extracted with RIPA buffer (50 mM Tris pH8, 1% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 150 mM NaCl) supplemented with Halt Protease and Phosphatase Inhibitor (PI) Cocktail (Pierce Biotechnology) on ice. TCL was collected by centrifugation and quantified using the BCA method (Thermo Fisher Scientific). About 20 µg of the TCL was resolved on SDS-PAGE gel and proteins were transferred onto PVDF membranes (Millipore). Membranes were blocked with 5% (w/v) milk in TBST (0.1% (v/v) Tween 20) and probed with primary antibodies (1:1000 dilution in 1% (w/v) BSA) overnight at 4°C. Horseradish peroxidase (HRP)-conjugated secondary antibodies (1:10,000 dilution in 5% milk) were probed for one hour at room temperature. For signal development, WesternBright Quantum HRP substrate (Advansta Inc) was used and visualized using the FluorChem HD2 imaging systems (Alpha Innotech). To normalize for loading, the blots were re-probed with an anti-tubulin monoclonal antibody (1:1000 dilution in 1% BSA) and processed as described above. List of primary and secondary antibodies used is found in <xref ref-type="supplementary-material" rid="supp12">Supplementary file 12</xref>. Uncropped western blot images can be found in <xref ref-type="supplementary-material" rid="supp13">Supplementary file 13</xref>.</p></sec><sec id="s4-16"><title>Total RNA extraction and qPCR</title><p>Cas9-expressing cells were transduced with selected sgRNA to achieve single gene or double gene knockout, as described above. On day 4 post-transduction, total RNA was extracted using TRIzol Reagent (Thermo Fisher Scientific). Total RNA (1 μg) was used for reverse transcription to complementary DNA (cDNA) using high-capacity cDNA reverse transcription kit (Applied Biosystems). Real-time quantitative PCR was performed using 1 μl of 5x diluted cDNA with PowerUp SYBR Green Master Mix and corresponding primers in 7500 Real-Time PCR System (Applied Biosystem). All reactions were performed in technical triplicates and repeated twice. Cycling conditions used are as follows: 50°C for 2 min, 95°C for 2 min, 40 cycles of 95°C for 15 s, and 60°C for 1 min. A default melt curve stage was included to allow inspection of primer specificity. Ribosomal protein L13 (RPL13) was used as an endogenous reference control for normalization. Sequences of all primers used can be found in <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>.</p></sec><sec id="s4-17"><title>Clonogenic assay</title><p>On 4- or 6 days post-transduction of sgRNA-containing lentiviruses, 2000 cells were seeded into six-well plate. After a week, cells were fixed using ice-cold methanol followed by staining with crystal violet solution.</p></sec><sec id="s4-18"><title>Cell viability assay</title><p>The 3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide (MTT) assay was used to access the effect of target gene knockdown/knockout on cell viability. Briefly, 4- or 6 days post-transduction with sgRNA, 2000 cells were seeded in triplicates in 96-well plate. 72 hr later, 50 μl MTT was added to each well and incubated for 4 hr at 37°C. After removing the media, 150 μl dimethyl sulfoxide was added to dissolve the formazan crystal and optical density was measured using Synergy H1M microplate reader (BioTek Instruments, USA) at 570 nm.</p></sec><sec id="s4-19"><title>Apoptosis assay</title><p>On 4- or 6 days post-transduction of sgRNA-containing lentiviruses, 30,000 cells were seeded into 24-well plate and harvested after 72 hr. Cells were pelleted down and washed with PBS. For detection of apoptotic cells, the cell pellet was resuspended in 1x Annexin V buffer containing 2.5 μl of Annexin V solution (BD Biosciences) and 2.5 μl of propidium iodide and incubated for 15 min in the dark. The proportion of apoptotic cells were analyzed using the LSR Fortessa X-20 cell analyser (BD Biosciences) and FlowJo (version 10.5.3, BD Biosciences), considering all single- and double-stained cells as apoptotic cells. Gating strategy for detection of apoptotic cells using flow cytometry can be found in <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>.</p></sec><sec id="s4-20"><title>DEGs signature based on dependency on YAP1 or WWTR1</title><p>Three representative cell lines with validated dependency on YAP1 or WWTR1 were used to derive gene expression signatures. ‘YAP1-dependent’ – ORL-48, ORL-204, SAS; ‘WWTR1-dependent’ – ORL-214, PE/CA-PJ15, ORL-174; ‘Compensable’ – BICR10, HSC-2 and HSC-4. DEGs for each group were computed using the limma package (Bioconductor) on the iRAP-processed, ComBat corrected FPKM matrix for these nine cell lines. Non-overlapping DEGs with significant p-value threshold &lt;0.01 and log fold change &gt;2 were retained. The final list of DEGs is found in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. Gene expression data of the HNSCC cohort in TCGA in the form of RSEM was downloaded from cbioportal (<ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/">https://www.cbioportal.org/</ext-link>) (<xref ref-type="bibr" rid="bib24">Gao et al., 2013</xref>). Gene expressions of all DEGs were then extracted for the 315 OSCC samples.</p><p>For all DEGs, Z-score was computed and a ‘dependency signature score’/ ‘compensable signature score’ was generated for each cell line/tumor sample, taking the difference between the average of all Z-score of upregulated DEGs and that of downregulated DEGs. For example, ‘YAP1-dependency signature score’ = (average of all Z-score of upregulated DEGs among YAP1-dependent cell lines) - (average of all Z-score of downregulated DEGs among YAP1-dependent cell lines).</p><p>Subsequently, cell lines and OSCC tumors were analyzed using hierarchical clustering and visualize with heatmap (generated using Morpheus, Broad Institute: <ext-link ext-link-type="uri" xlink:href="https://software.broadinstitute.org/morpheus">https://software.broadinstitute.org/morpheus</ext-link>) using the ‘YAP1 dependency signature score’, ‘WWTR1 dependency signature score’ and ‘Compensable signature score’.</p></sec><sec id="s4-21"><title>Correlation analysis and gene set enrichment analysis</title><p>Core OSCC samples with &gt;0.5 dependency signature score in one of the three groups were identified. There was a total of 43 OSCC samples with high YAP1 dependency signature score; 31 with high WWTR1 dependency signature score and 30 with high Compensable signature score. Clinical and genomic data of these core OSCC samples were accessed from cBioPortal (<xref ref-type="bibr" rid="bib24">Gao et al., 2013</xref>). Gene set enrichment analyses (GSEA) for the three groups of core OSCC samples were performed using the Broad Institute’s Molecular Signatures Database (MSigDB) hallmark gene sets as reference database (<xref ref-type="bibr" rid="bib53">Liberzon et al., 2015</xref>). Signatures reflective of the immune landscape of these core OSCC samples were extracted from the supplementary table 1 of <xref ref-type="bibr" rid="bib84">Thorsson et al., 2018</xref>. Single-sample GSEA (ssGSEA) was performed using the GenePatterns web-tool (<ext-link ext-link-type="uri" xlink:href="https://www.genepattern.org/">https://www.genepattern.org/</ext-link>) (<xref ref-type="bibr" rid="bib70">Reich et al., 2006</xref>) with the 18-genes T-cell inflamed Gene Expression Profile (GEP) gene set, which was found to be predictive biomarkers for response to pembrolizumab in HNSCC clinical trial (<xref ref-type="bibr" rid="bib1">Ayers et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Cristescu et al., 2018</xref>).</p></sec><sec id="s4-22"><title>Statistical analysis</title><p>All statistical significance analyses were performed using unpaired parametric two-tailed t-test in GraphPad Prism (version 8, GraphPad Software Inc) unless otherwise stated. Unpaired t-test with Welch’s correction (Welch’s t-test) was used for all analyses in <xref ref-type="fig" rid="fig6">Figure 6</xref> and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref> due to unequal sample size. For estimation of the Pearson correlation, the <italic>cor.test</italic> function in Rstudio (version 1.2.1335, Rstudio Inc) was used.</p></sec><sec id="s4-23"><title>Code availability</title><p>No unreported or custom code was used in this study. Open source softwares were used for data analysis and codes are available upon request.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Kosuke Yusa for providing the CRISPR Library v1 and Dr. Iuan Sheau Chin for technical assistance in propagating the CRISPR Library v1. This work was supported by the Newton-Ungku Omar Fund and the Medical Research Council, United Kingdom (MR/P013457/1) and other sponsors of Cancer Research Malaysia. Work in MJG lab is supported by Wellcome (206194). Cancer Research Malaysia is a non-profit research organization, committed to an understanding of cancer prevention, diagnosis and treatment through a fundamental research program.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is affiliated with AstraZeneca</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Software, Formal analysis, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Data curation, Software, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Supervision, Funding acquisition, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Supervision, Funding acquisition, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Number of MAGeCK defined fitness genes and percentage overlap with core fitness gene.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>List of core fitness genes from four different sources.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>KEGG pathway analysis results for fitness genes.</title><p>(A) KEGG pathway analysis results for all 2539 essential genes identified from CRISPR screen of 21 OSCC cell lines. (B) KEGG pathway analysis results for 918 essential genes after filtering out core fitness genes.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Details of driver mutations in 43 genes identified from whole exome sequencing on 21 OSCC cell lines.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp4-v2.xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Classification of the 918 non-core essential genes based on target tractability.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp5-v2.xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Differentially expressed genes (DEGs) used to derived Z-score for computing of dependency scores.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp6-v2.xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>GSEA enrichment analysis on cancer hallmarks for cell lines and OSCC tumors.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp7-v2.xlsx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Representative figures exemplifying gating strategies in flow cytometry analysis.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-57761-supp8-v2.pdf"/></supplementary-material><supplementary-material id="supp9"><label>Supplementary file 9.</label><caption><title>List of primers.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp9-v2.xlsx"/></supplementary-material><supplementary-material id="supp10"><label>Supplementary file 10.</label><caption><title>Quality assessment of the genome-wide CRISPR-Cas9 screen.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp10-v2.xlsx"/></supplementary-material><supplementary-material id="supp11"><label>Supplementary file 11.</label><caption><title>List of sgRNA and their sequences.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp11-v2.xlsx"/></supplementary-material><supplementary-material id="supp12"><label>Supplementary file 12.</label><caption><title>List of antibodies.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57761-supp12-v2.xlsx"/></supplementary-material><supplementary-material id="supp13"><label>Supplementary file 13.</label><caption><title>All uncropped western blot images.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-57761-supp13-v2.pdf"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-57761-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All main data generated or analysed during this study are included in the manuscript and supplementary files. Source data files for each figures and supplements have also been provided. The larger datasets of CRISPR screens, WES and RNA-sequencing output are available from Figshare (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.11919753">https://doi.org/10.6084/m9.figshare.11919753</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Annie</surname><given-names>WYC</given-names></name><collab>PSY</collab><collab>SP</collab><collab>SMY</collab><collab>HML</collab><collab>VKHT</collab><collab>EG</collab><collab>FB</collab><collab>JB</collab><collab>JG</collab><collab>ACT</collab><collab>UMD</collab><collab>MJG</collab><collab>SCC</collab></person-group><year iso-8601-date="2020">2020</year><data-title>Genome-wide CRISPR screens reveal fitness genes in the Hippo pathway for oral squamous cell carcinoma</data-title><source>figshare</source><pub-id assigning-authority="figshare" pub-id-type="doi">10.6084/m9.figshare.11919753</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Cance Genome Atlas Network</collab></person-group><year iso-8601-date="2015">2015</year><data-title>Head and Neck Squamous Cell Carcinoma (TCGA, Nature 2015)</data-title><source>cbioportal</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="http://www.cbioportal.org/study/summary?id=hnsc_tcga_pub">hnsc_tcga_pub</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayers</surname> <given-names>M</given-names></name><name><surname>Lunceford</surname> <given-names>J</given-names></name><name><surname>Nebozhyn</surname> <given-names>M</given-names></name><name><surname>Murphy</surname> <given-names>E</given-names></name><name><surname>Loboda</surname> <given-names>A</given-names></name><name><surname>Kaufman</surname> <given-names>DR</given-names></name><name><surname>Albright</surname> <given-names>A</given-names></name><name><surname>Cheng</surname> <given-names>JD</given-names></name><name><surname>Kang</surname> <given-names>SP</given-names></name><name><surname>Shankaran</surname> <given-names>V</given-names></name><name><surname>Piha-Paul</surname> <given-names>SA</given-names></name><name><surname>Yearley</surname> <given-names>J</given-names></name><name><surname>Seiwert</surname> <given-names>TY</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>McClanahan</surname> <given-names>TK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>2930</fpage><lpage>2940</lpage><pub-id pub-id-type="doi">10.1172/JCI91190</pub-id><pub-id pub-id-type="pmid">28650338</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname> <given-names>MH</given-names></name><name><surname>Tokheim</surname> <given-names>C</given-names></name><name><surname>Porta-Pardo</surname> <given-names>E</given-names></name><name><surname>Sengupta</surname> <given-names>S</given-names></name><name><surname>Bertrand</surname> <given-names>D</given-names></name><name><surname>Weerasinghe</surname> <given-names>A</given-names></name><name><surname>Colaprico</surname> <given-names>A</given-names></name><name><surname>Wendl</surname> <given-names>MC</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Reardon</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Comprehensive characterization of Cancer driver genes and mutations</article-title><source>Cell</source><volume>385</volume><elocation-id>e318</elocation-id><pub-id pub-id-type="doi">10.1016/j.cell.2018.02.060</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barazas</surname> <given-names>M</given-names></name><name><surname>Annunziato</surname> <given-names>S</given-names></name><name><surname>Pettitt</surname> <given-names>SJ</given-names></name><name><surname>de Krijger</surname> <given-names>I</given-names></name><name><surname>Ghezraoui</surname> <given-names>H</given-names></name><name><surname>Roobol</surname> <given-names>SJ</given-names></name><name><surname>Lutz</surname> <given-names>C</given-names></name><name><surname>Frankum</surname> <given-names>J</given-names></name><name><surname>Song</surname> <given-names>FF</given-names></name><name><surname>Brough</surname> <given-names>R</given-names></name><name><surname>Evers</surname> <given-names>B</given-names></name><name><surname>Gogola</surname> <given-names>E</given-names></name><name><surname>Bhin</surname> <given-names>J</given-names></name><name><surname>van de Ven</surname> <given-names>M</given-names></name><name><surname>van Gent</surname> <given-names>DC</given-names></name><name><surname>Jacobs</surname> <given-names>JJL</given-names></name><name><surname>Chapman</surname> <given-names>R</given-names></name><name><surname>Lord</surname> <given-names>CJ</given-names></name><name><surname>Jonkers</surname> <given-names>J</given-names></name><name><surname>Rottenberg</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The CST complex mediates end protection at Double-Strand breaks and promotes PARP inhibitor sensitivity in BRCA1-Deficient cells</article-title><source>Cell Reports</source><volume>23</volume><fpage>2107</fpage><lpage>2118</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.046</pub-id><pub-id pub-id-type="pmid">29768208</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname> <given-names>BM</given-names></name><name><surname>Shanmugavelandy</surname> <given-names>SS</given-names></name><name><surname>Tacelosky</surname> <given-names>DM</given-names></name><name><surname>Kester</surname> <given-names>M</given-names></name><name><surname>Morad</surname> <given-names>SAF</given-names></name><name><surname>Cabot</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Gaucher's Disease and Cancer: A Sphingolipid Perspective</article-title><source>Critical Reviews in Oncogenesis</source><volume>18</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1615/CritRevOncog.2013005814</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauml</surname> <given-names>J</given-names></name><name><surname>Seiwert</surname> <given-names>TY</given-names></name><name><surname>Pfister</surname> <given-names>DG</given-names></name><name><surname>Worden</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>SV</given-names></name><name><surname>Gilbert</surname> <given-names>J</given-names></name><name><surname>Saba</surname> <given-names>NF</given-names></name><name><surname>Weiss</surname> <given-names>J</given-names></name><name><surname>Wirth</surname> <given-names>L</given-names></name><name><surname>Sukari</surname> <given-names>A</given-names></name><name><surname>Kang</surname> <given-names>H</given-names></name><name><surname>Gibson</surname> <given-names>MK</given-names></name><name><surname>Massarelli</surname> <given-names>E</given-names></name><name><surname>Powell</surname> <given-names>S</given-names></name><name><surname>Meister</surname> <given-names>A</given-names></name><name><surname>Shu</surname> <given-names>X</given-names></name><name><surname>Cheng</surname> <given-names>JD</given-names></name><name><surname>Haddad</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pembrolizumab for platinum- and Cetuximab-Refractory head and neck Cancer: results from a Single-Arm, phase II study</article-title><source>Journal of Clinical Oncology</source><volume>35</volume><fpage>1542</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.70.1524</pub-id><pub-id pub-id-type="pmid">28328302</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behan</surname> <given-names>FM</given-names></name><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Picco</surname> <given-names>G</given-names></name><name><surname>Gonçalves</surname> <given-names>E</given-names></name><name><surname>Beaver</surname> <given-names>CM</given-names></name><name><surname>Migliardi</surname> <given-names>G</given-names></name><name><surname>Santos</surname> <given-names>R</given-names></name><name><surname>Rao</surname> <given-names>Y</given-names></name><name><surname>Sassi</surname> <given-names>F</given-names></name><name><surname>Pinnelli</surname> <given-names>M</given-names></name><name><surname>Ansari</surname> <given-names>R</given-names></name><name><surname>Harper</surname> <given-names>S</given-names></name><name><surname>Jackson</surname> <given-names>DA</given-names></name><name><surname>McRae</surname> <given-names>R</given-names></name><name><surname>Pooley</surname> <given-names>R</given-names></name><name><surname>Wilkinson</surname> <given-names>P</given-names></name><name><surname>van der Meer</surname> <given-names>D</given-names></name><name><surname>Dow</surname> <given-names>D</given-names></name><name><surname>Buser-Doepner</surname> <given-names>C</given-names></name><name><surname>Bertotti</surname> <given-names>A</given-names></name><name><surname>Trusolino</surname> <given-names>L</given-names></name><name><surname>Stronach</surname> <given-names>EA</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Yusa</surname> <given-names>K</given-names></name><name><surname>Garnett</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Prioritization of Cancer therapeutic targets using CRISPR-Cas9 screens</article-title><source>Nature</source><volume>568</volume><fpage>511</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1103-9</pub-id><pub-id pub-id-type="pmid">30971826</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berndt</surname> <given-names>A</given-names></name><name><surname>Hyckel</surname> <given-names>P</given-names></name><name><surname>Könneker</surname> <given-names>A</given-names></name><name><surname>Katenkamp</surname> <given-names>D</given-names></name><name><surname>Kosmehl</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Oral squamous cell carcinoma invasion is associated with a laminin-5 matrix re-organization but independent of basement membrane and hemidesmosome formation clues from an in vitro invasion model</article-title><source>Invasion &amp; Metastasis</source><volume>17</volume><fpage>251</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">9876219</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname> <given-names>F</given-names></name><name><surname>Ferlay</surname> <given-names>J</given-names></name><name><surname>Soerjomataram</surname> <given-names>I</given-names></name><name><surname>Siegel</surname> <given-names>RL</given-names></name><name><surname>Torre</surname> <given-names>LA</given-names></name><name><surname>Jemal</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Global Cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA: A Cancer Journal for Clinicians</source><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>KK</given-names></name><name><surname>Hann</surname> <given-names>MM</given-names></name><name><surname>Lakdawala</surname> <given-names>AS</given-names></name><name><surname>Santos</surname> <given-names>R</given-names></name><name><surname>Thomas</surname> <given-names>PJ</given-names></name><name><surname>Todd</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Approaches to target tractability assessment – a practical perspective</article-title><source>MedChemComm</source><volume>9</volume><fpage>606</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1039/C7MD00633K</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burtness</surname> <given-names>B</given-names></name><name><surname>Harrington</surname> <given-names>KJ</given-names></name><name><surname>Greil</surname> <given-names>R</given-names></name><name><surname>Soulières</surname> <given-names>D</given-names></name><name><surname>Tahara</surname> <given-names>M</given-names></name><name><surname>de Castro</surname> <given-names>G</given-names></name><name><surname>Psyrri</surname> <given-names>A</given-names></name><name><surname>Basté</surname> <given-names>N</given-names></name><name><surname>Neupane</surname> <given-names>P</given-names></name><name><surname>Bratland</surname> <given-names>Åse</given-names></name><name><surname>Fuereder</surname> <given-names>T</given-names></name><name><surname>Hughes</surname> <given-names>BGM</given-names></name><name><surname>Mesía</surname> <given-names>R</given-names></name><name><surname>Ngamphaiboon</surname> <given-names>N</given-names></name><name><surname>Rordorf</surname> <given-names>T</given-names></name><name><surname>Wan Ishak</surname> <given-names>WZ</given-names></name><name><surname>Hong</surname> <given-names>R-L</given-names></name><name><surname>González Mendoza</surname> <given-names>R</given-names></name><name><surname>Roy</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Gumuscu</surname> <given-names>B</given-names></name><name><surname>Cheng</surname> <given-names>JD</given-names></name><name><surname>Jin</surname> <given-names>F</given-names></name><name><surname>Rischin</surname> <given-names>D</given-names></name><name><surname>Lerzo</surname> <given-names>G</given-names></name><name><surname>Tatangelo</surname> <given-names>M</given-names></name><name><surname>Varela</surname> <given-names>M</given-names></name><name><surname>Zarba</surname> <given-names>JJ</given-names></name><name><surname>Boyer</surname> <given-names>M</given-names></name><name><surname>Gan</surname> <given-names>H</given-names></name><name><surname>Gao</surname> <given-names>B</given-names></name><name><surname>Hughes</surname> <given-names>B</given-names></name><name><surname>Mallesara</surname> <given-names>G</given-names></name><name><surname>Rischin</surname> <given-names>D</given-names></name><name><surname>Taylor</surname> <given-names>A</given-names></name><name><surname>Burian</surname> <given-names>M</given-names></name><name><surname>Fuereder</surname> <given-names>T</given-names></name><name><surname>Greil</surname> <given-names>R</given-names></name><name><surname>Barrios</surname> <given-names>CH</given-names></name><name><surname>de Castro Junior</surname> <given-names>DO</given-names></name><name><surname>Castro</surname> <given-names>G</given-names></name><name><surname>Franke</surname> <given-names>FA</given-names></name><name><surname>Girotto</surname> <given-names>G</given-names></name><name><surname>Lima</surname> <given-names>IPF</given-names></name><name><surname>Nicolau</surname> <given-names>UR</given-names></name><name><surname>Pinto</surname> <given-names>GDJ</given-names></name><name><surname>Santos</surname> <given-names>L</given-names></name><name><surname>Victorino</surname> <given-names>A-P</given-names></name><name><surname>Chua</surname> <given-names>N</given-names></name><name><surname>Couture</surname> <given-names>F</given-names></name><name><surname>Gregg</surname> <given-names>R</given-names></name><name><surname>Hansen</surname> <given-names>A</given-names></name><name><surname>Hilton</surname> <given-names>J</given-names></name><name><surname>McCarthy</surname> <given-names>J</given-names></name><name><surname>Soulieres</surname> <given-names>D</given-names></name><name><surname>Ascui</surname> <given-names>R</given-names></name><name><surname>Gonzalez</surname> <given-names>P</given-names></name><name><surname>Villanueva</surname> <given-names>L</given-names></name><name><surname>Torregroza</surname> <given-names>M</given-names></name><name><surname>Zambrano</surname> <given-names>A</given-names></name><name><surname>Holeckova</surname> <given-names>P</given-names></name><name><surname>Kral</surname> <given-names>Z</given-names></name><name><surname>Melichar</surname> <given-names>B</given-names></name><name><surname>Prausova</surname> <given-names>J</given-names></name><name><surname>Vosmik</surname> <given-names>M</given-names></name><name><surname>Andersen</surname> <given-names>M</given-names></name><name><surname>Gyldenkerne</surname> <given-names>N</given-names></name><name><surname>Jurgens</surname> <given-names>H</given-names></name><name><surname>Putnik</surname> <given-names>K</given-names></name><name><surname>Reinikainen</surname> <given-names>P</given-names></name><name><surname>Gruenwald</surname> <given-names>V</given-names></name><name><surname>Laban</surname> <given-names>S</given-names></name><name><surname>Aravantinos</surname> <given-names>G</given-names></name><name><surname>Boukovinas</surname> <given-names>I</given-names></name><name><surname>Georgoulias</surname> <given-names>V</given-names></name><name><surname>Psyrri</surname> <given-names>A</given-names></name><name><surname>Kwong</surname> <given-names>D</given-names></name><name><surname>Al-Farhat</surname> <given-names>Y</given-names></name><name><surname>Csoszi</surname> <given-names>T</given-names></name><name><surname>Erfan</surname> <given-names>J</given-names></name><name><surname>Horvai</surname> <given-names>G</given-names></name><name><surname>Landherr</surname> <given-names>L</given-names></name><name><surname>Remenar</surname> <given-names>E</given-names></name><name><surname>Ruzsa</surname> <given-names>A</given-names></name><name><surname>Szota</surname> <given-names>J</given-names></name><name><surname>Billan</surname> <given-names>S</given-names></name><name><surname>Gluck</surname> <given-names>I</given-names></name><name><surname>Gutfeld</surname> <given-names>O</given-names></name><name><surname>Popovtzer</surname> <given-names>A</given-names></name><name><surname>Benasso</surname> <given-names>M</given-names></name><name><surname>Bui</surname> <given-names>S</given-names></name><name><surname>Ferrari</surname> <given-names>V</given-names></name><name><surname>Licitra</surname> <given-names>L</given-names></name><name><surname>Nole</surname> <given-names>F</given-names></name><name><surname>Fujii</surname> <given-names>T</given-names></name><name><surname>Fujimoto</surname> <given-names>Y</given-names></name><name><surname>Hanai</surname> <given-names>N</given-names></name><name><surname>Hara</surname> <given-names>H</given-names></name><name><surname>Matsumoto</surname> <given-names>K</given-names></name><name><surname>Mitsugi</surname> <given-names>K</given-names></name><name><surname>Monden</surname> <given-names>N</given-names></name><name><surname>Nakayama</surname> <given-names>M</given-names></name><name><surname>Okami</surname> <given-names>K</given-names></name><name><surname>Oridate</surname> <given-names>N</given-names></name><name><surname>Shiga</surname> <given-names>K</given-names></name><name><surname>Shimizu</surname> <given-names>Y</given-names></name><name><surname>Sugasawa</surname> <given-names>M</given-names></name><name><surname>Tahara</surname> <given-names>M</given-names></name><name><surname>Takahashi</surname> <given-names>M</given-names></name><name><surname>Takahashi</surname> <given-names>S</given-names></name><name><surname>Tanaka</surname> <given-names>K</given-names></name><name><surname>Ueda</surname> <given-names>T</given-names></name><name><surname>Yamaguchi</surname> <given-names>H</given-names></name><name><surname>Yamazaki</surname> <given-names>T</given-names></name><name><surname>Yasumatsu</surname> <given-names>R</given-names></name><name><surname>Yokota</surname> <given-names>T</given-names></name><name><surname>Yoshizaki</surname> <given-names>T</given-names></name><name><surname>Kudaba</surname> <given-names>I</given-names></name><name><surname>Stara</surname> <given-names>Z</given-names></name><name><surname>Wan Ishak</surname> <given-names>WZ</given-names></name><name><surname>Cheah</surname> <given-names>SK</given-names></name><name><surname>Aguilar Ponce</surname> <given-names>J</given-names></name><name><surname>Gonzalez Mendoza</surname> <given-names>R</given-names></name><name><surname>Hernandez Hernandez</surname> <given-names>C</given-names></name><name><surname>Medina Soto</surname> <given-names>F</given-names></name><name><surname>Buter</surname> <given-names>J</given-names></name><name><surname>Hoeben</surname> <given-names>A</given-names></name><name><surname>Oosting</surname> <given-names>S</given-names></name><name><surname>Suijkerbuijk</surname> <given-names>K</given-names></name><name><surname>Bratland</surname> <given-names>A</given-names></name><name><surname>Brydoey</surname> <given-names>M</given-names></name><name><surname>Alvarez</surname> <given-names>R</given-names></name><name><surname>Mas</surname> <given-names>L</given-names></name><name><surname>Caguioa</surname> <given-names>P</given-names></name><name><surname>Querol</surname> <given-names>J</given-names></name><name><surname>Regala</surname> <given-names>EE</given-names></name><name><surname>Tamayo</surname> <given-names>MB</given-names></name><name><surname>Villegas</surname> <given-names>EM</given-names></name><name><surname>Kawecki</surname> <given-names>A</given-names></name><name><surname>Karpenko</surname> <given-names>A</given-names></name><name><surname>Klochikhin</surname> <given-names>A</given-names></name><name><surname>Smolin</surname> <given-names>A</given-names></name><name><surname>Zarubenkov</surname> <given-names>O</given-names></name><name><surname>Goh</surname> <given-names>BC</given-names></name><name><surname>Cohen</surname> <given-names>G</given-names></name><name><surname>du Toit</surname> <given-names>J</given-names></name><name><surname>Jordaan</surname> <given-names>C</given-names></name><name><surname>Landers</surname> <given-names>G</given-names></name><name><surname>Ruff</surname> <given-names>P</given-names></name><name><surname>Szpak</surname> <given-names>W</given-names></name><name><surname>Tabane</surname> <given-names>N</given-names></name><name><surname>Brana</surname> <given-names>I</given-names></name><name><surname>Iglesias Docampo</surname> <given-names>L</given-names></name><name><surname>Lavernia</surname> <given-names>J</given-names></name><name><surname>Mesia</surname> <given-names>R</given-names></name><name><surname>Abel</surname> <given-names>E</given-names></name><name><surname>Muratidu</surname> <given-names>V</given-names></name><name><surname>Nielsen</surname> <given-names>N</given-names></name><name><surname>Cristina</surname> <given-names>V</given-names></name><name><surname>Rordorf</surname> <given-names>T</given-names></name><name><surname>Rothschild</surname> <given-names>S</given-names></name><name><surname>Hong</surname> <given-names>R-L</given-names></name><name><surname>Wang</surname> <given-names>H-M</given-names></name><name><surname>Yang</surname> <given-names>M-H</given-names></name><name><surname>Yeh</surname> <given-names>S-P</given-names></name><name><surname>Yen</surname> <given-names>C-J</given-names></name><name><surname>Ngamphaiboon</surname> <given-names>N</given-names></name><name><surname>Soparattanapaisarn</surname> <given-names>N</given-names></name><name><surname>Sriuranpong</surname> <given-names>V</given-names></name><name><surname>Aksoy</surname> <given-names>S</given-names></name><name><surname>Cicin</surname> <given-names>I</given-names></name><name><surname>Ekenel</surname> <given-names>M</given-names></name><name><surname>Harputluoglu</surname> <given-names>H</given-names></name><name><surname>Ozyilkan</surname> <given-names>O</given-names></name><name><surname>Harrington</surname> <given-names>K</given-names></name><name><surname>Agarwala</surname> <given-names>S</given-names></name><name><surname>Ali</surname> <given-names>H</given-names></name><name><surname>Alter</surname> <given-names>R</given-names></name><name><surname>Anderson</surname> <given-names>D</given-names></name><name><surname>Bruce</surname> <given-names>J</given-names></name><name><surname>Burtness</surname> <given-names>B</given-names></name><name><surname>Campbell</surname> <given-names>N</given-names></name><name><surname>Conde</surname> <given-names>M</given-names></name><name><surname>Deeken</surname> <given-names>J</given-names></name><name><surname>Edenfield</surname> <given-names>W</given-names></name><name><surname>Feldman</surname> <given-names>L</given-names></name><name><surname>Gaughan</surname> <given-names>E</given-names></name><name><surname>Goueli</surname> <given-names>B</given-names></name><name><surname>Halmos</surname> <given-names>B</given-names></name><name><surname>Hegde</surname> <given-names>U</given-names></name><name><surname>Hunis</surname> <given-names>B</given-names></name><name><surname>Jotte</surname> <given-names>R</given-names></name><name><surname>Karnad</surname> <given-names>A</given-names></name><name><surname>Khan</surname> <given-names>S</given-names></name><name><surname>Laudi</surname> <given-names>N</given-names></name><name><surname>Laux</surname> <given-names>D</given-names></name><name><surname>Martincic</surname> <given-names>D</given-names></name><name><surname>McCune</surname> <given-names>S</given-names></name><name><surname>McGaughey</surname> <given-names>D</given-names></name><name><surname>Misiukiewicz</surname> <given-names>K</given-names></name><name><surname>Mulford</surname> <given-names>D</given-names></name><name><surname>Nadler</surname> <given-names>E</given-names></name><name><surname>Neupane</surname> <given-names>P</given-names></name><name><surname>Nunnink</surname> <given-names>J</given-names></name><name><surname>Ohr</surname> <given-names>J</given-names></name><name><surname>O'Malley</surname> <given-names>M</given-names></name><name><surname>Patson</surname> <given-names>B</given-names></name><name><surname>Paul</surname> <given-names>D</given-names></name><name><surname>Popa</surname> <given-names>E</given-names></name><name><surname>Powell</surname> <given-names>S</given-names></name><name><surname>Redman</surname> <given-names>R</given-names></name><name><surname>Rella</surname> <given-names>V</given-names></name><name><surname>Rocha Lima</surname> <given-names>C</given-names></name><name><surname>Sivapiragasam</surname> <given-names>A</given-names></name><name><surname>Su</surname> <given-names>Y</given-names></name><name><surname>Sukari</surname> <given-names>A</given-names></name><name><surname>Wong</surname> <given-names>S</given-names></name><name><surname>Yilmaz</surname> <given-names>E</given-names></name><name><surname>Yorio</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study</article-title><source>The Lancet</source><volume>394</volume><fpage>1915</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)32591-7</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callus</surname> <given-names>BA</given-names></name><name><surname>Finch-Edmondson</surname> <given-names>ML</given-names></name><name><surname>Fletcher</surname> <given-names>S</given-names></name><name><surname>Wilton</surname> <given-names>SD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>YAPping about and not forgetting TAZ</article-title><source>FEBS Letters</source><volume>593</volume><fpage>253</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.13318</pub-id><pub-id pub-id-type="pmid">30570758</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>JD</given-names></name><name><surname>Yau</surname> <given-names>C</given-names></name><name><surname>Bowlby</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Brennan</surname> <given-names>K</given-names></name><name><surname>Fan</surname> <given-names>H</given-names></name><name><surname>Taylor</surname> <given-names>AM</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Walter</surname> <given-names>V</given-names></name><name><surname>Akbani</surname> <given-names>R</given-names></name><name><surname>Byers</surname> <given-names>LA</given-names></name><name><surname>Creighton</surname> <given-names>CJ</given-names></name><name><surname>Coarfa</surname> <given-names>C</given-names></name><name><surname>Shih</surname> <given-names>J</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Gevaert</surname> <given-names>O</given-names></name><name><surname>Prunello</surname> <given-names>M</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Anur</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Cheng</surname> <given-names>H</given-names></name><name><surname>Hayes</surname> <given-names>DN</given-names></name><name><surname>Bullman</surname> <given-names>S</given-names></name><name><surname>Pedamallu</surname> <given-names>CS</given-names></name><name><surname>Ojesina</surname> <given-names>AI</given-names></name><name><surname>Sadeghi</surname> <given-names>S</given-names></name><name><surname>Mungall</surname> <given-names>KL</given-names></name><name><surname>Robertson</surname> <given-names>AG</given-names></name><name><surname>Benz</surname> <given-names>C</given-names></name><name><surname>Schultz</surname> <given-names>A</given-names></name><name><surname>Kanchi</surname> <given-names>RS</given-names></name><name><surname>Gay</surname> <given-names>CM</given-names></name><name><surname>Hegde</surname> <given-names>A</given-names></name><name><surname>Diao</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Ma</surname> <given-names>W</given-names></name><name><surname>Sumazin</surname> <given-names>P</given-names></name><name><surname>Chiu</surname> <given-names>H-S</given-names></name><name><surname>Chen</surname> <given-names>T-W</given-names></name><name><surname>Gunaratne</surname> <given-names>P</given-names></name><name><surname>Donehower</surname> <given-names>L</given-names></name><name><surname>Rader</surname> <given-names>JS</given-names></name><name><surname>Zuna</surname> <given-names>R</given-names></name><name><surname>Al-Ahmadie</surname> <given-names>H</given-names></name><name><surname>Lazar</surname> <given-names>AJ</given-names></name><name><surname>Flores</surname> <given-names>ER</given-names></name><name><surname>Tsai</surname> <given-names>KY</given-names></name><name><surname>Zhou</surname> <given-names>JH</given-names></name><name><surname>Rustgi</surname> <given-names>AK</given-names></name><name><surname>Drill</surname> <given-names>E</given-names></name><name><surname>Shen</surname> <given-names>R</given-names></name><name><surname>Wong</surname> <given-names>CK</given-names></name><name><surname>Stuart</surname> <given-names>JM</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Peto</surname> <given-names>M</given-names></name><name><surname>Pickering</surname> <given-names>CR</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Van Waes</surname> <given-names>C</given-names></name><name><surname>Caesar-Johnson</surname> <given-names>SJ</given-names></name><name><surname>Demchok</surname> <given-names>JA</given-names></name><name><surname>Felau</surname> <given-names>I</given-names></name><name><surname>Kasapi</surname> <given-names>M</given-names></name><name><surname>Ferguson</surname> <given-names>ML</given-names></name><name><surname>Hutter</surname> <given-names>CM</given-names></name><name><surname>Sofia</surname> <given-names>HJ</given-names></name><name><surname>Tarnuzzer</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Zenklusen</surname> <given-names>JC</given-names></name><name><surname>Zhang</surname> <given-names>JJ</given-names></name><name><surname>Chudamani</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Lolla</surname> <given-names>L</given-names></name><name><surname>Naresh</surname> <given-names>R</given-names></name><name><surname>Pihl</surname> <given-names>T</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Wan</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Cho</surname> <given-names>J</given-names></name><name><surname>DeFreitas</surname> <given-names>T</given-names></name><name><surname>Frazer</surname> <given-names>S</given-names></name><name><surname>Gehlenborg</surname> <given-names>N</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Heiman</surname> <given-names>DI</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Lin</surname> <given-names>P</given-names></name><name><surname>Meier</surname> <given-names>S</given-names></name><name><surname>Noble</surname> <given-names>MS</given-names></name><name><surname>Saksena</surname> <given-names>G</given-names></name><name><surname>Voet</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Bernard</surname> <given-names>B</given-names></name><name><surname>Chambwe</surname> <given-names>N</given-names></name><name><surname>Dhankani</surname> <given-names>V</given-names></name><name><surname>Knijnenburg</surname> <given-names>T</given-names></name><name><surname>Kramer</surname> <given-names>R</given-names></name><name><surname>Leinonen</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Miller</surname> <given-names>M</given-names></name><name><surname>Reynolds</surname> <given-names>S</given-names></name><name><surname>Shmulevich</surname> <given-names>I</given-names></name><name><surname>Thorsson</surname> <given-names>V</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Akbani</surname> <given-names>R</given-names></name><name><surname>Broom</surname> <given-names>BM</given-names></name><name><surname>Hegde</surname> <given-names>AM</given-names></name><name><surname>Ju</surname> <given-names>Z</given-names></name><name><surname>Kanchi</surname> <given-names>RS</given-names></name><name><surname>Korkut</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Liang</surname> <given-names>H</given-names></name><name><surname>Ling</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Ng</surname> <given-names>K-S</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name><name><surname>Ryan</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Abeshouse</surname> <given-names>A</given-names></name><name><surname>Armenia</surname> <given-names>J</given-names></name><name><surname>Chakravarty</surname> <given-names>D</given-names></name><name><surname>Chatila</surname> <given-names>WK</given-names></name><name><surname>de Bruijn</surname> <given-names>I</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Gross</surname> <given-names>BE</given-names></name><name><surname>Heins</surname> <given-names>ZJ</given-names></name><name><surname>Kundra</surname> <given-names>R</given-names></name><name><surname>La</surname> <given-names>K</given-names></name><name><surname>Ladanyi</surname> <given-names>M</given-names></name><name><surname>Luna</surname> <given-names>A</given-names></name><name><surname>Nissan</surname> <given-names>MG</given-names></name><name><surname>Ochoa</surname> <given-names>A</given-names></name><name><surname>Phillips</surname> <given-names>SM</given-names></name><name><surname>Reznik</surname> <given-names>E</given-names></name><name><surname>Sanchez-Vega</surname> <given-names>F</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Sheridan</surname> <given-names>R</given-names></name><name><surname>Sumer</surname> <given-names>SO</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Taylor</surname> <given-names>BS</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Anur</surname> <given-names>P</given-names></name><name><surname>Peto</surname> <given-names>M</given-names></name><name><surname>Spellman</surname> <given-names>P</given-names></name><name><surname>Benz</surname> <given-names>C</given-names></name><name><surname>Stuart</surname> <given-names>JM</given-names></name><name><surname>Wong</surname> <given-names>CK</given-names></name><name><surname>Yau</surname> <given-names>C</given-names></name><name><surname>Hayes</surname> <given-names>DN</given-names></name><name><surname>Parker</surname> <given-names>JS</given-names></name><name><surname>Wilkerson</surname> <given-names>MD</given-names></name><name><surname>Ally</surname> <given-names>A</given-names></name><name><surname>Balasundaram</surname> <given-names>M</given-names></name><name><surname>Bowlby</surname> <given-names>R</given-names></name><name><surname>Brooks</surname> <given-names>D</given-names></name><name><surname>Carlsen</surname> <given-names>R</given-names></name><name><surname>Chuah</surname> <given-names>E</given-names></name><name><surname>Dhalla</surname> <given-names>N</given-names></name><name><surname>Holt</surname> <given-names>R</given-names></name><name><surname>Jones</surname> <given-names>SJM</given-names></name><name><surname>Kasaian</surname> <given-names>K</given-names></name><name><surname>Lee</surname> <given-names>D</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name><name><surname>Mayo</surname> <given-names>M</given-names></name><name><surname>Moore</surname> <given-names>RA</given-names></name><name><surname>Mungall</surname> <given-names>AJ</given-names></name><name><surname>Mungall</surname> <given-names>K</given-names></name><name><surname>Robertson</surname> <given-names>AG</given-names></name><name><surname>Sadeghi</surname> <given-names>S</given-names></name><name><surname>Schein</surname> <given-names>JE</given-names></name><name><surname>Sipahimalani</surname> <given-names>P</given-names></name><name><surname>Tam</surname> <given-names>A</given-names></name><name><surname>Thiessen</surname> <given-names>N</given-names></name><name><surname>Tse</surname> <given-names>K</given-names></name><name><surname>Wong</surname> <given-names>T</given-names></name><name><surname>Berger</surname> <given-names>AC</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Cibulskis</surname> <given-names>C</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Gao</surname> <given-names>GF</given-names></name><name><surname>Ha</surname> <given-names>G</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Schumacher</surname> <given-names>SE</given-names></name><name><surname>Shih</surname> <given-names>J</given-names></name><name><surname>Kucherlapati</surname> <given-names>MH</given-names></name><name><surname>Kucherlapati</surname> <given-names>RS</given-names></name><name><surname>Baylin</surname> <given-names>S</given-names></name><name><surname>Cope</surname> <given-names>L</given-names></name><name><surname>Danilova</surname> <given-names>L</given-names></name><name><surname>Bootwalla</surname> <given-names>MS</given-names></name><name><surname>Lai</surname> <given-names>PH</given-names></name><name><surname>Maglinte</surname> <given-names>DT</given-names></name><name><surname>Van Den Berg</surname> <given-names>DJ</given-names></name><name><surname>Weisenberger</surname> <given-names>DJ</given-names></name><name><surname>Auman</surname> <given-names>JT</given-names></name><name><surname>Balu</surname> <given-names>S</given-names></name><name><surname>Bodenheimer</surname> <given-names>T</given-names></name><name><surname>Fan</surname> <given-names>C</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>Hoyle</surname> <given-names>AP</given-names></name><name><surname>Jefferys</surname> <given-names>SR</given-names></name><name><surname>Jones</surname> <given-names>CD</given-names></name><name><surname>Meng</surname> <given-names>S</given-names></name><name><surname>Mieczkowski</surname> <given-names>PA</given-names></name><name><surname>Mose</surname> <given-names>LE</given-names></name><name><surname>Perou</surname> <given-names>AH</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Roach</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Simons</surname> <given-names>JV</given-names></name><name><surname>Skelly</surname> <given-names>T</given-names></name><name><surname>Soloway</surname> <given-names>MG</given-names></name><name><surname>Tan</surname> <given-names>D</given-names></name><name><surname>Veluvolu</surname> <given-names>U</given-names></name><name><surname>Fan</surname> <given-names>H</given-names></name><name><surname>Hinoue</surname> <given-names>T</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>W</given-names></name><name><surname>Bellair</surname> <given-names>M</given-names></name><name><surname>Chang</surname> <given-names>K</given-names></name><name><surname>Covington</surname> <given-names>K</given-names></name><name><surname>Creighton</surname> <given-names>CJ</given-names></name><name><surname>Dinh</surname> <given-names>H</given-names></name><name><surname>Doddapaneni</surname> <given-names>H</given-names></name><name><surname>Donehower</surname> <given-names>LA</given-names></name><name><surname>Drummond</surname> <given-names>J</given-names></name><name><surname>Gibbs</surname> <given-names>RA</given-names></name><name><surname>Glenn</surname> <given-names>R</given-names></name><name><surname>Hale</surname> <given-names>W</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Korchina</surname> <given-names>V</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Lewis</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Morgan</surname> <given-names>M</given-names></name><name><surname>Morton</surname> <given-names>D</given-names></name><name><surname>Muzny</surname> <given-names>D</given-names></name><name><surname>Santibanez</surname> <given-names>J</given-names></name><name><surname>Sheth</surname> <given-names>M</given-names></name><name><surname>Shinbrot</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Wheeler</surname> <given-names>DA</given-names></name><name><surname>Xi</surname> <given-names>L</given-names></name><name><surname>Zhao</surname> <given-names>F</given-names></name><name><surname>Hess</surname> <given-names>J</given-names></name><name><surname>Appelbaum</surname> <given-names>EL</given-names></name><name><surname>Bailey</surname> <given-names>M</given-names></name><name><surname>Cordes</surname> <given-names>MG</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Fronick</surname> <given-names>CC</given-names></name><name><surname>Fulton</surname> <given-names>LA</given-names></name><name><surname>Fulton</surname> <given-names>RS</given-names></name><name><surname>Kandoth</surname> <given-names>C</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name><name><surname>McLellan</surname> <given-names>MD</given-names></name><name><surname>Miller</surname> <given-names>CA</given-names></name><name><surname>Schmidt</surname> <given-names>HK</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Crain</surname> <given-names>D</given-names></name><name><surname>Curley</surname> <given-names>E</given-names></name><name><surname>Gardner</surname> <given-names>J</given-names></name><name><surname>Lau</surname> <given-names>K</given-names></name><name><surname>Mallery</surname> <given-names>D</given-names></name><name><surname>Morris</surname> <given-names>S</given-names></name><name><surname>Paulauskis</surname> <given-names>J</given-names></name><name><surname>Penny</surname> <given-names>R</given-names></name><name><surname>Shelton</surname> <given-names>C</given-names></name><name><surname>Shelton</surname> <given-names>T</given-names></name><name><surname>Sherman</surname> <given-names>M</given-names></name><name><surname>Thompson</surname> <given-names>E</given-names></name><name><surname>Yena</surname> <given-names>P</given-names></name><name><surname>Bowen</surname> <given-names>J</given-names></name><name><surname>Gastier-Foster</surname> <given-names>JM</given-names></name><name><surname>Gerken</surname> <given-names>M</given-names></name><name><surname>Leraas</surname> <given-names>KM</given-names></name><name><surname>Lichtenberg</surname> <given-names>TM</given-names></name><name><surname>Ramirez</surname> <given-names>NC</given-names></name><name><surname>Wise</surname> <given-names>L</given-names></name><name><surname>Zmuda</surname> <given-names>E</given-names></name><name><surname>Corcoran</surname> <given-names>N</given-names></name><name><surname>Costello</surname> <given-names>T</given-names></name><name><surname>Hovens</surname> <given-names>C</given-names></name><name><surname>Carvalho</surname> <given-names>AL</given-names></name><name><surname>de Carvalho</surname> <given-names>AC</given-names></name><name><surname>Fregnani</surname> <given-names>JH</given-names></name><name><surname>Longatto-Filho</surname> <given-names>A</given-names></name><name><surname>Reis</surname> <given-names>RM</given-names></name><name><surname>Scapulatempo-Neto</surname> <given-names>C</given-names></name><name><surname>Silveira</surname> <given-names>HCS</given-names></name><name><surname>Vidal</surname> <given-names>DO</given-names></name><name><surname>Burnette</surname> <given-names>A</given-names></name><name><surname>Eschbacher</surname> <given-names>J</given-names></name><name><surname>Hermes</surname> <given-names>B</given-names></name><name><surname>Noss</surname> <given-names>A</given-names></name><name><surname>Singh</surname> <given-names>R</given-names></name><name><surname>Anderson</surname> <given-names>ML</given-names></name><name><surname>Castro</surname> <given-names>PD</given-names></name><name><surname>Ittmann</surname> <given-names>M</given-names></name><name><surname>Huntsman</surname> <given-names>D</given-names></name><name><surname>Kohl</surname> <given-names>B</given-names></name><name><surname>Le</surname> <given-names>X</given-names></name><name><surname>Thorp</surname> <given-names>R</given-names></name><name><surname>Andry</surname> <given-names>C</given-names></name><name><surname>Duffy</surname> <given-names>ER</given-names></name><name><surname>Lyadov</surname> <given-names>V</given-names></name><name><surname>Paklina</surname> <given-names>O</given-names></name><name><surname>Setdikova</surname> <given-names>G</given-names></name><name><surname>Shabunin</surname> <given-names>A</given-names></name><name><surname>Tavobilov</surname> <given-names>M</given-names></name><name><surname>McPherson</surname> <given-names>C</given-names></name><name><surname>Warnick</surname> <given-names>R</given-names></name><name><surname>Berkowitz</surname> <given-names>R</given-names></name><name><surname>Cramer</surname> <given-names>D</given-names></name><name><surname>Feltmate</surname> <given-names>C</given-names></name><name><surname>Horowitz</surname> <given-names>N</given-names></name><name><surname>Kibel</surname> <given-names>A</given-names></name><name><surname>Muto</surname> <given-names>M</given-names></name><name><surname>Raut</surname> <given-names>CP</given-names></name><name><surname>Malykh</surname> <given-names>A</given-names></name><name><surname>Barnholtz-Sloan</surname> <given-names>JS</given-names></name><name><surname>Barrett</surname> <given-names>W</given-names></name><name><surname>Devine</surname> <given-names>K</given-names></name><name><surname>Fulop</surname> <given-names>J</given-names></name><name><surname>Ostrom</surname> <given-names>QT</given-names></name><name><surname>Shimmel</surname> <given-names>K</given-names></name><name><surname>Wolinsky</surname> <given-names>Y</given-names></name><name><surname>Sloan</surname> <given-names>AE</given-names></name><name><surname>De Rose</surname> <given-names>A</given-names></name><name><surname>Giuliante</surname> <given-names>F</given-names></name><name><surname>Goodman</surname> <given-names>M</given-names></name><name><surname>Karlan</surname> <given-names>BY</given-names></name><name><surname>Hagedorn</surname> <given-names>CH</given-names></name><name><surname>Eckman</surname> <given-names>J</given-names></name><name><surname>Harr</surname> <given-names>J</given-names></name><name><surname>Myers</surname> <given-names>J</given-names></name><name><surname>Tucker</surname> <given-names>K</given-names></name><name><surname>Zach</surname> <given-names>LA</given-names></name><name><surname>Deyarmin</surname> <given-names>B</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Kvecher</surname> <given-names>L</given-names></name><name><surname>Larson</surname> <given-names>C</given-names></name><name><surname>Mural</surname> <given-names>RJ</given-names></name><name><surname>Somiari</surname> <given-names>S</given-names></name><name><surname>Vicha</surname> <given-names>A</given-names></name><name><surname>Zelinka</surname> <given-names>T</given-names></name><name><surname>Bennett</surname> <given-names>J</given-names></name><name><surname>Iacocca</surname> <given-names>M</given-names></name><name><surname>Rabeno</surname> <given-names>B</given-names></name><name><surname>Swanson</surname> <given-names>P</given-names></name><name><surname>Latour</surname> <given-names>M</given-names></name><name><surname>Lacombe</surname> <given-names>L</given-names></name><name><surname>Têtu</surname> <given-names>B</given-names></name><name><surname>Bergeron</surname> <given-names>A</given-names></name><name><surname>McGraw</surname> <given-names>M</given-names></name><name><surname>Staugaitis</surname> <given-names>SM</given-names></name><name><surname>Chabot</surname> <given-names>J</given-names></name><name><surname>Hibshoosh</surname> <given-names>H</given-names></name><name><surname>Sepulveda</surname> <given-names>A</given-names></name><name><surname>Su</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Potapova</surname> <given-names>O</given-names></name><name><surname>Voronina</surname> <given-names>O</given-names></name><name><surname>Desjardins</surname> <given-names>L</given-names></name><name><surname>Mariani</surname> <given-names>O</given-names></name><name><surname>Roman-Roman</surname> <given-names>S</given-names></name><name><surname>Sastre</surname> <given-names>X</given-names></name><name><surname>Stern</surname> <given-names>M-H</given-names></name><name><surname>Cheng</surname> <given-names>F</given-names></name><name><surname>Signoretti</surname> <given-names>S</given-names></name><name><surname>Berchuck</surname> <given-names>A</given-names></name><name><surname>Bigner</surname> <given-names>D</given-names></name><name><surname>Lipp</surname> <given-names>E</given-names></name><name><surname>Marks</surname> <given-names>J</given-names></name><name><surname>McCall</surname> <given-names>S</given-names></name><name><surname>McLendon</surname> <given-names>R</given-names></name><name><surname>Secord</surname> <given-names>A</given-names></name><name><surname>Sharp</surname> <given-names>A</given-names></name><name><surname>Behera</surname> <given-names>M</given-names></name><name><surname>Brat</surname> <given-names>DJ</given-names></name><name><surname>Chen</surname> <given-names>A</given-names></name><name><surname>Delman</surname> <given-names>K</given-names></name><name><surname>Force</surname> <given-names>S</given-names></name><name><surname>Khuri</surname> <given-names>F</given-names></name><name><surname>Magliocca</surname> <given-names>K</given-names></name><name><surname>Maithel</surname> <given-names>S</given-names></name><name><surname>Olson</surname> <given-names>JJ</given-names></name><name><surname>Owonikoko</surname> <given-names>T</given-names></name><name><surname>Pickens</surname> <given-names>A</given-names></name><name><surname>Ramalingam</surname> <given-names>S</given-names></name><name><surname>Shin</surname> <given-names>DM</given-names></name><name><surname>Sica</surname> <given-names>G</given-names></name><name><surname>Van Meir</surname> <given-names>EG</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Eijckenboom</surname> <given-names>W</given-names></name><name><surname>Gillis</surname> <given-names>A</given-names></name><name><surname>Korpershoek</surname> <given-names>E</given-names></name><name><surname>Looijenga</surname> <given-names>L</given-names></name><name><surname>Oosterhuis</surname> <given-names>W</given-names></name><name><surname>Stoop</surname> <given-names>H</given-names></name><name><surname>van Kessel</surname> <given-names>KE</given-names></name><name><surname>Zwarthoff</surname> <given-names>EC</given-names></name><name><surname>Calatozzolo</surname> <given-names>C</given-names></name><name><surname>Cuppini</surname> <given-names>L</given-names></name><name><surname>Cuzzubbo</surname> <given-names>S</given-names></name><name><surname>DiMeco</surname> <given-names>F</given-names></name><name><surname>Finocchiaro</surname> <given-names>G</given-names></name><name><surname>Mattei</surname> <given-names>L</given-names></name><name><surname>Perin</surname> <given-names>A</given-names></name><name><surname>Pollo</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Houck</surname> <given-names>J</given-names></name><name><surname>Lohavanichbutr</surname> <given-names>P</given-names></name><name><surname>Hartmann</surname> <given-names>A</given-names></name><name><surname>Stoehr</surname> <given-names>C</given-names></name><name><surname>Stoehr</surname> <given-names>R</given-names></name><name><surname>Taubert</surname> <given-names>H</given-names></name><name><surname>Wach</surname> <given-names>S</given-names></name><name><surname>Wullich</surname> <given-names>B</given-names></name><name><surname>Kycler</surname> <given-names>W</given-names></name><name><surname>Murawa</surname> <given-names>D</given-names></name><name><surname>Wiznerowicz</surname> <given-names>M</given-names></name><name><surname>Chung</surname> <given-names>K</given-names></name><name><surname>Edenfield</surname> <given-names>WJ</given-names></name><name><surname>Martin</surname> <given-names>J</given-names></name><name><surname>Baudin</surname> <given-names>E</given-names></name><name><surname>Bubley</surname> <given-names>G</given-names></name><name><surname>Bueno</surname> <given-names>R</given-names></name><name><surname>De Rienzo</surname> <given-names>A</given-names></name><name><surname>Richards</surname> <given-names>WG</given-names></name><name><surname>Kalkanis</surname> <given-names>S</given-names></name><name><surname>Mikkelsen</surname> <given-names>T</given-names></name><name><surname>Noushmehr</surname> <given-names>H</given-names></name><name><surname>Scarpace</surname> <given-names>L</given-names></name><name><surname>Girard</surname> <given-names>N</given-names></name><name><surname>Aymerich</surname> <given-names>M</given-names></name><name><surname>Campo</surname> <given-names>E</given-names></name><name><surname>Giné</surname> <given-names>E</given-names></name><name><surname>Guillermo</surname> <given-names>AL</given-names></name><name><surname>Van Bang</surname> <given-names>N</given-names></name><name><surname>Hanh</surname> <given-names>PT</given-names></name><name><surname>Phu</surname> <given-names>BD</given-names></name><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Colman</surname> <given-names>H</given-names></name><name><surname>Evason</surname> <given-names>K</given-names></name><name><surname>Dottino</surname> <given-names>PR</given-names></name><name><surname>Martignetti</surname> <given-names>JA</given-names></name><name><surname>Gabra</surname> <given-names>H</given-names></name><name><surname>Juhl</surname> <given-names>H</given-names></name><name><surname>Akeredolu</surname> <given-names>T</given-names></name><name><surname>Stepa</surname> <given-names>S</given-names></name><name><surname>Hoon</surname> <given-names>D</given-names></name><name><surname>Ahn</surname> <given-names>K</given-names></name><name><surname>Kang</surname> <given-names>KJ</given-names></name><name><surname>Beuschlein</surname> <given-names>F</given-names></name><name><surname>Breggia</surname> <given-names>A</given-names></name><name><surname>Birrer</surname> <given-names>M</given-names></name><name><surname>Bell</surname> <given-names>D</given-names></name><name><surname>Borad</surname> <given-names>M</given-names></name><name><surname>Bryce</surname> <given-names>AH</given-names></name><name><surname>Castle</surname> <given-names>E</given-names></name><name><surname>Chandan</surname> <given-names>V</given-names></name><name><surname>Cheville</surname> <given-names>J</given-names></name><name><surname>Copland</surname> <given-names>JA</given-names></name><name><surname>Farnell</surname> <given-names>M</given-names></name><name><surname>Flotte</surname> <given-names>T</given-names></name><name><surname>Giama</surname> <given-names>N</given-names></name><name><surname>Ho</surname> <given-names>T</given-names></name><name><surname>Kendrick</surname> <given-names>M</given-names></name><name><surname>Kocher</surname> <given-names>J-P</given-names></name><name><surname>Kopp</surname> <given-names>K</given-names></name><name><surname>Moser</surname> <given-names>C</given-names></name><name><surname>Nagorney</surname> <given-names>D</given-names></name><name><surname>O’Brien</surname> <given-names>D</given-names></name><name><surname>O’Neill</surname> <given-names>BP</given-names></name><name><surname>Patel</surname> <given-names>T</given-names></name><name><surname>Petersen</surname> <given-names>G</given-names></name><name><surname>Que</surname> <given-names>F</given-names></name><name><surname>Rivera</surname> <given-names>M</given-names></name><name><surname>Roberts</surname> <given-names>L</given-names></name><name><surname>Smallridge</surname> <given-names>R</given-names></name><name><surname>Smyrk</surname> <given-names>T</given-names></name><name><surname>Stanton</surname> <given-names>M</given-names></name><name><surname>Thompson</surname> <given-names>RH</given-names></name><name><surname>Torbenson</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>JD</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Brimo</surname> <given-names>F</given-names></name><name><surname>Ajani</surname> <given-names>JA</given-names></name><name><surname>Gonzalez</surname> <given-names>AMA</given-names></name><name><surname>Behrens</surname> <given-names>C</given-names></name><name><surname>Bondaruk</surname> <given-names>J</given-names></name><name><surname>Broaddus</surname> <given-names>R</given-names></name><name><surname>Czerniak</surname> <given-names>B</given-names></name><name><surname>Esmaeli</surname> <given-names>B</given-names></name><name><surname>Fujimoto</surname> <given-names>J</given-names></name><name><surname>Gershenwald</surname> <given-names>J</given-names></name><name><surname>Guo</surname> <given-names>C</given-names></name><name><surname>Lazar</surname> <given-names>AJ</given-names></name><name><surname>Logothetis</surname> <given-names>C</given-names></name><name><surname>Meric-Bernstam</surname> <given-names>F</given-names></name><name><surname>Moran</surname> <given-names>C</given-names></name><name><surname>Ramondetta</surname> <given-names>L</given-names></name><name><surname>Rice</surname> <given-names>D</given-names></name><name><surname>Sood</surname> <given-names>A</given-names></name><name><surname>Tamboli</surname> <given-names>P</given-names></name><name><surname>Thompson</surname> <given-names>T</given-names></name><name><surname>Troncoso</surname> <given-names>P</given-names></name><name><surname>Tsao</surname> <given-names>A</given-names></name><name><surname>Wistuba</surname> <given-names>I</given-names></name><name><surname>Carter</surname> <given-names>C</given-names></name><name><surname>Haydu</surname> <given-names>L</given-names></name><name><surname>Hersey</surname> <given-names>P</given-names></name><name><surname>Jakrot</surname> <given-names>V</given-names></name><name><surname>Kakavand</surname> <given-names>H</given-names></name><name><surname>Kefford</surname> <given-names>R</given-names></name><name><surname>Lee</surname> <given-names>K</given-names></name><name><surname>Long</surname> <given-names>G</given-names></name><name><surname>Mann</surname> <given-names>G</given-names></name><name><surname>Quinn</surname> <given-names>M</given-names></name><name><surname>Saw</surname> <given-names>R</given-names></name><name><surname>Scolyer</surname> <given-names>R</given-names></name><name><surname>Shannon</surname> <given-names>K</given-names></name><name><surname>Spillane</surname> <given-names>A</given-names></name><name><surname>Stretch</surname> <given-names>O</given-names></name><name><surname>Synott</surname> <given-names>M</given-names></name><name><surname>Thompson</surname> <given-names>J</given-names></name><name><surname>Wilmott</surname> <given-names>J</given-names></name><name><surname>Al-Ahmadie</surname> <given-names>H</given-names></name><name><surname>Chan</surname> <given-names>TA</given-names></name><name><surname>Ghossein</surname> <given-names>R</given-names></name><name><surname>Gopalan</surname> <given-names>A</given-names></name><name><surname>Levine</surname> <given-names>DA</given-names></name><name><surname>Reuter</surname> <given-names>V</given-names></name><name><surname>Singer</surname> <given-names>S</given-names></name><name><surname>Singh</surname> <given-names>B</given-names></name><name><surname>Tien</surname> <given-names>NV</given-names></name><name><surname>Broudy</surname> <given-names>T</given-names></name><name><surname>Mirsaidi</surname> <given-names>C</given-names></name><name><surname>Nair</surname> <given-names>P</given-names></name><name><surname>Drwiega</surname> <given-names>P</given-names></name><name><surname>Miller</surname> <given-names>J</given-names></name><name><surname>Smith</surname> <given-names>J</given-names></name><name><surname>Zaren</surname> <given-names>H</given-names></name><name><surname>Park</surname> <given-names>J-W</given-names></name><name><surname>Hung</surname> <given-names>NP</given-names></name><name><surname>Kebebew</surname> <given-names>E</given-names></name><name><surname>Linehan</surname> <given-names>WM</given-names></name><name><surname>Metwalli</surname> <given-names>AR</given-names></name><name><surname>Pacak</surname> <given-names>K</given-names></name><name><surname>Pinto</surname> <given-names>PA</given-names></name><name><surname>Schiffman</surname> <given-names>M</given-names></name><name><surname>Schmidt</surname> <given-names>LS</given-names></name><name><surname>Vocke</surname> <given-names>CD</given-names></name><name><surname>Wentzensen</surname> <given-names>N</given-names></name><name><surname>Worrell</surname> <given-names>R</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Moncrieff</surname> <given-names>M</given-names></name><name><surname>Goparaju</surname> <given-names>C</given-names></name><name><surname>Melamed</surname> <given-names>J</given-names></name><name><surname>Pass</surname> <given-names>H</given-names></name><name><surname>Botnariuc</surname> <given-names>N</given-names></name><name><surname>Caraman</surname> <given-names>I</given-names></name><name><surname>Cernat</surname> <given-names>M</given-names></name><name><surname>Chemencedji</surname> <given-names>I</given-names></name><name><surname>Clipca</surname> <given-names>A</given-names></name><name><surname>Doruc</surname> <given-names>S</given-names></name><name><surname>Gorincioi</surname> <given-names>G</given-names></name><name><surname>Mura</surname> <given-names>S</given-names></name><name><surname>Pirtac</surname> <given-names>M</given-names></name><name><surname>Stancul</surname> <given-names>I</given-names></name><name><surname>Tcaciuc</surname> <given-names>D</given-names></name><name><surname>Albert</surname> <given-names>M</given-names></name><name><surname>Alexopoulou</surname> <given-names>I</given-names></name><name><surname>Arnaout</surname> <given-names>A</given-names></name><name><surname>Bartlett</surname> <given-names>J</given-names></name><name><surname>Engel</surname> <given-names>J</given-names></name><name><surname>Gilbert</surname> <given-names>S</given-names></name><name><surname>Parfitt</surname> <given-names>J</given-names></name><name><surname>Sekhon</surname> <given-names>H</given-names></name><name><surname>Thomas</surname> <given-names>G</given-names></name><name><surname>Rassl</surname> <given-names>DM</given-names></name><name><surname>Rintoul</surname> <given-names>RC</given-names></name><name><surname>Bifulco</surname> <given-names>C</given-names></name><name><surname>Tamakawa</surname> <given-names>R</given-names></name><name><surname>Urba</surname> <given-names>W</given-names></name><name><surname>Hayward</surname> <given-names>N</given-names></name><name><surname>Timmers</surname> <given-names>H</given-names></name><name><surname>Antenucci</surname> <given-names>A</given-names></name><name><surname>Facciolo</surname> <given-names>F</given-names></name><name><surname>Grazi</surname> <given-names>G</given-names></name><name><surname>Marino</surname> <given-names>M</given-names></name><name><surname>Merola</surname> <given-names>R</given-names></name><name><surname>de Krijger</surname> <given-names>R</given-names></name><name><surname>Gimenez-Roqueplo</surname> <given-names>A-P</given-names></name><name><surname>Piché</surname> <given-names>A</given-names></name><name><surname>Chevalier</surname> <given-names>S</given-names></name><name><surname>McKercher</surname> <given-names>G</given-names></name><name><surname>Birsoy</surname> <given-names>K</given-names></name><name><surname>Barnett</surname> <given-names>G</given-names></name><name><surname>Brewer</surname> <given-names>C</given-names></name><name><surname>Farver</surname> <given-names>C</given-names></name><name><surname>Naska</surname> <given-names>T</given-names></name><name><surname>Pennell</surname> <given-names>NA</given-names></name><name><surname>Raymond</surname> <given-names>D</given-names></name><name><surname>Schilero</surname> <given-names>C</given-names></name><name><surname>Smolenski</surname> <given-names>K</given-names></name><name><surname>Williams</surname> <given-names>F</given-names></name><name><surname>Morrison</surname> <given-names>C</given-names></name><name><surname>Borgia</surname> <given-names>JA</given-names></name><name><surname>Liptay</surname> <given-names>MJ</given-names></name><name><surname>Pool</surname> <given-names>M</given-names></name><name><surname>Seder</surname> <given-names>CW</given-names></name><name><surname>Junker</surname> <given-names>K</given-names></name><name><surname>Omberg</surname> <given-names>L</given-names></name><name><surname>Dinkin</surname> <given-names>M</given-names></name><name><surname>Manikhas</surname> <given-names>G</given-names></name><name><surname>Alvaro</surname> <given-names>D</given-names></name><name><surname>Bragazzi</surname> <given-names>MC</given-names></name><name><surname>Cardinale</surname> <given-names>V</given-names></name><name><surname>Carpino</surname> <given-names>G</given-names></name><name><surname>Gaudio</surname> <given-names>E</given-names></name><name><surname>Chesla</surname> <given-names>D</given-names></name><name><surname>Cottingham</surname> <given-names>S</given-names></name><name><surname>Dubina</surname> <given-names>M</given-names></name><name><surname>Moiseenko</surname> <given-names>F</given-names></name><name><surname>Dhanasekaran</surname> <given-names>R</given-names></name><name><surname>Becker</surname> <given-names>K-F</given-names></name><name><surname>Janssen</surname> <given-names>K-P</given-names></name><name><surname>Slotta-Huspenina</surname> <given-names>J</given-names></name><name><surname>Abdel-Rahman</surname> <given-names>MH</given-names></name><name><surname>Aziz</surname> <given-names>D</given-names></name><name><surname>Bell</surname> <given-names>S</given-names></name><name><surname>Cebulla</surname> <given-names>CM</given-names></name><name><surname>Davis</surname> <given-names>A</given-names></name><name><surname>Duell</surname> <given-names>R</given-names></name><name><surname>Elder</surname> <given-names>JB</given-names></name><name><surname>Hilty</surname> <given-names>J</given-names></name><name><surname>Kumar</surname> <given-names>B</given-names></name><name><surname>Lang</surname> <given-names>J</given-names></name><name><surname>Lehman</surname> <given-names>NL</given-names></name><name><surname>Mandt</surname> <given-names>R</given-names></name><name><surname>Nguyen</surname> <given-names>P</given-names></name><name><surname>Pilarski</surname> <given-names>R</given-names></name><name><surname>Rai</surname> <given-names>K</given-names></name><name><surname>Schoenfield</surname> <given-names>L</given-names></name><name><surname>Senecal</surname> <given-names>K</given-names></name><name><surname>Wakely</surname> <given-names>P</given-names></name><name><surname>Hansen</surname> <given-names>P</given-names></name><name><surname>Lechan</surname> <given-names>R</given-names></name><name><surname>Powers</surname> <given-names>J</given-names></name><name><surname>Tischler</surname> <given-names>A</given-names></name><name><surname>Grizzle</surname> <given-names>WE</given-names></name><name><surname>Sexton</surname> <given-names>KC</given-names></name><name><surname>Kastl</surname> <given-names>A</given-names></name><name><surname>Henderson</surname> <given-names>J</given-names></name><name><surname>Porten</surname> <given-names>S</given-names></name><name><surname>Waldmann</surname> <given-names>J</given-names></name><name><surname>Fassnacht</surname> <given-names>M</given-names></name><name><surname>Asa</surname> <given-names>SL</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><name><surname>Couce</surname> <given-names>M</given-names></name><name><surname>Graefen</surname> <given-names>M</given-names></name><name><surname>Huland</surname> <given-names>H</given-names></name><name><surname>Sauter</surname> <given-names>G</given-names></name><name><surname>Schlomm</surname> <given-names>T</given-names></name><name><surname>Simon</surname> <given-names>R</given-names></name><name><surname>Tennstedt</surname> <given-names>P</given-names></name><name><surname>Olabode</surname> <given-names>O</given-names></name><name><surname>Nelson</surname> <given-names>M</given-names></name><name><surname>Bathe</surname> <given-names>O</given-names></name><name><surname>Carroll</surname> <given-names>PR</given-names></name><name><surname>Chan</surname> <given-names>JM</given-names></name><name><surname>Disaia</surname> <given-names>P</given-names></name><name><surname>Glenn</surname> <given-names>P</given-names></name><name><surname>Kelley</surname> <given-names>RK</given-names></name><name><surname>Landen</surname> <given-names>CN</given-names></name><name><surname>Phillips</surname> <given-names>J</given-names></name><name><surname>Prados</surname> <given-names>M</given-names></name><name><surname>Simko</surname> <given-names>J</given-names></name><name><surname>Smith-McCune</surname> <given-names>K</given-names></name><name><surname>VandenBerg</surname> <given-names>S</given-names></name><name><surname>Roggin</surname> <given-names>K</given-names></name><name><surname>Fehrenbach</surname> <given-names>A</given-names></name><name><surname>Kendler</surname> <given-names>A</given-names></name><name><surname>Sifri</surname> <given-names>S</given-names></name><name><surname>Steele</surname> <given-names>R</given-names></name><name><surname>Jimeno</surname> <given-names>A</given-names></name><name><surname>Carey</surname> <given-names>F</given-names></name><name><surname>Forgie</surname> <given-names>I</given-names></name><name><surname>Mannelli</surname> <given-names>M</given-names></name><name><surname>Carney</surname> <given-names>M</given-names></name><name><surname>Hernandez</surname> <given-names>B</given-names></name><name><surname>Campos</surname> <given-names>B</given-names></name><name><surname>Herold-Mende</surname> <given-names>C</given-names></name><name><surname>Jungk</surname> <given-names>C</given-names></name><name><surname>Unterberg</surname> <given-names>A</given-names></name><name><surname>von Deimling</surname> <given-names>A</given-names></name><name><surname>Bossler</surname> <given-names>A</given-names></name><name><surname>Galbraith</surname> <given-names>J</given-names></name><name><surname>Jacobus</surname> <given-names>L</given-names></name><name><surname>Knudson</surname> <given-names>M</given-names></name><name><surname>Knutson</surname> <given-names>T</given-names></name><name><surname>Ma</surname> <given-names>D</given-names></name><name><surname>Milhem</surname> <given-names>M</given-names></name><name><surname>Sigmund</surname> <given-names>R</given-names></name><name><surname>Godwin</surname> <given-names>AK</given-names></name><name><surname>Madan</surname> <given-names>R</given-names></name><name><surname>Rosenthal</surname> <given-names>HG</given-names></name><name><surname>Adebamowo</surname> <given-names>C</given-names></name><name><surname>Adebamowo</surname> <given-names>SN</given-names></name><name><surname>Boussioutas</surname> <given-names>A</given-names></name><name><surname>Beer</surname> <given-names>D</given-names></name><name><surname>Giordano</surname> <given-names>T</given-names></name><name><surname>Mes-Masson</surname> <given-names>A-M</given-names></name><name><surname>Saad</surname> <given-names>F</given-names></name><name><surname>Bocklage</surname> <given-names>T</given-names></name><name><surname>Landrum</surname> <given-names>L</given-names></name><name><surname>Mannel</surname> <given-names>R</given-names></name><name><surname>Moore</surname> <given-names>K</given-names></name><name><surname>Moxley</surname> <given-names>K</given-names></name><name><surname>Postier</surname> <given-names>R</given-names></name><name><surname>Walker</surname> <given-names>J</given-names></name><name><surname>Zuna</surname> <given-names>R</given-names></name><name><surname>Feldman</surname> <given-names>M</given-names></name><name><surname>Valdivieso</surname> <given-names>F</given-names></name><name><surname>Dhir</surname> <given-names>R</given-names></name><name><surname>Luketich</surname> <given-names>J</given-names></name><name><surname>Pinero</surname> <given-names>EMM</given-names></name><name><surname>Quintero-Aguilo</surname> <given-names>M</given-names></name><name><surname>Carlotti</surname> <given-names>CG</given-names></name><name><surname>Dos Santos</surname> <given-names>JS</given-names></name><name><surname>Kemp</surname> <given-names>R</given-names></name><name><surname>Sankarankuty</surname> <given-names>A</given-names></name><name><surname>Tirapelli</surname> <given-names>D</given-names></name><name><surname>Catto</surname> <given-names>J</given-names></name><name><surname>Agnew</surname> <given-names>K</given-names></name><name><surname>Swisher</surname> <given-names>E</given-names></name><name><surname>Creaney</surname> <given-names>J</given-names></name><name><surname>Robinson</surname> <given-names>B</given-names></name><name><surname>Shelley</surname> <given-names>CS</given-names></name><name><surname>Godwin</surname> <given-names>EM</given-names></name><name><surname>Kendall</surname> <given-names>S</given-names></name><name><surname>Shipman</surname> <given-names>C</given-names></name><name><surname>Bradford</surname> <given-names>C</given-names></name><name><surname>Carey</surname> <given-names>T</given-names></name><name><surname>Haddad</surname> <given-names>A</given-names></name><name><surname>Moyer</surname> <given-names>J</given-names></name><name><surname>Peterson</surname> <given-names>L</given-names></name><name><surname>Prince</surname> <given-names>M</given-names></name><name><surname>Rozek</surname> <given-names>L</given-names></name><name><surname>Wolf</surname> <given-names>G</given-names></name><name><surname>Bowman</surname> <given-names>R</given-names></name><name><surname>Fong</surname> <given-names>KM</given-names></name><name><surname>Yang</surname> <given-names>I</given-names></name><name><surname>Korst</surname> <given-names>R</given-names></name><name><surname>Rathmell</surname> <given-names>WK</given-names></name><name><surname>Fantacone-Campbell</surname> <given-names>JL</given-names></name><name><surname>Hooke</surname> <given-names>JA</given-names></name><name><surname>Kovatich</surname> <given-names>AJ</given-names></name><name><surname>Shriver</surname> <given-names>CD</given-names></name><name><surname>DiPersio</surname> <given-names>J</given-names></name><name><surname>Drake</surname> <given-names>B</given-names></name><name><surname>Govindan</surname> <given-names>R</given-names></name><name><surname>Heath</surname> <given-names>S</given-names></name><name><surname>Ley</surname> <given-names>T</given-names></name><name><surname>Van Tine</surname> <given-names>B</given-names></name><name><surname>Westervelt</surname> <given-names>P</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Lee</surname> <given-names>JI</given-names></name><name><surname>Aredes</surname> <given-names>ND</given-names></name><name><surname>Mariamidze</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genomic, pathway network, and immunologic features distinguishing squamous carcinomas</article-title><source>Cell Reports</source><volume>23</volume><fpage>194</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.03.063</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname> <given-names>AWY</given-names></name><name><surname>Lim</surname> <given-names>KP</given-names></name><name><surname>Cheong</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Translational genomics and recent advances in oral squamous cell carcinoma</article-title><source>Seminars in Cancer Biology</source><volume>61</volume><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.09.011</pub-id><pub-id pub-id-type="pmid">31542510</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheong</surname> <given-names>SC</given-names></name><name><surname>Vatanasapt</surname> <given-names>P</given-names></name><name><surname>Yi-Hsin</surname> <given-names>Y</given-names></name><name><surname>Zain</surname> <given-names>RB</given-names></name><name><surname>Kerr</surname> <given-names>AR</given-names></name><name><surname>Johnson</surname> <given-names>NW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Oral Cancer in South East Asia:current status and future directions</article-title><source>Translational Research in Oral Oncology</source><volume>2</volume><elocation-id>17702921</elocation-id><pub-id pub-id-type="doi">10.1177/2057178X17702921</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname> <given-names>SL</given-names></name><name><surname>Chen</surname> <given-names>PH</given-names></name><name><surname>Lee</surname> <given-names>CH</given-names></name><name><surname>Ko</surname> <given-names>AM</given-names></name><name><surname>Lee</surname> <given-names>KW</given-names></name><name><surname>Lin</surname> <given-names>YC</given-names></name><name><surname>Ho</surname> <given-names>PS</given-names></name><name><surname>Tu</surname> <given-names>HP</given-names></name><name><surname>Wu</surname> <given-names>DC</given-names></name><name><surname>Shieh</surname> <given-names>TY</given-names></name><name><surname>Ko</surname> <given-names>YC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Up-regulation of inflammatory signalings by Areca nut extract and role of cyclooxygenase-2 -1195G&gt;a polymorphism reveal risk of oral Cancer</article-title><source>Cancer Research</source><volume>68</volume><fpage>8489</fpage><lpage>8498</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0823</pub-id><pub-id pub-id-type="pmid">18922923</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciriello</surname> <given-names>G</given-names></name><name><surname>Miller</surname> <given-names>ML</given-names></name><name><surname>Aksoy</surname> <given-names>BA</given-names></name><name><surname>Senbabaoglu</surname> <given-names>Y</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Emerging landscape of oncogenic signatures across human cancers</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1127</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1038/ng.2762</pub-id><pub-id pub-id-type="pmid">24071851</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname> <given-names>EEW</given-names></name><name><surname>Bell</surname> <given-names>RB</given-names></name><name><surname>Bifulco</surname> <given-names>CB</given-names></name><name><surname>Burtness</surname> <given-names>B</given-names></name><name><surname>Gillison</surname> <given-names>ML</given-names></name><name><surname>Harrington</surname> <given-names>KJ</given-names></name><name><surname>Le</surname> <given-names>QT</given-names></name><name><surname>Lee</surname> <given-names>NY</given-names></name><name><surname>Leidner</surname> <given-names>R</given-names></name><name><surname>Lewis</surname> <given-names>RL</given-names></name><name><surname>Licitra</surname> <given-names>L</given-names></name><name><surname>Mehanna</surname> <given-names>H</given-names></name><name><surname>Mell</surname> <given-names>LK</given-names></name><name><surname>Raben</surname> <given-names>A</given-names></name><name><surname>Sikora</surname> <given-names>AG</given-names></name><name><surname>Uppaluri</surname> <given-names>R</given-names></name><name><surname>Whitworth</surname> <given-names>F</given-names></name><name><surname>Zandberg</surname> <given-names>DP</given-names></name><name><surname>Ferris</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The society for immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)</article-title><source>Journal for ImmunoTherapy of Cancer</source><volume>7</volume><elocation-id>184</elocation-id><pub-id pub-id-type="doi">10.1186/s40425-019-0662-5</pub-id><pub-id pub-id-type="pmid">31307547</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristescu</surname> <given-names>R</given-names></name><name><surname>Mogg</surname> <given-names>R</given-names></name><name><surname>Ayers</surname> <given-names>M</given-names></name><name><surname>Albright</surname> <given-names>A</given-names></name><name><surname>Murphy</surname> <given-names>E</given-names></name><name><surname>Yearley</surname> <given-names>J</given-names></name><name><surname>Sher</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>XQ</given-names></name><name><surname>Lu</surname> <given-names>H</given-names></name><name><surname>Nebozhyn</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Lunceford</surname> <given-names>JK</given-names></name><name><surname>Joe</surname> <given-names>A</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Webber</surname> <given-names>AL</given-names></name><name><surname>Ibrahim</surname> <given-names>N</given-names></name><name><surname>Plimack</surname> <given-names>ER</given-names></name><name><surname>Ott</surname> <given-names>PA</given-names></name><name><surname>Seiwert</surname> <given-names>TY</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>McClanahan</surname> <given-names>TK</given-names></name><name><surname>Tomassini</surname> <given-names>JE</given-names></name><name><surname>Loboda</surname> <given-names>A</given-names></name><name><surname>Kaufman</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy</article-title><source>Science</source><volume>362</volume><elocation-id>eaar3593</elocation-id><pub-id pub-id-type="doi">10.1126/science.aar3593</pub-id><pub-id pub-id-type="pmid">30309915</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dey</surname> <given-names>A</given-names></name><name><surname>Varelas</surname> <given-names>X</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting the hippo pathway in Cancer, fibrosis, wound healing and regenerative medicine</article-title><source>Nature Reviews Drug Discovery</source><volume>19</volume><fpage>480</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1038/s41573-020-0070-z</pub-id><pub-id pub-id-type="pmid">32555376</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edington</surname> <given-names>KG</given-names></name><name><surname>Loughran</surname> <given-names>OP</given-names></name><name><surname>Berry</surname> <given-names>IJ</given-names></name><name><surname>Parkinson</surname> <given-names>EK</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Cellular immortality: a late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss</article-title><source>Molecular Carcinogenesis</source><volume>13</volume><fpage>254</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1002/mc.2940130408</pub-id><pub-id pub-id-type="pmid">7646764</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadlullah</surname> <given-names>MZ</given-names></name><name><surname>Chiang</surname> <given-names>IK</given-names></name><name><surname>Dionne</surname> <given-names>KR</given-names></name><name><surname>Yee</surname> <given-names>PS</given-names></name><name><surname>Gan</surname> <given-names>CP</given-names></name><name><surname>Sam</surname> <given-names>KK</given-names></name><name><surname>Tiong</surname> <given-names>KH</given-names></name><name><surname>Ng</surname> <given-names>AK</given-names></name><name><surname>Martin</surname> <given-names>D</given-names></name><name><surname>Lim</surname> <given-names>KP</given-names></name><name><surname>Kallarakkal</surname> <given-names>TG</given-names></name><name><surname>Mustafa</surname> <given-names>WM</given-names></name><name><surname>Lau</surname> <given-names>SH</given-names></name><name><surname>Abraham</surname> <given-names>MT</given-names></name><name><surname>Zain</surname> <given-names>RB</given-names></name><name><surname>Rahman</surname> <given-names>ZA</given-names></name><name><surname>Molinolo</surname> <given-names>A</given-names></name><name><surname>Patel</surname> <given-names>V</given-names></name><name><surname>Gutkind</surname> <given-names>JS</given-names></name><name><surname>Tan</surname> <given-names>AC</given-names></name><name><surname>Cheong</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies</article-title><source>Oncotarget</source><volume>7</volume><fpage>27802</fpage><lpage>27818</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8533</pub-id><pub-id pub-id-type="pmid">27050151</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>R</given-names></name><name><surname>Kim</surname> <given-names>NG</given-names></name><name><surname>Gumbiner</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulation of hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1</article-title><source>PNAS</source><volume>110</volume><fpage>2569</fpage><lpage>2574</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216462110</pub-id><pub-id pub-id-type="pmid">23359693</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferris</surname> <given-names>RL</given-names></name><name><surname>Blumenschein</surname> <given-names>G</given-names></name><name><surname>Fayette</surname> <given-names>J</given-names></name><name><surname>Guigay</surname> <given-names>J</given-names></name><name><surname>Colevas</surname> <given-names>AD</given-names></name><name><surname>Licitra</surname> <given-names>L</given-names></name><name><surname>Harrington</surname> <given-names>K</given-names></name><name><surname>Kasper</surname> <given-names>S</given-names></name><name><surname>Vokes</surname> <given-names>EE</given-names></name><name><surname>Even</surname> <given-names>C</given-names></name><name><surname>Worden</surname> <given-names>F</given-names></name><name><surname>Saba</surname> <given-names>NF</given-names></name><name><surname>Iglesias Docampo</surname> <given-names>LC</given-names></name><name><surname>Haddad</surname> <given-names>R</given-names></name><name><surname>Rordorf</surname> <given-names>T</given-names></name><name><surname>Kiyota</surname> <given-names>N</given-names></name><name><surname>Tahara</surname> <given-names>M</given-names></name><name><surname>Monga</surname> <given-names>M</given-names></name><name><surname>Lynch</surname> <given-names>M</given-names></name><name><surname>Geese</surname> <given-names>WJ</given-names></name><name><surname>Kopit</surname> <given-names>J</given-names></name><name><surname>Shaw</surname> <given-names>JW</given-names></name><name><surname>Gillison</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Nivolumab for recurrent Squamous-Cell carcinoma of the head and neck</article-title><source>New England Journal of Medicine</source><volume>375</volume><fpage>1856</fpage><lpage>1867</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1602252</pub-id><pub-id pub-id-type="pmid">27718784</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Aksoy</surname> <given-names>BA</given-names></name><name><surname>Dogrusoz</surname> <given-names>U</given-names></name><name><surname>Dresdner</surname> <given-names>G</given-names></name><name><surname>Gross</surname> <given-names>B</given-names></name><name><surname>Sumer</surname> <given-names>SO</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Jacobsen</surname> <given-names>A</given-names></name><name><surname>Sinha</surname> <given-names>R</given-names></name><name><surname>Larsson</surname> <given-names>E</given-names></name><name><surname>Cerami</surname> <given-names>E</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>pl1</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Escudero</surname> <given-names>R</given-names></name><name><surname>Segrelles</surname> <given-names>C</given-names></name><name><surname>Dueñas</surname> <given-names>M</given-names></name><name><surname>Pombo</surname> <given-names>M</given-names></name><name><surname>Ballestín</surname> <given-names>C</given-names></name><name><surname>Alonso-Riaño</surname> <given-names>M</given-names></name><name><surname>Nenclares</surname> <given-names>P</given-names></name><name><surname>Álvarez-Rodríguez</surname> <given-names>R</given-names></name><name><surname>Sánchez-Aniceto</surname> <given-names>G</given-names></name><name><surname>Ruíz-Alonso</surname> <given-names>A</given-names></name><name><surname>López-Cedrún</surname> <given-names>JL</given-names></name><name><surname>Paramio</surname> <given-names>JM</given-names></name><name><surname>Lorz</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway</article-title><source>Oral Oncology</source><volume>79</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2018.02.014</pub-id><pub-id pub-id-type="pmid">29598951</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname> <given-names>L</given-names></name><name><surname>Smail</surname> <given-names>M</given-names></name><name><surname>Meng</surname> <given-names>W</given-names></name><name><surname>Shyr</surname> <given-names>Y</given-names></name><name><surname>Ye</surname> <given-names>F</given-names></name><name><surname>Fan</surname> <given-names>KH</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Zhou</surname> <given-names>HM</given-names></name><name><surname>Bhowmick</surname> <given-names>NA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e27529</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0027529</pub-id><pub-id pub-id-type="pmid">22096589</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>S</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Xiong</surname> <given-names>X</given-names></name><name><surname>Hong</surname> <given-names>L</given-names></name><name><surname>Xie</surname> <given-names>C</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Peng</surname> <given-names>J</given-names></name><name><surname>Johnson</surname> <given-names>RL</given-names></name><name><surname>Xiao</surname> <given-names>N</given-names></name><name><surname>Lu</surname> <given-names>L</given-names></name><name><surname>Han</surname> <given-names>J</given-names></name><name><surname>Zhou</surname> <given-names>D</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The transcriptional coactivator TAZ regulates reciprocal differentiation of TH17 cells and Treg cells</article-title><source>Nature Immunology</source><volume>18</volume><fpage>800</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/ni.3748</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerhards</surname> <given-names>NM</given-names></name><name><surname>Rottenberg</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>New tools for old drugs: functional genetic screens to optimize current chemotherapy</article-title><source>Drug Resistance Updates</source><volume>36</volume><fpage>30</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2018.01.001</pub-id><pub-id pub-id-type="pmid">29499836</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guha</surname> <given-names>N</given-names></name><name><surname>Warnakulasuriya</surname> <given-names>S</given-names></name><name><surname>Vlaanderen</surname> <given-names>J</given-names></name><name><surname>Straif</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Betel quid chewing and the risk of oral and oropharyngeal cancers: a meta-analysis with implications for Cancer control</article-title><source>International Journal of Cancer</source><volume>135</volume><fpage>1433</fpage><lpage>1443</lpage><pub-id pub-id-type="doi">10.1002/ijc.28643</pub-id><pub-id pub-id-type="pmid">24302487</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Teng</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>YAP/TAZ for Cancer therapy: opportunities and challenges (review)</article-title><source>International Journal of Oncology</source><volume>46</volume><fpage>1444</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.3892/ijo.2015.2877</pub-id><pub-id pub-id-type="pmid">25652178</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname> <given-names>Y</given-names></name><name><surname>Samuels</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Krokowski</surname> <given-names>D</given-names></name><name><surname>Guan</surname> <given-names>BJ</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Jin</surname> <given-names>Z</given-names></name><name><surname>Dong</surname> <given-names>B</given-names></name><name><surname>Cao</surname> <given-names>B</given-names></name><name><surname>Feng</surname> <given-names>X</given-names></name><name><surname>Xiang</surname> <given-names>M</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Fink</surname> <given-names>S</given-names></name><name><surname>Meropol</surname> <given-names>NJ</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Conlon</surname> <given-names>RA</given-names></name><name><surname>Markowitz</surname> <given-names>S</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name><name><surname>Brunengraber</surname> <given-names>H</given-names></name><name><surname>Willis</surname> <given-names>JE</given-names></name><name><surname>LaFramboise</surname> <given-names>T</given-names></name><name><surname>Hatzoglou</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>GF</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal Cancer</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11971</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11971</pub-id><pub-id pub-id-type="pmid">27321283</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname> <given-names>T</given-names></name><name><surname>Brown</surname> <given-names>KR</given-names></name><name><surname>Sircoulomb</surname> <given-names>F</given-names></name><name><surname>Rottapel</surname> <given-names>R</given-names></name><name><surname>Moffat</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Measuring error rates in genomic perturbation screens: gold standards for human functional genomics</article-title><source>Molecular Systems Biology</source><volume>10</volume><elocation-id>733</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20145216</pub-id><pub-id pub-id-type="pmid">24987113</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname> <given-names>T</given-names></name><name><surname>Tong</surname> <given-names>AHY</given-names></name><name><surname>Chan</surname> <given-names>K</given-names></name><name><surname>Van Leeuwen</surname> <given-names>J</given-names></name><name><surname>Seetharaman</surname> <given-names>A</given-names></name><name><surname>Aregger</surname> <given-names>M</given-names></name><name><surname>Chandrashekhar</surname> <given-names>M</given-names></name><name><surname>Hustedt</surname> <given-names>N</given-names></name><name><surname>Seth</surname> <given-names>S</given-names></name><name><surname>Noonan</surname> <given-names>A</given-names></name><name><surname>Habsid</surname> <given-names>A</given-names></name><name><surname>Sizova</surname> <given-names>O</given-names></name><name><surname>Nedyalkova</surname> <given-names>L</given-names></name><name><surname>Climie</surname> <given-names>R</given-names></name><name><surname>Tworzyanski</surname> <given-names>L</given-names></name><name><surname>Lawson</surname> <given-names>K</given-names></name><name><surname>Sartori</surname> <given-names>MA</given-names></name><name><surname>Alibeh</surname> <given-names>S</given-names></name><name><surname>Tieu</surname> <given-names>D</given-names></name><name><surname>Masud</surname> <given-names>S</given-names></name><name><surname>Mero</surname> <given-names>P</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>Brown</surname> <given-names>KR</given-names></name><name><surname>Usaj</surname> <given-names>M</given-names></name><name><surname>Billmann</surname> <given-names>M</given-names></name><name><surname>Rahman</surname> <given-names>M</given-names></name><name><surname>Costanzo</surname> <given-names>M</given-names></name><name><surname>Myers</surname> <given-names>CL</given-names></name><name><surname>Andrews</surname> <given-names>BJ</given-names></name><name><surname>Boone</surname> <given-names>C</given-names></name><name><surname>Durocher</surname> <given-names>D</given-names></name><name><surname>Moffat</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Evaluation and design of Genome-Wide CRISPR/SpCas9 knockout screens</article-title><source>G3: Genes, Genomes, Genetics</source><volume>7</volume><fpage>2719</fpage><lpage>2727</lpage><pub-id pub-id-type="doi">10.1534/g3.117.041277</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hast</surname> <given-names>BE</given-names></name><name><surname>Cloer</surname> <given-names>EW</given-names></name><name><surname>Goldfarb</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Siesser</surname> <given-names>PF</given-names></name><name><surname>Yan</surname> <given-names>F</given-names></name><name><surname>Walter</surname> <given-names>V</given-names></name><name><surname>Zheng</surname> <given-names>N</given-names></name><name><surname>Hayes</surname> <given-names>DN</given-names></name><name><surname>Major</surname> <given-names>MB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination</article-title><source>Cancer Research</source><volume>74</volume><fpage>808</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1655</pub-id><pub-id pub-id-type="pmid">24322982</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiemer</surname> <given-names>SE</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Kartha</surname> <given-names>VK</given-names></name><name><surname>Packer</surname> <given-names>TS</given-names></name><name><surname>Almershed</surname> <given-names>M</given-names></name><name><surname>Noonan</surname> <given-names>V</given-names></name><name><surname>Kukuruzinska</surname> <given-names>M</given-names></name><name><surname>Bais</surname> <given-names>MV</given-names></name><name><surname>Monti</surname> <given-names>S</given-names></name><name><surname>Varelas</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A YAP/TAZ-Regulated molecular signature is associated with oral squamous cell carcinoma</article-title><source>Molecular Cancer Research</source><volume>13</volume><fpage>957</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-14-0580</pub-id><pub-id pub-id-type="pmid">25794680</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates</article-title><source>Journal of Cellular Biochemistry</source><volume>91</volume><fpage>491</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1002/jcb.10759</pub-id><pub-id pub-id-type="pmid">14755680</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname> <given-names>P</given-names></name><name><surname>Wu</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Qi</surname> <given-names>R</given-names></name><name><surname>Bhavanasi</surname> <given-names>D</given-names></name><name><surname>Zuo</surname> <given-names>Z</given-names></name><name><surname>Dos Santos</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Zheng</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Perl</surname> <given-names>A</given-names></name><name><surname>Guo</surname> <given-names>D</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A Genome-Wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220</article-title><source>Cancer Research</source><volume>77</volume><fpage>4402</fpage><lpage>4413</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1627</pub-id><pub-id pub-id-type="pmid">28625976</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname> <given-names>LL</given-names></name><name><surname>Wang</surname> <given-names>PF</given-names></name><name><surname>Chen</surname> <given-names>IH</given-names></name><name><surname>Liao</surname> <given-names>CT</given-names></name><name><surname>Wang</surname> <given-names>HM</given-names></name><name><surname>Chen</surname> <given-names>MC</given-names></name><name><surname>Chang</surname> <given-names>JT</given-names></name><name><surname>Cheng</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in taiwanese</article-title><source>Carcinogenesis</source><volume>22</volume><fpage>1497</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.1093/carcin/22.9.1497</pub-id><pub-id pub-id-type="pmid">11532872</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Pan</surname> <given-names>Y</given-names></name><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Deng</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Ma</surname> <given-names>X</given-names></name><name><surname>Hou</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Hu</surname> <given-names>G</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Ji</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YAP suppresses lung squamous cell carcinoma progression via deregulation of the DNp63-GPX2 Axis and ROS accumulation</article-title><source>Cancer Research</source><volume>77</volume><fpage>5769</fpage><lpage>5781</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0449</pub-id><pub-id pub-id-type="pmid">28916653</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>India Project Team of the International Cancer Genome Consortium</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>2873</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3873</pub-id><pub-id pub-id-type="pmid">24292195</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Knijnenburg</surname> <given-names>TA</given-names></name><name><surname>Vis</surname> <given-names>DJ</given-names></name><name><surname>Bignell</surname> <given-names>GR</given-names></name><name><surname>Menden</surname> <given-names>MP</given-names></name><name><surname>Schubert</surname> <given-names>M</given-names></name><name><surname>Aben</surname> <given-names>N</given-names></name><name><surname>Gonçalves</surname> <given-names>E</given-names></name><name><surname>Barthorpe</surname> <given-names>S</given-names></name><name><surname>Lightfoot</surname> <given-names>H</given-names></name><name><surname>Cokelaer</surname> <given-names>T</given-names></name><name><surname>Greninger</surname> <given-names>P</given-names></name><name><surname>van Dyk</surname> <given-names>E</given-names></name><name><surname>Chang</surname> <given-names>H</given-names></name><name><surname>de Silva</surname> <given-names>H</given-names></name><name><surname>Heyn</surname> <given-names>H</given-names></name><name><surname>Deng</surname> <given-names>X</given-names></name><name><surname>Egan</surname> <given-names>RK</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Mironenko</surname> <given-names>T</given-names></name><name><surname>Mitropoulos</surname> <given-names>X</given-names></name><name><surname>Richardson</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Moran</surname> <given-names>S</given-names></name><name><surname>Sayols</surname> <given-names>S</given-names></name><name><surname>Soleimani</surname> <given-names>M</given-names></name><name><surname>Tamborero</surname> <given-names>D</given-names></name><name><surname>Lopez-Bigas</surname> <given-names>N</given-names></name><name><surname>Ross-Macdonald</surname> <given-names>P</given-names></name><name><surname>Esteller</surname> <given-names>M</given-names></name><name><surname>Gray</surname> <given-names>NS</given-names></name><name><surname>Haber</surname> <given-names>DA</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Benes</surname> <given-names>CH</given-names></name><name><surname>Wessels</surname> <given-names>LFA</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Garnett</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A landscape of pharmacogenomic interactions in Cancer</article-title><source>Cell</source><volume>166</volume><fpage>740</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.017</pub-id><pub-id pub-id-type="pmid">27397505</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Behan</surname> <given-names>FM</given-names></name><name><surname>Gonçalves</surname> <given-names>E</given-names></name><name><surname>Bhosle</surname> <given-names>SG</given-names></name><name><surname>Chen</surname> <given-names>E</given-names></name><name><surname>Shepherd</surname> <given-names>R</given-names></name><name><surname>Beaver</surname> <given-names>C</given-names></name><name><surname>Ansari</surname> <given-names>R</given-names></name><name><surname>Pooley</surname> <given-names>R</given-names></name><name><surname>Wilkinson</surname> <given-names>P</given-names></name><name><surname>Harper</surname> <given-names>S</given-names></name><name><surname>Butler</surname> <given-names>AP</given-names></name><name><surname>Stronach</surname> <given-names>EA</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Yusa</surname> <given-names>K</given-names></name><name><surname>Garnett</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting</article-title><source>BMC Genomics</source><volume>19</volume><elocation-id>604</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-018-4989-y</pub-id><pub-id pub-id-type="pmid">30103702</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname> <given-names>S</given-names></name><name><surname>Muthumala</surname> <given-names>M</given-names></name><name><surname>Matsuoka</surname> <given-names>H</given-names></name><name><surname>Uehara</surname> <given-names>O</given-names></name><name><surname>Kuramitsu</surname> <given-names>Y</given-names></name><name><surname>Chiba</surname> <given-names>I</given-names></name><name><surname>Abiko</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>How each component of betel quid is involved in oral carcinogenesis: mutual interactions and synergistic effects with other Carcinogens-a review article</article-title><source>Current Oncology Reports</source><volume>21</volume><elocation-id>53</elocation-id><pub-id pub-id-type="doi">10.1007/s11912-019-0800-8</pub-id><pub-id pub-id-type="pmid">31028548</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janse van Rensburg</surname> <given-names>HJ</given-names></name><name><surname>Azad</surname> <given-names>T</given-names></name><name><surname>Ling</surname> <given-names>M</given-names></name><name><surname>Hao</surname> <given-names>Y</given-names></name><name><surname>Snetsinger</surname> <given-names>B</given-names></name><name><surname>Khanal</surname> <given-names>P</given-names></name><name><surname>Minassian</surname> <given-names>LM</given-names></name><name><surname>Graham</surname> <given-names>CH</given-names></name><name><surname>Rauh</surname> <given-names>MJ</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The hippo pathway component TAZ promotes immune evasion in human Cancer through PD-L1</article-title><source>Cancer Research</source><volume>78</volume><fpage>1457</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3139</pub-id><pub-id pub-id-type="pmid">29339539</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaan</surname> <given-names>HYK</given-names></name><name><surname>Chan</surname> <given-names>SW</given-names></name><name><surname>Tan</surname> <given-names>SKJ</given-names></name><name><surname>Guo</surname> <given-names>F</given-names></name><name><surname>Lim</surname> <given-names>CJ</given-names></name><name><surname>Hong</surname> <given-names>W</given-names></name><name><surname>Song</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>2035</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-02219-9</pub-id><pub-id pub-id-type="pmid">28515457</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamburov</surname> <given-names>A</given-names></name><name><surname>Stelzl</surname> <given-names>U</given-names></name><name><surname>Lehrach</surname> <given-names>H</given-names></name><name><surname>Herwig</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The ConsensusPathDB interaction database: 2013 update</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>D793</fpage><lpage>D800</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1055</pub-id><pub-id pub-id-type="pmid">23143270</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname> <given-names>A</given-names></name><name><surname>Yao</surname> <given-names>W</given-names></name><name><surname>Ying</surname> <given-names>H</given-names></name><name><surname>Hua</surname> <given-names>S</given-names></name><name><surname>Liewen</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Zhong</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>CJ</given-names></name><name><surname>Sadanandam</surname> <given-names>A</given-names></name><name><surname>Hu</surname> <given-names>B</given-names></name><name><surname>Chang</surname> <given-names>Q</given-names></name><name><surname>Chu</surname> <given-names>GC</given-names></name><name><surname>Al-Khalil</surname> <given-names>R</given-names></name><name><surname>Jiang</surname> <given-names>S</given-names></name><name><surname>Xia</surname> <given-names>H</given-names></name><name><surname>Fletcher-Sananikone</surname> <given-names>E</given-names></name><name><surname>Lim</surname> <given-names>C</given-names></name><name><surname>Horwitz</surname> <given-names>GI</given-names></name><name><surname>Viale</surname> <given-names>A</given-names></name><name><surname>Pettazzoni</surname> <given-names>P</given-names></name><name><surname>Sanchez</surname> <given-names>N</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Protopopov</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Heffernan</surname> <given-names>T</given-names></name><name><surname>Johnson</surname> <given-names>RL</given-names></name><name><surname>Chin</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>YA</given-names></name><name><surname>Draetta</surname> <given-names>G</given-names></name><name><surname>DePinho</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Yap1 activation enables bypass of oncogenic kras addiction in pancreatic Cancer</article-title><source>Cell</source><volume>158</volume><fpage>185</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.06.003</pub-id><pub-id pub-id-type="pmid">24954535</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>M</given-names></name><name><surname>Nanavati</surname> <given-names>R</given-names></name><name><surname>Modi</surname> <given-names>TG</given-names></name><name><surname>Dobariya</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oral Cancer: etiology and risk factors: a review</article-title><source>Journal of Cancer Research and Therapeutics</source><volume>12</volume><fpage>458</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.4103/0973-1482.186696</pub-id><pub-id pub-id-type="pmid">27461593</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazaridis</surname> <given-names>G</given-names></name><name><surname>Kotoula</surname> <given-names>V</given-names></name><name><surname>Vrettou</surname> <given-names>E</given-names></name><name><surname>Kostopoulos</surname> <given-names>I</given-names></name><name><surname>Manousou</surname> <given-names>K</given-names></name><name><surname>Papadopoulou</surname> <given-names>K</given-names></name><name><surname>Giannoulatou</surname> <given-names>E</given-names></name><name><surname>Bobos</surname> <given-names>M</given-names></name><name><surname>Sotiropoulou</surname> <given-names>M</given-names></name><name><surname>Pentheroudakis</surname> <given-names>G</given-names></name><name><surname>Efstratiou</surname> <given-names>I</given-names></name><name><surname>Papoudou-Bai</surname> <given-names>A</given-names></name><name><surname>Psyrri</surname> <given-names>A</given-names></name><name><surname>Christodoulou</surname> <given-names>C</given-names></name><name><surname>Gogas</surname> <given-names>H</given-names></name><name><surname>Koutras</surname> <given-names>A</given-names></name><name><surname>Timotheadou</surname> <given-names>E</given-names></name><name><surname>Pectasides</surname> <given-names>D</given-names></name><name><surname>Zagouri</surname> <given-names>F</given-names></name><name><surname>Fountzilas</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Opposite prognostic impact of single PTEN-loss and <italic>PIK3CA</italic> Mutations in Early High-risk Breast Cancer</article-title><source>Cancer Genomics - Proteomics</source><volume>16</volume><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.21873/cgp.20125</pub-id><pub-id pub-id-type="pmid">31018950</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leek</surname> <given-names>JT</given-names></name><name><surname>Johnson</surname> <given-names>WE</given-names></name><name><surname>Parker</surname> <given-names>HS</given-names></name><name><surname>Jaffe</surname> <given-names>AE</given-names></name><name><surname>Storey</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The sva package for removing batch effects and other unwanted variation in high-throughput experiments</article-title><source>Bioinformatics</source><volume>28</volume><fpage>882</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts034</pub-id><pub-id pub-id-type="pmid">22257669</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Xiao</surname> <given-names>T</given-names></name><name><surname>Cong</surname> <given-names>L</given-names></name><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Irizarry</surname> <given-names>RA</given-names></name><name><surname>Liu</surname> <given-names>JS</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>554</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0554-4</pub-id><pub-id pub-id-type="pmid">25476604</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>Ye</surname> <given-names>J</given-names></name><name><surname>Song</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The hippo effector TAZ promotes Cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma</article-title><source>Cell Death &amp; Disease</source><volume>10</volume><elocation-id>603</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-019-1838-0</pub-id><pub-id pub-id-type="pmid">31399556</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname> <given-names>A</given-names></name><name><surname>Birger</surname> <given-names>C</given-names></name><name><surname>Thorvaldsdóttir</surname> <given-names>H</given-names></name><name><surname>Ghandi</surname> <given-names>M</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The molecular signatures database (MSigDB) hallmark gene set collection</article-title><source>Cell Systems</source><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>SC</given-names></name><name><surname>Lu</surname> <given-names>SY</given-names></name><name><surname>Lee</surname> <given-names>SY</given-names></name><name><surname>Lin</surname> <given-names>CY</given-names></name><name><surname>Chen</surname> <given-names>CH</given-names></name><name><surname>Chang</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Areca (betel) nut extract activates mitogen-activated protein kinases and NF-kappaB in oral keratinocytes</article-title><source>International Journal of Cancer</source><volume>116</volume><fpage>526</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1002/ijc.21104</pub-id><pub-id pub-id-type="pmid">15825184</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martens-de Kemp</surname> <given-names>SR</given-names></name><name><surname>Nagel</surname> <given-names>R</given-names></name><name><surname>Stigter-van Walsum</surname> <given-names>M</given-names></name><name><surname>van der Meulen</surname> <given-names>IH</given-names></name><name><surname>van Beusechem</surname> <given-names>VW</given-names></name><name><surname>Braakhuis</surname> <given-names>BJ</given-names></name><name><surname>Brakenhoff</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung Cancer</article-title><source>Clinical Cancer Research</source><volume>19</volume><fpage>1994</fpage><lpage>2003</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2539</pub-id><pub-id pub-id-type="pmid">23444224</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>D</given-names></name><name><surname>Degese</surname> <given-names>MS</given-names></name><name><surname>Vitale-Cross</surname> <given-names>L</given-names></name><name><surname>Iglesias-Bartolome</surname> <given-names>R</given-names></name><name><surname>Valera</surname> <given-names>JLC</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Feng</surname> <given-names>X</given-names></name><name><surname>Yeerna</surname> <given-names>H</given-names></name><name><surname>Vadmal</surname> <given-names>V</given-names></name><name><surname>Moroishi</surname> <given-names>T</given-names></name><name><surname>Thorne</surname> <given-names>RF</given-names></name><name><surname>Zaida</surname> <given-names>M</given-names></name><name><surname>Siegele</surname> <given-names>B</given-names></name><name><surname>Cheong</surname> <given-names>SC</given-names></name><name><surname>Molinolo</surname> <given-names>AA</given-names></name><name><surname>Samuels</surname> <given-names>Y</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name><name><surname>Lippman</surname> <given-names>SM</given-names></name><name><surname>Lyons</surname> <given-names>JG</given-names></name><name><surname>Gutkind</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Assembly and activation of the hippo signalome by FAT1 tumor suppressor</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2372</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04590-1</pub-id><pub-id pub-id-type="pmid">29985391</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martincorena</surname> <given-names>I</given-names></name><name><surname>Raine</surname> <given-names>KM</given-names></name><name><surname>Gerstung</surname> <given-names>M</given-names></name><name><surname>Dawson</surname> <given-names>KJ</given-names></name><name><surname>Haase</surname> <given-names>K</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Davies</surname> <given-names>H</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Universal Patterns of Selection in Cancer and Somatic Tissues</article-title><source>Cell</source><volume>173</volume><elocation-id>1823</elocation-id><pub-id pub-id-type="doi">10.1016/j.cell.2018.06.001</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname> <given-names>ER</given-names></name><name><surname>de Weck</surname> <given-names>A</given-names></name><name><surname>Schlabach</surname> <given-names>MR</given-names></name><name><surname>Billy</surname> <given-names>E</given-names></name><name><surname>Mavrakis</surname> <given-names>KJ</given-names></name><name><surname>Hoffman</surname> <given-names>GR</given-names></name><name><surname>Belur</surname> <given-names>D</given-names></name><name><surname>Castelletti</surname> <given-names>D</given-names></name><name><surname>Frias</surname> <given-names>E</given-names></name><name><surname>Gampa</surname> <given-names>K</given-names></name><name><surname>Golji</surname> <given-names>J</given-names></name><name><surname>Kao</surname> <given-names>I</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Megel</surname> <given-names>P</given-names></name><name><surname>Perkins</surname> <given-names>TA</given-names></name><name><surname>Ramadan</surname> <given-names>N</given-names></name><name><surname>Ruddy</surname> <given-names>DA</given-names></name><name><surname>Silver</surname> <given-names>SJ</given-names></name><name><surname>Sovath</surname> <given-names>S</given-names></name><name><surname>Stump</surname> <given-names>M</given-names></name><name><surname>Weber</surname> <given-names>O</given-names></name><name><surname>Widmer</surname> <given-names>R</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>K</given-names></name><name><surname>Yue</surname> <given-names>Y</given-names></name><name><surname>Abramowski</surname> <given-names>D</given-names></name><name><surname>Ackley</surname> <given-names>E</given-names></name><name><surname>Barrett</surname> <given-names>R</given-names></name><name><surname>Berger</surname> <given-names>J</given-names></name><name><surname>Bernard</surname> <given-names>JL</given-names></name><name><surname>Billig</surname> <given-names>R</given-names></name><name><surname>Brachmann</surname> <given-names>SM</given-names></name><name><surname>Buxton</surname> <given-names>F</given-names></name><name><surname>Caothien</surname> <given-names>R</given-names></name><name><surname>Caushi</surname> <given-names>JX</given-names></name><name><surname>Chung</surname> <given-names>FS</given-names></name><name><surname>Cortés-Cros</surname> <given-names>M</given-names></name><name><surname>deBeaumont</surname> <given-names>RS</given-names></name><name><surname>Delaunay</surname> <given-names>C</given-names></name><name><surname>Desplat</surname> <given-names>A</given-names></name><name><surname>Duong</surname> <given-names>W</given-names></name><name><surname>Dwoske</surname> <given-names>DA</given-names></name><name><surname>Eldridge</surname> <given-names>RS</given-names></name><name><surname>Farsidjani</surname> <given-names>A</given-names></name><name><surname>Feng</surname> <given-names>F</given-names></name><name><surname>Feng</surname> <given-names>J</given-names></name><name><surname>Flemming</surname> <given-names>D</given-names></name><name><surname>Forrester</surname> <given-names>W</given-names></name><name><surname>Galli</surname> <given-names>GG</given-names></name><name><surname>Gao</surname> <given-names>Z</given-names></name><name><surname>Gauter</surname> <given-names>F</given-names></name><name><surname>Gibaja</surname> <given-names>V</given-names></name><name><surname>Haas</surname> <given-names>K</given-names></name><name><surname>Hattenberger</surname> <given-names>M</given-names></name><name><surname>Hood</surname> <given-names>T</given-names></name><name><surname>Hurov</surname> <given-names>KE</given-names></name><name><surname>Jagani</surname> <given-names>Z</given-names></name><name><surname>Jenal</surname> <given-names>M</given-names></name><name><surname>Johnson</surname> <given-names>JA</given-names></name><name><surname>Jones</surname> <given-names>MD</given-names></name><name><surname>Kapoor</surname> <given-names>A</given-names></name><name><surname>Korn</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Loo</surname> <given-names>AT</given-names></name><name><surname>Macchi</surname> <given-names>KJ</given-names></name><name><surname>Martin</surname> <given-names>T</given-names></name><name><surname>McAllister</surname> <given-names>G</given-names></name><name><surname>Meyer</surname> <given-names>A</given-names></name><name><surname>Mollé</surname> <given-names>S</given-names></name><name><surname>Pagliarini</surname> <given-names>RA</given-names></name><name><surname>Phadke</surname> <given-names>T</given-names></name><name><surname>Repko</surname> <given-names>B</given-names></name><name><surname>Schouwey</surname> <given-names>T</given-names></name><name><surname>Shanahan</surname> <given-names>F</given-names></name><name><surname>Shen</surname> <given-names>Q</given-names></name><name><surname>Stamm</surname> <given-names>C</given-names></name><name><surname>Stephan</surname> <given-names>C</given-names></name><name><surname>Stucke</surname> <given-names>VM</given-names></name><name><surname>Tiedt</surname> <given-names>R</given-names></name><name><surname>Varadarajan</surname> <given-names>M</given-names></name><name><surname>Venkatesan</surname> <given-names>K</given-names></name><name><surname>Vitari</surname> <given-names>AC</given-names></name><name><surname>Wallroth</surname> <given-names>M</given-names></name><name><surname>Weiler</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Mickanin</surname> <given-names>C</given-names></name><name><surname>Myer</surname> <given-names>VE</given-names></name><name><surname>Porter</surname> <given-names>JA</given-names></name><name><surname>Lai</surname> <given-names>A</given-names></name><name><surname>Bitter</surname> <given-names>H</given-names></name><name><surname>Lees</surname> <given-names>E</given-names></name><name><surname>Keen</surname> <given-names>N</given-names></name><name><surname>Kauffmann</surname> <given-names>A</given-names></name><name><surname>Stegmeier</surname> <given-names>F</given-names></name><name><surname>Hofmann</surname> <given-names>F</given-names></name><name><surname>Schmelzle</surname> <given-names>T</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Project DRIVE: a compendium of Cancer dependencies and synthetic lethal relationships uncovered by Large-Scale, deep RNAi screening</article-title><source>Cell</source><volume>170</volume><fpage>577</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.07.005</pub-id><pub-id pub-id-type="pmid">28753431</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname> <given-names>RM</given-names></name><name><surname>Bryan</surname> <given-names>JG</given-names></name><name><surname>McFarland</surname> <given-names>JM</given-names></name><name><surname>Weir</surname> <given-names>BA</given-names></name><name><surname>Sizemore</surname> <given-names>AE</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Dharia</surname> <given-names>NV</given-names></name><name><surname>Montgomery</surname> <given-names>PG</given-names></name><name><surname>Cowley</surname> <given-names>GS</given-names></name><name><surname>Pantel</surname> <given-names>S</given-names></name><name><surname>Goodale</surname> <given-names>A</given-names></name><name><surname>Lee</surname> <given-names>Y</given-names></name><name><surname>Ali</surname> <given-names>LD</given-names></name><name><surname>Jiang</surname> <given-names>G</given-names></name><name><surname>Lubonja</surname> <given-names>R</given-names></name><name><surname>Harrington</surname> <given-names>WF</given-names></name><name><surname>Strickland</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>T</given-names></name><name><surname>Hawes</surname> <given-names>DC</given-names></name><name><surname>Zhivich</surname> <given-names>VA</given-names></name><name><surname>Wyatt</surname> <given-names>MR</given-names></name><name><surname>Kalani</surname> <given-names>Z</given-names></name><name><surname>Chang</surname> <given-names>JJ</given-names></name><name><surname>Okamoto</surname> <given-names>M</given-names></name><name><surname>Stegmaier</surname> <given-names>K</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Boehm</surname> <given-names>JS</given-names></name><name><surname>Vazquez</surname> <given-names>F</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Tsherniak</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in Cancer cells</article-title><source>Nature Genetics</source><volume>49</volume><fpage>1779</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1038/ng.3984</pub-id><pub-id pub-id-type="pmid">29083409</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname> <given-names>H</given-names></name><name><surname>Muruganujan</surname> <given-names>A</given-names></name><name><surname>Casagrande</surname> <given-names>JT</given-names></name><name><surname>Thomas</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Large-scale gene function analysis with the PANTHER classification system</article-title><source>Nature Protocols</source><volume>8</volume><fpage>1551</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.092</pub-id><pub-id pub-id-type="pmid">23868073</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyauchi</surname> <given-names>S</given-names></name><name><surname>Moroyama</surname> <given-names>T</given-names></name><name><surname>Sakamoto</surname> <given-names>T</given-names></name><name><surname>Okamoto</surname> <given-names>T</given-names></name><name><surname>Takada</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Establishment of human tumor cell line (Ueda-1) derived from squamous cell carcinoma of the floor of the mouth</article-title><source>Japanese Journal of Oral &amp; Maxillofacial Surgery</source><volume>31</volume><fpage>1347</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.5794/jjoms.31.1347</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momose</surname> <given-names>F</given-names></name><name><surname>Araida</surname> <given-names>T</given-names></name><name><surname>Negishi</surname> <given-names>A</given-names></name><name><surname>Ichijo</surname> <given-names>H</given-names></name><name><surname>Shioda</surname> <given-names>S</given-names></name><name><surname>Sasaki</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas</article-title><source>Journal of Oral Pathology and Medicine</source><volume>18</volume><fpage>391</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0714.1989.tb01570.x</pub-id><pub-id pub-id-type="pmid">2585303</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroishi</surname> <given-names>T</given-names></name><name><surname>Hayashi</surname> <given-names>T</given-names></name><name><surname>Pan</surname> <given-names>WW</given-names></name><name><surname>Fujita</surname> <given-names>Y</given-names></name><name><surname>Holt</surname> <given-names>MV</given-names></name><name><surname>Qin</surname> <given-names>J</given-names></name><name><surname>Carson</surname> <given-names>DA</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The hippo pathway kinases LATS1/2 suppress cancer immunity</article-title><source>Cell</source><volume>167</volume><fpage>1525</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.11.005</pub-id><pub-id pub-id-type="pmid">27912060</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omori</surname> <given-names>H</given-names></name><name><surname>Nishio</surname> <given-names>M</given-names></name><name><surname>Masuda</surname> <given-names>M</given-names></name><name><surname>Miyachi</surname> <given-names>Y</given-names></name><name><surname>Ueda</surname> <given-names>F</given-names></name><name><surname>Nakano</surname> <given-names>T</given-names></name><name><surname>Sato</surname> <given-names>K</given-names></name><name><surname>Mimori</surname> <given-names>K</given-names></name><name><surname>Taguchi</surname> <given-names>K</given-names></name><name><surname>Hikasa</surname> <given-names>H</given-names></name><name><surname>Nishina</surname> <given-names>H</given-names></name><name><surname>Tashiro</surname> <given-names>H</given-names></name><name><surname>Kiyono</surname> <given-names>T</given-names></name><name><surname>Mak</surname> <given-names>TW</given-names></name><name><surname>Nakao</surname> <given-names>K</given-names></name><name><surname>Nakagawa</surname> <given-names>T</given-names></name><name><surname>Maehama</surname> <given-names>T</given-names></name><name><surname>Suzuki</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eaay3324</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aay3324</pub-id><pub-id pub-id-type="pmid">32206709</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname> <given-names>Z</given-names></name><name><surname>Tian</surname> <given-names>Y</given-names></name><name><surname>Cao</surname> <given-names>C</given-names></name><name><surname>Niu</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The emerging role of YAP/TAZ in tumor immunity</article-title><source>Molecular Cancer Research</source><volume>17</volume><fpage>1777</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-19-0375</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pattschull</surname> <given-names>G</given-names></name><name><surname>Walz</surname> <given-names>S</given-names></name><name><surname>Gründl</surname> <given-names>M</given-names></name><name><surname>Schwab</surname> <given-names>M</given-names></name><name><surname>Rühl</surname> <given-names>E</given-names></name><name><surname>Baluapuri</surname> <given-names>A</given-names></name><name><surname>Cindric-Vranesic</surname> <given-names>A</given-names></name><name><surname>Kneitz</surname> <given-names>S</given-names></name><name><surname>Wolf</surname> <given-names>E</given-names></name><name><surname>Ade</surname> <given-names>CP</given-names></name><name><surname>Rosenwald</surname> <given-names>A</given-names></name><name><surname>von Eyss</surname> <given-names>B</given-names></name><name><surname>Gaubatz</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Myb-MuvB complex is required for YAP-Dependent transcription of mitotic genes</article-title><source>Cell Reports</source><volume>27</volume><fpage>3533</fpage><lpage>3546</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.05.071</pub-id><pub-id pub-id-type="pmid">31216474</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picco</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>ED</given-names></name><name><surname>Alonso</surname> <given-names>LG</given-names></name><name><surname>Behan</surname> <given-names>FM</given-names></name><name><surname>Gonçalves</surname> <given-names>E</given-names></name><name><surname>Bignell</surname> <given-names>G</given-names></name><name><surname>Matchan</surname> <given-names>A</given-names></name><name><surname>Fu</surname> <given-names>B</given-names></name><name><surname>Banerjee</surname> <given-names>R</given-names></name><name><surname>Anderson</surname> <given-names>E</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Benes</surname> <given-names>CH</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Dow</surname> <given-names>D</given-names></name><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Stronach</surname> <given-names>E</given-names></name><name><surname>Yang</surname> <given-names>F</given-names></name><name><surname>Yusa</surname> <given-names>K</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Garnett</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Functional linkage of gene fusions to Cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2198</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09940-1</pub-id><pub-id pub-id-type="pmid">31097696</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickering</surname> <given-names>CR</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Yoo</surname> <given-names>SY</given-names></name><name><surname>Bengtsson</surname> <given-names>L</given-names></name><name><surname>Moorthy</surname> <given-names>S</given-names></name><name><surname>Neskey</surname> <given-names>DM</given-names></name><name><surname>Zhao</surname> <given-names>M</given-names></name><name><surname>Ortega Alves</surname> <given-names>MV</given-names></name><name><surname>Chang</surname> <given-names>K</given-names></name><name><surname>Drummond</surname> <given-names>J</given-names></name><name><surname>Cortez</surname> <given-names>E</given-names></name><name><surname>Xie</surname> <given-names>TX</given-names></name><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Chung</surname> <given-names>W</given-names></name><name><surname>Issa</surname> <given-names>JP</given-names></name><name><surname>Zweidler-McKay</surname> <given-names>PA</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>El-Naggar</surname> <given-names>AK</given-names></name><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Muzny</surname> <given-names>DM</given-names></name><name><surname>Gibbs</surname> <given-names>RA</given-names></name><name><surname>Wheeler</surname> <given-names>DA</given-names></name><name><surname>Myers</surname> <given-names>JN</given-names></name><name><surname>Frederick</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers</article-title><source>Cancer Discovery</source><volume>3</volume><fpage>770</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0537</pub-id><pub-id pub-id-type="pmid">23619168</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plouffe</surname> <given-names>SW</given-names></name><name><surname>Lin</surname> <given-names>KC</given-names></name><name><surname>Moore</surname> <given-names>JL</given-names></name><name><surname>Tan</surname> <given-names>FE</given-names></name><name><surname>Ma</surname> <given-names>S</given-names></name><name><surname>Ye</surname> <given-names>Z</given-names></name><name><surname>Qiu</surname> <given-names>Y</given-names></name><name><surname>Ren</surname> <given-names>B</given-names></name><name><surname>Guan</surname> <given-names>K-L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell</article-title><source>Journal of Biological Chemistry</source><volume>293</volume><fpage>11230</fpage><lpage>11240</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.002715</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reich</surname> <given-names>M</given-names></name><name><surname>Liefeld</surname> <given-names>T</given-names></name><name><surname>Gould</surname> <given-names>J</given-names></name><name><surname>Lerner</surname> <given-names>J</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>GenePattern 2.0</article-title><source>Nature Genetics</source><volume>38</volume><fpage>500</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/ng0506-500</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rheinwald</surname> <given-names>JG</given-names></name><name><surname>Beckett</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas</article-title><source>Cancer Research</source><volume>41</volume><fpage>1657</fpage><lpage>1663</lpage><pub-id pub-id-type="pmid">7214336</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saladi</surname> <given-names>SV</given-names></name><name><surname>Ross</surname> <given-names>K</given-names></name><name><surname>Karaayvaz</surname> <given-names>M</given-names></name><name><surname>Tata</surname> <given-names>PR</given-names></name><name><surname>Mou</surname> <given-names>H</given-names></name><name><surname>Rajagopal</surname> <given-names>J</given-names></name><name><surname>Ramaswamy</surname> <given-names>S</given-names></name><name><surname>Ellisen</surname> <given-names>LW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ACTL6A is Co-Amplified with p63 in squamous cell carcinoma to drive YAP activation, regenerative proliferation, and poor prognosis</article-title><source>Cancer Cell</source><volume>31</volume><fpage>35</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.12.001</pub-id><pub-id pub-id-type="pmid">28041841</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salahshourifar</surname> <given-names>I</given-names></name><name><surname>Vincent-Chong</surname> <given-names>VK</given-names></name><name><surname>Kallarakkal</surname> <given-names>TG</given-names></name><name><surname>Zain</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genomic DNA copy number alterations from precursor oral lesions to oral squamous cell carcinoma</article-title><source>Oral Oncology</source><volume>50</volume><fpage>404</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2014.02.005</pub-id><pub-id pub-id-type="pmid">24613650</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saloura</surname> <given-names>V</given-names></name><name><surname>Izumchenko</surname> <given-names>E</given-names></name><name><surname>Zuo</surname> <given-names>Z</given-names></name><name><surname>Bao</surname> <given-names>R</given-names></name><name><surname>Korzinkin</surname> <given-names>M</given-names></name><name><surname>Ozerov</surname> <given-names>I</given-names></name><name><surname>Zhavoronkov</surname> <given-names>A</given-names></name><name><surname>Sidransky</surname> <given-names>D</given-names></name><name><surname>Bedi</surname> <given-names>A</given-names></name><name><surname>Hoque</surname> <given-names>MO</given-names></name><name><surname>Koeppen</surname> <given-names>H</given-names></name><name><surname>Keck</surname> <given-names>MK</given-names></name><name><surname>Khattri</surname> <given-names>A</given-names></name><name><surname>London</surname> <given-names>N</given-names></name><name><surname>Kotlov</surname> <given-names>N</given-names></name><name><surname>Fatima</surname> <given-names>A</given-names></name><name><surname>Vougiouklakis</surname> <given-names>T</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Lingen</surname> <given-names>M</given-names></name><name><surname>Agrawal</surname> <given-names>N</given-names></name><name><surname>Savage</surname> <given-names>PA</given-names></name><name><surname>Kron</surname> <given-names>S</given-names></name><name><surname>Kline</surname> <given-names>J</given-names></name><name><surname>Kowanetz</surname> <given-names>M</given-names></name><name><surname>Seiwert</surname> <given-names>TY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immune profiles in primary squamous cell carcinoma of the head and neck</article-title><source>Oral Oncology</source><volume>96</volume><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2019.06.032</pub-id><pub-id pub-id-type="pmid">31422218</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos-de-Frutos</surname> <given-names>K</given-names></name><name><surname>Segrelles</surname> <given-names>C</given-names></name><name><surname>Lorz</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hippo pathway and YAP signaling alterations in squamous Cancer of the head and neck</article-title><source>Journal of Clinical Medicine</source><volume>8</volume><elocation-id>2131</elocation-id><pub-id pub-id-type="doi">10.3390/jcm8122131</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname> <given-names>G</given-names></name><name><surname>Chaturvedi</surname> <given-names>P</given-names></name><name><surname>Vaishampayan</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Arecanut as an emerging etiology of oral cancers in India</article-title><source>Indian Journal of Medical and Paediatric Oncology</source><volume>33</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.4103/0971-5851.99726</pub-id><pub-id pub-id-type="pmid">22988348</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname> <given-names>T</given-names></name><name><surname>Ohta</surname> <given-names>T</given-names></name><name><surname>Tong</surname> <given-names>KI</given-names></name><name><surname>Kokubu</surname> <given-names>A</given-names></name><name><surname>Odogawa</surname> <given-names>R</given-names></name><name><surname>Tsuta</surname> <given-names>K</given-names></name><name><surname>Asamura</surname> <given-names>H</given-names></name><name><surname>Yamamoto</surname> <given-names>M</given-names></name><name><surname>Hirohashi</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy</article-title><source>PNAS</source><volume>105</volume><fpage>13568</fpage><lpage>13573</lpage><pub-id pub-id-type="doi">10.1073/pnas.0806268105</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shield</surname> <given-names>KD</given-names></name><name><surname>Ferlay</surname> <given-names>J</given-names></name><name><surname>Jemal</surname> <given-names>A</given-names></name><name><surname>Sankaranarayanan</surname> <given-names>R</given-names></name><name><surname>Chaturvedi</surname> <given-names>AK</given-names></name><name><surname>Bray</surname> <given-names>F</given-names></name><name><surname>Soerjomataram</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012</article-title><source>CA: A Cancer Journal for Clinicians</source><volume>67</volume><fpage>51</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.3322/caac.21384</pub-id><pub-id pub-id-type="pmid">28076666</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>S</given-names></name><name><surname>Xie</surname> <given-names>M</given-names></name><name><surname>Scott</surname> <given-names>AW</given-names></name><name><surname>Jin</surname> <given-names>J</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Dong</surname> <given-names>X</given-names></name><name><surname>Skinner</surname> <given-names>HD</given-names></name><name><surname>Johnson</surname> <given-names>RL</given-names></name><name><surname>Ding</surname> <given-names>S</given-names></name><name><surname>Ajani</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A novel YAP1 inhibitor targets CSC-Enriched Radiation-Resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma</article-title><source>Molecular Cancer Therapeutics</source><volume>17</volume><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0560</pub-id><pub-id pub-id-type="pmid">29167315</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinhart</surname> <given-names>Z</given-names></name><name><surname>Pavlovic</surname> <given-names>Z</given-names></name><name><surname>Chandrashekhar</surname> <given-names>M</given-names></name><name><surname>Hart</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Robitaille</surname> <given-names>M</given-names></name><name><surname>Brown</surname> <given-names>KR</given-names></name><name><surname>Jaksani</surname> <given-names>S</given-names></name><name><surname>Overmeer</surname> <given-names>R</given-names></name><name><surname>Boj</surname> <given-names>SF</given-names></name><name><surname>Adams</surname> <given-names>J</given-names></name><name><surname>Pan</surname> <given-names>J</given-names></name><name><surname>Clevers</surname> <given-names>H</given-names></name><name><surname>Sidhu</surname> <given-names>S</given-names></name><name><surname>Moffat</surname> <given-names>J</given-names></name><name><surname>Angers</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors</article-title><source>Nature Medicine</source><volume>23</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/nm.4219</pub-id><pub-id pub-id-type="pmid">27869803</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>SC</given-names></name><name><surname>Lin</surname> <given-names>CW</given-names></name><name><surname>Liu</surname> <given-names>YF</given-names></name><name><surname>Fan</surname> <given-names>WL</given-names></name><name><surname>Chen</surname> <given-names>MK</given-names></name><name><surname>Yu</surname> <given-names>CP</given-names></name><name><surname>Yang</surname> <given-names>WE</given-names></name><name><surname>Su</surname> <given-names>CW</given-names></name><name><surname>Chuang</surname> <given-names>CY</given-names></name><name><surname>Li</surname> <given-names>WH</given-names></name><name><surname>Chung</surname> <given-names>WH</given-names></name><name><surname>Yang</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Exome sequencing of oral squamous cell carcinoma reveals molecular subgroups and novel therapeutic opportunities</article-title><source>Theranostics</source><volume>7</volume><fpage>1088</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.7150/thno.18551</pub-id><pub-id pub-id-type="pmid">28435450</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname> <given-names>K</given-names></name><name><surname>Kanazawa</surname> <given-names>H</given-names></name><name><surname>Akiyama</surname> <given-names>Y</given-names></name><name><surname>Tazaki</surname> <given-names>S</given-names></name><name><surname>Takahara</surname> <given-names>M</given-names></name><name><surname>Muto</surname> <given-names>T</given-names></name><name><surname>Tanzawa</surname> <given-names>H</given-names></name><name><surname>Sato</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Establishment and characterization of a cell line (SAS) from poorly differentiated human squamous cell carcinoma of the tongue</article-title><source>Journal of the Japanese Stomatological Society</source><volume>38</volume><fpage>20</fpage><lpage>28</lpage></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Cancer Genome Atlas Network</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Comprehensive genomic characterization of head and neck squamous cell carcinomas</article-title><source>Nature</source><volume>517</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/nature14129</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorsson</surname> <given-names>V</given-names></name><name><surname>Gibbs</surname> <given-names>DL</given-names></name><name><surname>Brown</surname> <given-names>SD</given-names></name><name><surname>Wolf</surname> <given-names>D</given-names></name><name><surname>Bortone</surname> <given-names>DS</given-names></name><name><surname>Ou Yang</surname> <given-names>TH</given-names></name><name><surname>Porta-Pardo</surname> <given-names>E</given-names></name><name><surname>Gao</surname> <given-names>GF</given-names></name><name><surname>Plaisier</surname> <given-names>CL</given-names></name><name><surname>Eddy</surname> <given-names>JA</given-names></name><name><surname>Ziv</surname> <given-names>E</given-names></name><name><surname>Culhane</surname> <given-names>AC</given-names></name><name><surname>Paull</surname> <given-names>EO</given-names></name><name><surname>Sivakumar</surname> <given-names>IKA</given-names></name><name><surname>Gentles</surname> <given-names>AJ</given-names></name><name><surname>Malhotra</surname> <given-names>R</given-names></name><name><surname>Farshidfar</surname> <given-names>F</given-names></name><name><surname>Colaprico</surname> <given-names>A</given-names></name><name><surname>Parker</surname> <given-names>JS</given-names></name><name><surname>Mose</surname> <given-names>LE</given-names></name><name><surname>Vo</surname> <given-names>NS</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Rader</surname> <given-names>J</given-names></name><name><surname>Dhankani</surname> <given-names>V</given-names></name><name><surname>Reynolds</surname> <given-names>SM</given-names></name><name><surname>Bowlby</surname> <given-names>R</given-names></name><name><surname>Califano</surname> <given-names>A</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Anastassiou</surname> <given-names>D</given-names></name><name><surname>Bedognetti</surname> <given-names>D</given-names></name><name><surname>Mokrab</surname> <given-names>Y</given-names></name><name><surname>Newman</surname> <given-names>AM</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Krasnitz</surname> <given-names>A</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Malta</surname> <given-names>TM</given-names></name><name><surname>Noushmehr</surname> <given-names>H</given-names></name><name><surname>Pedamallu</surname> <given-names>CS</given-names></name><name><surname>Bullman</surname> <given-names>S</given-names></name><name><surname>Ojesina</surname> <given-names>AI</given-names></name><name><surname>Lamb</surname> <given-names>A</given-names></name><name><surname>Zhou</surname> <given-names>W</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Choueiri</surname> <given-names>TK</given-names></name><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Guinney</surname> <given-names>J</given-names></name><name><surname>Saltz</surname> <given-names>J</given-names></name><name><surname>Holt</surname> <given-names>RA</given-names></name><name><surname>Rabkin</surname> <given-names>CS</given-names></name><name><surname>Lazar</surname> <given-names>AJ</given-names></name><name><surname>Serody</surname> <given-names>JS</given-names></name><name><surname>Demicco</surname> <given-names>EG</given-names></name><name><surname>Disis</surname> <given-names>ML</given-names></name><name><surname>Vincent</surname> <given-names>BG</given-names></name><name><surname>Shmulevich</surname> <given-names>I</given-names></name><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2018">2018</year><article-title>The immune landscape of Cancer</article-title><source>Immunity</source><volume>48</volume><fpage>812</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.023</pub-id><pub-id pub-id-type="pmid">29628290</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsherniak</surname> <given-names>A</given-names></name><name><surname>Vazquez</surname> <given-names>F</given-names></name><name><surname>Montgomery</surname> <given-names>PG</given-names></name><name><surname>Weir</surname> <given-names>BA</given-names></name><name><surname>Kryukov</surname> <given-names>G</given-names></name><name><surname>Cowley</surname> <given-names>GS</given-names></name><name><surname>Gill</surname> <given-names>S</given-names></name><name><surname>Harrington</surname> <given-names>WF</given-names></name><name><surname>Pantel</surname> <given-names>S</given-names></name><name><surname>Krill-Burger</surname> <given-names>JM</given-names></name><name><surname>Meyers</surname> <given-names>RM</given-names></name><name><surname>Ali</surname> <given-names>L</given-names></name><name><surname>Goodale</surname> <given-names>A</given-names></name><name><surname>Lee</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>G</given-names></name><name><surname>Hsiao</surname> <given-names>J</given-names></name><name><surname>Gerath</surname> <given-names>WFJ</given-names></name><name><surname>Howell</surname> <given-names>S</given-names></name><name><surname>Merkel</surname> <given-names>E</given-names></name><name><surname>Ghandi</surname> <given-names>M</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Boehm</surname> <given-names>JS</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Defining a Cancer dependency map</article-title><source>Cell</source><volume>170</volume><fpage>564</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.010</pub-id><pub-id pub-id-type="pmid">28753430</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzelepis</surname> <given-names>K</given-names></name><name><surname>Koike-Yusa</surname> <given-names>H</given-names></name><name><surname>De Braekeleer</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Metzakopian</surname> <given-names>E</given-names></name><name><surname>Dovey</surname> <given-names>OM</given-names></name><name><surname>Mupo</surname> <given-names>A</given-names></name><name><surname>Grinkevich</surname> <given-names>V</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Mazan</surname> <given-names>M</given-names></name><name><surname>Gozdecka</surname> <given-names>M</given-names></name><name><surname>Ohnishi</surname> <given-names>S</given-names></name><name><surname>Cooper</surname> <given-names>J</given-names></name><name><surname>Patel</surname> <given-names>M</given-names></name><name><surname>McKerrell</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Domingues</surname> <given-names>AF</given-names></name><name><surname>Gallipoli</surname> <given-names>P</given-names></name><name><surname>Teichmann</surname> <given-names>S</given-names></name><name><surname>Ponstingl</surname> <given-names>H</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Huntly</surname> <given-names>BJP</given-names></name><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Pina</surname> <given-names>C</given-names></name><name><surname>Vassiliou</surname> <given-names>GS</given-names></name><name><surname>Yusa</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia</article-title><source>Cell Reports</source><volume>17</volume><fpage>1193</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.09.079</pub-id><pub-id pub-id-type="pmid">27760321</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermorken</surname> <given-names>JB</given-names></name><name><surname>Mesia</surname> <given-names>R</given-names></name><name><surname>Rivera</surname> <given-names>F</given-names></name><name><surname>Remenar</surname> <given-names>E</given-names></name><name><surname>Kawecki</surname> <given-names>A</given-names></name><name><surname>Rottey</surname> <given-names>S</given-names></name><name><surname>Erfan</surname> <given-names>J</given-names></name><name><surname>Zabolotnyy</surname> <given-names>D</given-names></name><name><surname>Kienzer</surname> <given-names>HR</given-names></name><name><surname>Cupissol</surname> <given-names>D</given-names></name><name><surname>Peyrade</surname> <given-names>F</given-names></name><name><surname>Benasso</surname> <given-names>M</given-names></name><name><surname>Vynnychenko</surname> <given-names>I</given-names></name><name><surname>De Raucourt</surname> <given-names>D</given-names></name><name><surname>Bokemeyer</surname> <given-names>C</given-names></name><name><surname>Schueler</surname> <given-names>A</given-names></name><name><surname>Amellal</surname> <given-names>N</given-names></name><name><surname>Hitt</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Platinum-based chemotherapy plus cetuximab in head and neck Cancer</article-title><source>New England Journal of Medicine</source><volume>359</volume><fpage>1116</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802656</pub-id><pub-id pub-id-type="pmid">18784101</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Hughes</surname> <given-names>NW</given-names></name><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Kendirli</surname> <given-names>A</given-names></name><name><surname>Klein</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>WW</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras</article-title><source>Cell</source><volume>168</volume><fpage>890</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.01.013</pub-id><pub-id pub-id-type="pmid">28162770</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Maglic</surname> <given-names>D</given-names></name><name><surname>Dill</surname> <given-names>MT</given-names></name><name><surname>Mojumdar</surname> <given-names>K</given-names></name><name><surname>Ng</surname> <given-names>PK-S</given-names></name><name><surname>Jeong</surname> <given-names>KJ</given-names></name><name><surname>Tsang</surname> <given-names>YH</given-names></name><name><surname>Moreno</surname> <given-names>D</given-names></name><name><surname>Bhavana</surname> <given-names>VH</given-names></name><name><surname>Peng</surname> <given-names>X</given-names></name><name><surname>Ge</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Han</surname> <given-names>L</given-names></name><name><surname>Du</surname> <given-names>D</given-names></name><name><surname>Creighton</surname> <given-names>CJ</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Camargo</surname> <given-names>F</given-names></name><name><surname>Liang</surname> <given-names>H</given-names></name><name><surname>Caesar-Johnson</surname> <given-names>SJ</given-names></name><name><surname>Demchok</surname> <given-names>JA</given-names></name><name><surname>Felau</surname> <given-names>I</given-names></name><name><surname>Kasapi</surname> <given-names>M</given-names></name><name><surname>Ferguson</surname> <given-names>ML</given-names></name><name><surname>Hutter</surname> <given-names>CM</given-names></name><name><surname>Sofia</surname> <given-names>HJ</given-names></name><name><surname>Tarnuzzer</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Zenklusen</surname> <given-names>JC</given-names></name><name><surname>Zhang</surname> <given-names>JJ</given-names></name><name><surname>Chudamani</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Lolla</surname> <given-names>L</given-names></name><name><surname>Naresh</surname> <given-names>R</given-names></name><name><surname>Pihl</surname> <given-names>T</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Wan</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Cho</surname> <given-names>J</given-names></name><name><surname>DeFreitas</surname> <given-names>T</given-names></name><name><surname>Frazer</surname> <given-names>S</given-names></name><name><surname>Gehlenborg</surname> <given-names>N</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Heiman</surname> <given-names>DI</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Lin</surname> <given-names>P</given-names></name><name><surname>Meier</surname> <given-names>S</given-names></name><name><surname>Noble</surname> <given-names>MS</given-names></name><name><surname>Saksena</surname> <given-names>G</given-names></name><name><surname>Voet</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Bernard</surname> <given-names>B</given-names></name><name><surname>Chambwe</surname> <given-names>N</given-names></name><name><surname>Dhankani</surname> <given-names>V</given-names></name><name><surname>Knijnenburg</surname> <given-names>T</given-names></name><name><surname>Kramer</surname> <given-names>R</given-names></name><name><surname>Leinonen</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Miller</surname> <given-names>M</given-names></name><name><surname>Reynolds</surname> <given-names>S</given-names></name><name><surname>Shmulevich</surname> <given-names>I</given-names></name><name><surname>Thorsson</surname> <given-names>V</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Akbani</surname> <given-names>R</given-names></name><name><surname>Broom</surname> <given-names>BM</given-names></name><name><surname>Hegde</surname> <given-names>AM</given-names></name><name><surname>Ju</surname> <given-names>Z</given-names></name><name><surname>Kanchi</surname> <given-names>RS</given-names></name><name><surname>Korkut</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Liang</surname> <given-names>H</given-names></name><name><surname>Ling</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Ng</surname> <given-names>K-S</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name><name><surname>Ryan</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Abeshouse</surname> <given-names>A</given-names></name><name><surname>Armenia</surname> <given-names>J</given-names></name><name><surname>Chakravarty</surname> <given-names>D</given-names></name><name><surname>Chatila</surname> <given-names>WK</given-names></name><name><surname>de Bruijn</surname> <given-names>I</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Gross</surname> <given-names>BE</given-names></name><name><surname>Heins</surname> <given-names>ZJ</given-names></name><name><surname>Kundra</surname> <given-names>R</given-names></name><name><surname>La</surname> <given-names>K</given-names></name><name><surname>Ladanyi</surname> <given-names>M</given-names></name><name><surname>Luna</surname> <given-names>A</given-names></name><name><surname>Nissan</surname> <given-names>MG</given-names></name><name><surname>Ochoa</surname> <given-names>A</given-names></name><name><surname>Phillips</surname> <given-names>SM</given-names></name><name><surname>Reznik</surname> <given-names>E</given-names></name><name><surname>Sanchez-Vega</surname> <given-names>F</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Sheridan</surname> <given-names>R</given-names></name><name><surname>Sumer</surname> <given-names>SO</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Taylor</surname> <given-names>BS</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Anur</surname> <given-names>P</given-names></name><name><surname>Peto</surname> <given-names>M</given-names></name><name><surname>Spellman</surname> <given-names>P</given-names></name><name><surname>Benz</surname> <given-names>C</given-names></name><name><surname>Stuart</surname> <given-names>JM</given-names></name><name><surname>Wong</surname> <given-names>CK</given-names></name><name><surname>Yau</surname> <given-names>C</given-names></name><name><surname>Hayes</surname> <given-names>DN</given-names></name><name><surname>Parker</surname> <given-names>JS</given-names></name><name><surname>Wilkerson</surname> <given-names>MD</given-names></name><name><surname>Ally</surname> <given-names>A</given-names></name><name><surname>Balasundaram</surname> <given-names>M</given-names></name><name><surname>Bowlby</surname> <given-names>R</given-names></name><name><surname>Brooks</surname> <given-names>D</given-names></name><name><surname>Carlsen</surname> <given-names>R</given-names></name><name><surname>Chuah</surname> <given-names>E</given-names></name><name><surname>Dhalla</surname> <given-names>N</given-names></name><name><surname>Holt</surname> <given-names>R</given-names></name><name><surname>Jones</surname> <given-names>SJM</given-names></name><name><surname>Kasaian</surname> <given-names>K</given-names></name><name><surname>Lee</surname> <given-names>D</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name><name><surname>Mayo</surname> <given-names>M</given-names></name><name><surname>Moore</surname> <given-names>RA</given-names></name><name><surname>Mungall</surname> <given-names>AJ</given-names></name><name><surname>Mungall</surname> <given-names>K</given-names></name><name><surname>Robertson</surname> <given-names>AG</given-names></name><name><surname>Sadeghi</surname> <given-names>S</given-names></name><name><surname>Schein</surname> <given-names>JE</given-names></name><name><surname>Sipahimalani</surname> <given-names>P</given-names></name><name><surname>Tam</surname> <given-names>A</given-names></name><name><surname>Thiessen</surname> <given-names>N</given-names></name><name><surname>Tse</surname> <given-names>K</given-names></name><name><surname>Wong</surname> <given-names>T</given-names></name><name><surname>Berger</surname> <given-names>AC</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Cibulskis</surname> <given-names>C</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Gao</surname> <given-names>GF</given-names></name><name><surname>Ha</surname> <given-names>G</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Schumacher</surname> <given-names>SE</given-names></name><name><surname>Shih</surname> <given-names>J</given-names></name><name><surname>Kucherlapati</surname> <given-names>MH</given-names></name><name><surname>Kucherlapati</surname> <given-names>RS</given-names></name><name><surname>Baylin</surname> <given-names>S</given-names></name><name><surname>Cope</surname> <given-names>L</given-names></name><name><surname>Danilova</surname> <given-names>L</given-names></name><name><surname>Bootwalla</surname> <given-names>MS</given-names></name><name><surname>Lai</surname> <given-names>PH</given-names></name><name><surname>Maglinte</surname> <given-names>DT</given-names></name><name><surname>Van Den Berg</surname> <given-names>DJ</given-names></name><name><surname>Weisenberger</surname> <given-names>DJ</given-names></name><name><surname>Auman</surname> <given-names>JT</given-names></name><name><surname>Balu</surname> <given-names>S</given-names></name><name><surname>Bodenheimer</surname> <given-names>T</given-names></name><name><surname>Fan</surname> <given-names>C</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>Hoyle</surname> <given-names>AP</given-names></name><name><surname>Jefferys</surname> <given-names>SR</given-names></name><name><surname>Jones</surname> <given-names>CD</given-names></name><name><surname>Meng</surname> <given-names>S</given-names></name><name><surname>Mieczkowski</surname> <given-names>PA</given-names></name><name><surname>Mose</surname> <given-names>LE</given-names></name><name><surname>Perou</surname> <given-names>AH</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Roach</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Simons</surname> <given-names>JV</given-names></name><name><surname>Skelly</surname> <given-names>T</given-names></name><name><surname>Soloway</surname> <given-names>MG</given-names></name><name><surname>Tan</surname> <given-names>D</given-names></name><name><surname>Veluvolu</surname> <given-names>U</given-names></name><name><surname>Fan</surname> <given-names>H</given-names></name><name><surname>Hinoue</surname> <given-names>T</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>W</given-names></name><name><surname>Bellair</surname> <given-names>M</given-names></name><name><surname>Chang</surname> <given-names>K</given-names></name><name><surname>Covington</surname> <given-names>K</given-names></name><name><surname>Creighton</surname> <given-names>CJ</given-names></name><name><surname>Dinh</surname> <given-names>H</given-names></name><name><surname>Doddapaneni</surname> <given-names>H</given-names></name><name><surname>Donehower</surname> <given-names>LA</given-names></name><name><surname>Drummond</surname> <given-names>J</given-names></name><name><surname>Gibbs</surname> <given-names>RA</given-names></name><name><surname>Glenn</surname> <given-names>R</given-names></name><name><surname>Hale</surname> <given-names>W</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Korchina</surname> <given-names>V</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Lewis</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Morgan</surname> <given-names>M</given-names></name><name><surname>Morton</surname> <given-names>D</given-names></name><name><surname>Muzny</surname> <given-names>D</given-names></name><name><surname>Santibanez</surname> <given-names>J</given-names></name><name><surname>Sheth</surname> <given-names>M</given-names></name><name><surname>Shinbrot</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Wheeler</surname> <given-names>DA</given-names></name><name><surname>Xi</surname> <given-names>L</given-names></name><name><surname>Zhao</surname> <given-names>F</given-names></name><name><surname>Hess</surname> <given-names>J</given-names></name><name><surname>Appelbaum</surname> <given-names>EL</given-names></name><name><surname>Bailey</surname> <given-names>M</given-names></name><name><surname>Cordes</surname> <given-names>MG</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Fronick</surname> <given-names>CC</given-names></name><name><surname>Fulton</surname> <given-names>LA</given-names></name><name><surname>Fulton</surname> <given-names>RS</given-names></name><name><surname>Kandoth</surname> <given-names>C</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name><name><surname>McLellan</surname> <given-names>MD</given-names></name><name><surname>Miller</surname> <given-names>CA</given-names></name><name><surname>Schmidt</surname> <given-names>HK</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Crain</surname> <given-names>D</given-names></name><name><surname>Curley</surname> <given-names>E</given-names></name><name><surname>Gardner</surname> <given-names>J</given-names></name><name><surname>Lau</surname> <given-names>K</given-names></name><name><surname>Mallery</surname> <given-names>D</given-names></name><name><surname>Morris</surname> <given-names>S</given-names></name><name><surname>Paulauskis</surname> <given-names>J</given-names></name><name><surname>Penny</surname> <given-names>R</given-names></name><name><surname>Shelton</surname> <given-names>C</given-names></name><name><surname>Shelton</surname> <given-names>T</given-names></name><name><surname>Sherman</surname> <given-names>M</given-names></name><name><surname>Thompson</surname> <given-names>E</given-names></name><name><surname>Yena</surname> <given-names>P</given-names></name><name><surname>Bowen</surname> <given-names>J</given-names></name><name><surname>Gastier-Foster</surname> <given-names>JM</given-names></name><name><surname>Gerken</surname> <given-names>M</given-names></name><name><surname>Leraas</surname> <given-names>KM</given-names></name><name><surname>Lichtenberg</surname> <given-names>TM</given-names></name><name><surname>Ramirez</surname> <given-names>NC</given-names></name><name><surname>Wise</surname> <given-names>L</given-names></name><name><surname>Zmuda</surname> <given-names>E</given-names></name><name><surname>Corcoran</surname> <given-names>N</given-names></name><name><surname>Costello</surname> <given-names>T</given-names></name><name><surname>Hovens</surname> <given-names>C</given-names></name><name><surname>Carvalho</surname> <given-names>AL</given-names></name><name><surname>de Carvalho</surname> <given-names>AC</given-names></name><name><surname>Fregnani</surname> <given-names>JH</given-names></name><name><surname>Longatto-Filho</surname> <given-names>A</given-names></name><name><surname>Reis</surname> <given-names>RM</given-names></name><name><surname>Scapulatempo-Neto</surname> <given-names>C</given-names></name><name><surname>Silveira</surname> <given-names>HCS</given-names></name><name><surname>Vidal</surname> <given-names>DO</given-names></name><name><surname>Burnette</surname> <given-names>A</given-names></name><name><surname>Eschbacher</surname> <given-names>J</given-names></name><name><surname>Hermes</surname> <given-names>B</given-names></name><name><surname>Noss</surname> <given-names>A</given-names></name><name><surname>Singh</surname> <given-names>R</given-names></name><name><surname>Anderson</surname> <given-names>ML</given-names></name><name><surname>Castro</surname> <given-names>PD</given-names></name><name><surname>Ittmann</surname> <given-names>M</given-names></name><name><surname>Huntsman</surname> <given-names>D</given-names></name><name><surname>Kohl</surname> <given-names>B</given-names></name><name><surname>Le</surname> <given-names>X</given-names></name><name><surname>Thorp</surname> <given-names>R</given-names></name><name><surname>Andry</surname> <given-names>C</given-names></name><name><surname>Duffy</surname> <given-names>ER</given-names></name><name><surname>Lyadov</surname> <given-names>V</given-names></name><name><surname>Paklina</surname> <given-names>O</given-names></name><name><surname>Setdikova</surname> <given-names>G</given-names></name><name><surname>Shabunin</surname> <given-names>A</given-names></name><name><surname>Tavobilov</surname> <given-names>M</given-names></name><name><surname>McPherson</surname> <given-names>C</given-names></name><name><surname>Warnick</surname> <given-names>R</given-names></name><name><surname>Berkowitz</surname> <given-names>R</given-names></name><name><surname>Cramer</surname> <given-names>D</given-names></name><name><surname>Feltmate</surname> <given-names>C</given-names></name><name><surname>Horowitz</surname> <given-names>N</given-names></name><name><surname>Kibel</surname> <given-names>A</given-names></name><name><surname>Muto</surname> <given-names>M</given-names></name><name><surname>Raut</surname> <given-names>CP</given-names></name><name><surname>Malykh</surname> <given-names>A</given-names></name><name><surname>Barnholtz-Sloan</surname> <given-names>JS</given-names></name><name><surname>Barrett</surname> <given-names>W</given-names></name><name><surname>Devine</surname> <given-names>K</given-names></name><name><surname>Fulop</surname> <given-names>J</given-names></name><name><surname>Ostrom</surname> <given-names>QT</given-names></name><name><surname>Shimmel</surname> <given-names>K</given-names></name><name><surname>Wolinsky</surname> <given-names>Y</given-names></name><name><surname>Sloan</surname> <given-names>AE</given-names></name><name><surname>De Rose</surname> <given-names>A</given-names></name><name><surname>Giuliante</surname> <given-names>F</given-names></name><name><surname>Goodman</surname> <given-names>M</given-names></name><name><surname>Karlan</surname> <given-names>BY</given-names></name><name><surname>Hagedorn</surname> <given-names>CH</given-names></name><name><surname>Eckman</surname> <given-names>J</given-names></name><name><surname>Harr</surname> <given-names>J</given-names></name><name><surname>Myers</surname> <given-names>J</given-names></name><name><surname>Tucker</surname> <given-names>K</given-names></name><name><surname>Zach</surname> <given-names>LA</given-names></name><name><surname>Deyarmin</surname> <given-names>B</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Kvecher</surname> <given-names>L</given-names></name><name><surname>Larson</surname> <given-names>C</given-names></name><name><surname>Mural</surname> <given-names>RJ</given-names></name><name><surname>Somiari</surname> <given-names>S</given-names></name><name><surname>Vicha</surname> <given-names>A</given-names></name><name><surname>Zelinka</surname> <given-names>T</given-names></name><name><surname>Bennett</surname> <given-names>J</given-names></name><name><surname>Iacocca</surname> <given-names>M</given-names></name><name><surname>Rabeno</surname> <given-names>B</given-names></name><name><surname>Swanson</surname> <given-names>P</given-names></name><name><surname>Latour</surname> <given-names>M</given-names></name><name><surname>Lacombe</surname> <given-names>L</given-names></name><name><surname>Têtu</surname> <given-names>B</given-names></name><name><surname>Bergeron</surname> <given-names>A</given-names></name><name><surname>McGraw</surname> <given-names>M</given-names></name><name><surname>Staugaitis</surname> <given-names>SM</given-names></name><name><surname>Chabot</surname> <given-names>J</given-names></name><name><surname>Hibshoosh</surname> <given-names>H</given-names></name><name><surname>Sepulveda</surname> <given-names>A</given-names></name><name><surname>Su</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Potapova</surname> <given-names>O</given-names></name><name><surname>Voronina</surname> <given-names>O</given-names></name><name><surname>Desjardins</surname> <given-names>L</given-names></name><name><surname>Mariani</surname> <given-names>O</given-names></name><name><surname>Roman-Roman</surname> <given-names>S</given-names></name><name><surname>Sastre</surname> <given-names>X</given-names></name><name><surname>Stern</surname> <given-names>M-H</given-names></name><name><surname>Cheng</surname> <given-names>F</given-names></name><name><surname>Signoretti</surname> <given-names>S</given-names></name><name><surname>Berchuck</surname> <given-names>A</given-names></name><name><surname>Bigner</surname> <given-names>D</given-names></name><name><surname>Lipp</surname> <given-names>E</given-names></name><name><surname>Marks</surname> <given-names>J</given-names></name><name><surname>McCall</surname> <given-names>S</given-names></name><name><surname>McLendon</surname> <given-names>R</given-names></name><name><surname>Secord</surname> <given-names>A</given-names></name><name><surname>Sharp</surname> <given-names>A</given-names></name><name><surname>Behera</surname> <given-names>M</given-names></name><name><surname>Brat</surname> <given-names>DJ</given-names></name><name><surname>Chen</surname> <given-names>A</given-names></name><name><surname>Delman</surname> <given-names>K</given-names></name><name><surname>Force</surname> <given-names>S</given-names></name><name><surname>Khuri</surname> <given-names>F</given-names></name><name><surname>Magliocca</surname> <given-names>K</given-names></name><name><surname>Maithel</surname> <given-names>S</given-names></name><name><surname>Olson</surname> <given-names>JJ</given-names></name><name><surname>Owonikoko</surname> <given-names>T</given-names></name><name><surname>Pickens</surname> <given-names>A</given-names></name><name><surname>Ramalingam</surname> <given-names>S</given-names></name><name><surname>Shin</surname> <given-names>DM</given-names></name><name><surname>Sica</surname> <given-names>G</given-names></name><name><surname>Van Meir</surname> <given-names>EG</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Eijckenboom</surname> <given-names>W</given-names></name><name><surname>Gillis</surname> <given-names>A</given-names></name><name><surname>Korpershoek</surname> <given-names>E</given-names></name><name><surname>Looijenga</surname> <given-names>L</given-names></name><name><surname>Oosterhuis</surname> <given-names>W</given-names></name><name><surname>Stoop</surname> <given-names>H</given-names></name><name><surname>van Kessel</surname> <given-names>KE</given-names></name><name><surname>Zwarthoff</surname> <given-names>EC</given-names></name><name><surname>Calatozzolo</surname> <given-names>C</given-names></name><name><surname>Cuppini</surname> <given-names>L</given-names></name><name><surname>Cuzzubbo</surname> <given-names>S</given-names></name><name><surname>DiMeco</surname> <given-names>F</given-names></name><name><surname>Finocchiaro</surname> <given-names>G</given-names></name><name><surname>Mattei</surname> <given-names>L</given-names></name><name><surname>Perin</surname> <given-names>A</given-names></name><name><surname>Pollo</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Houck</surname> <given-names>J</given-names></name><name><surname>Lohavanichbutr</surname> <given-names>P</given-names></name><name><surname>Hartmann</surname> <given-names>A</given-names></name><name><surname>Stoehr</surname> <given-names>C</given-names></name><name><surname>Stoehr</surname> <given-names>R</given-names></name><name><surname>Taubert</surname> <given-names>H</given-names></name><name><surname>Wach</surname> <given-names>S</given-names></name><name><surname>Wullich</surname> <given-names>B</given-names></name><name><surname>Kycler</surname> <given-names>W</given-names></name><name><surname>Murawa</surname> <given-names>D</given-names></name><name><surname>Wiznerowicz</surname> <given-names>M</given-names></name><name><surname>Chung</surname> <given-names>K</given-names></name><name><surname>Edenfield</surname> <given-names>WJ</given-names></name><name><surname>Martin</surname> <given-names>J</given-names></name><name><surname>Baudin</surname> <given-names>E</given-names></name><name><surname>Bubley</surname> <given-names>G</given-names></name><name><surname>Bueno</surname> <given-names>R</given-names></name><name><surname>De Rienzo</surname> <given-names>A</given-names></name><name><surname>Richards</surname> <given-names>WG</given-names></name><name><surname>Kalkanis</surname> <given-names>S</given-names></name><name><surname>Mikkelsen</surname> <given-names>T</given-names></name><name><surname>Noushmehr</surname> <given-names>H</given-names></name><name><surname>Scarpace</surname> <given-names>L</given-names></name><name><surname>Girard</surname> <given-names>N</given-names></name><name><surname>Aymerich</surname> <given-names>M</given-names></name><name><surname>Campo</surname> <given-names>E</given-names></name><name><surname>Giné</surname> <given-names>E</given-names></name><name><surname>Guillermo</surname> <given-names>AL</given-names></name><name><surname>Van Bang</surname> <given-names>N</given-names></name><name><surname>Hanh</surname> <given-names>PT</given-names></name><name><surname>Phu</surname> <given-names>BD</given-names></name><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Colman</surname> <given-names>H</given-names></name><name><surname>Evason</surname> <given-names>K</given-names></name><name><surname>Dottino</surname> <given-names>PR</given-names></name><name><surname>Martignetti</surname> <given-names>JA</given-names></name><name><surname>Gabra</surname> <given-names>H</given-names></name><name><surname>Juhl</surname> <given-names>H</given-names></name><name><surname>Akeredolu</surname> <given-names>T</given-names></name><name><surname>Stepa</surname> <given-names>S</given-names></name><name><surname>Hoon</surname> <given-names>D</given-names></name><name><surname>Ahn</surname> <given-names>K</given-names></name><name><surname>Kang</surname> <given-names>KJ</given-names></name><name><surname>Beuschlein</surname> <given-names>F</given-names></name><name><surname>Breggia</surname> <given-names>A</given-names></name><name><surname>Birrer</surname> <given-names>M</given-names></name><name><surname>Bell</surname> <given-names>D</given-names></name><name><surname>Borad</surname> <given-names>M</given-names></name><name><surname>Bryce</surname> <given-names>AH</given-names></name><name><surname>Castle</surname> <given-names>E</given-names></name><name><surname>Chandan</surname> <given-names>V</given-names></name><name><surname>Cheville</surname> <given-names>J</given-names></name><name><surname>Copland</surname> <given-names>JA</given-names></name><name><surname>Farnell</surname> <given-names>M</given-names></name><name><surname>Flotte</surname> <given-names>T</given-names></name><name><surname>Giama</surname> <given-names>N</given-names></name><name><surname>Ho</surname> <given-names>T</given-names></name><name><surname>Kendrick</surname> <given-names>M</given-names></name><name><surname>Kocher</surname> <given-names>J-P</given-names></name><name><surname>Kopp</surname> <given-names>K</given-names></name><name><surname>Moser</surname> <given-names>C</given-names></name><name><surname>Nagorney</surname> <given-names>D</given-names></name><name><surname>O’Brien</surname> <given-names>D</given-names></name><name><surname>O’Neill</surname> <given-names>BP</given-names></name><name><surname>Patel</surname> <given-names>T</given-names></name><name><surname>Petersen</surname> <given-names>G</given-names></name><name><surname>Que</surname> <given-names>F</given-names></name><name><surname>Rivera</surname> <given-names>M</given-names></name><name><surname>Roberts</surname> <given-names>L</given-names></name><name><surname>Smallridge</surname> <given-names>R</given-names></name><name><surname>Smyrk</surname> <given-names>T</given-names></name><name><surname>Stanton</surname> <given-names>M</given-names></name><name><surname>Thompson</surname> <given-names>RH</given-names></name><name><surname>Torbenson</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>JD</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Brimo</surname> <given-names>F</given-names></name><name><surname>Ajani</surname> <given-names>JA</given-names></name><name><surname>Gonzalez</surname> <given-names>AMA</given-names></name><name><surname>Behrens</surname> <given-names>C</given-names></name><name><surname>Bondaruk</surname> <given-names>J</given-names></name><name><surname>Broaddus</surname> <given-names>R</given-names></name><name><surname>Czerniak</surname> <given-names>B</given-names></name><name><surname>Esmaeli</surname> <given-names>B</given-names></name><name><surname>Fujimoto</surname> <given-names>J</given-names></name><name><surname>Gershenwald</surname> <given-names>J</given-names></name><name><surname>Guo</surname> <given-names>C</given-names></name><name><surname>Lazar</surname> <given-names>AJ</given-names></name><name><surname>Logothetis</surname> <given-names>C</given-names></name><name><surname>Meric-Bernstam</surname> <given-names>F</given-names></name><name><surname>Moran</surname> <given-names>C</given-names></name><name><surname>Ramondetta</surname> <given-names>L</given-names></name><name><surname>Rice</surname> <given-names>D</given-names></name><name><surname>Sood</surname> <given-names>A</given-names></name><name><surname>Tamboli</surname> <given-names>P</given-names></name><name><surname>Thompson</surname> <given-names>T</given-names></name><name><surname>Troncoso</surname> <given-names>P</given-names></name><name><surname>Tsao</surname> <given-names>A</given-names></name><name><surname>Wistuba</surname> <given-names>I</given-names></name><name><surname>Carter</surname> <given-names>C</given-names></name><name><surname>Haydu</surname> <given-names>L</given-names></name><name><surname>Hersey</surname> <given-names>P</given-names></name><name><surname>Jakrot</surname> <given-names>V</given-names></name><name><surname>Kakavand</surname> <given-names>H</given-names></name><name><surname>Kefford</surname> <given-names>R</given-names></name><name><surname>Lee</surname> <given-names>K</given-names></name><name><surname>Long</surname> <given-names>G</given-names></name><name><surname>Mann</surname> <given-names>G</given-names></name><name><surname>Quinn</surname> <given-names>M</given-names></name><name><surname>Saw</surname> <given-names>R</given-names></name><name><surname>Scolyer</surname> <given-names>R</given-names></name><name><surname>Shannon</surname> <given-names>K</given-names></name><name><surname>Spillane</surname> <given-names>A</given-names></name><name><surname>Stretch</surname> <given-names>J</given-names></name><name><surname>Synott</surname> <given-names>M</given-names></name><name><surname>Thompson</surname> <given-names>J</given-names></name><name><surname>Wilmott</surname> <given-names>J</given-names></name><name><surname>Al-Ahmadie</surname> <given-names>H</given-names></name><name><surname>Chan</surname> <given-names>TA</given-names></name><name><surname>Ghossein</surname> <given-names>R</given-names></name><name><surname>Gopalan</surname> <given-names>A</given-names></name><name><surname>Levine</surname> <given-names>DA</given-names></name><name><surname>Reuter</surname> <given-names>V</given-names></name><name><surname>Singer</surname> <given-names>S</given-names></name><name><surname>Singh</surname> <given-names>B</given-names></name><name><surname>Tien</surname> <given-names>NV</given-names></name><name><surname>Broudy</surname> <given-names>T</given-names></name><name><surname>Mirsaidi</surname> <given-names>C</given-names></name><name><surname>Nair</surname> <given-names>P</given-names></name><name><surname>Drwiega</surname> <given-names>P</given-names></name><name><surname>Miller</surname> <given-names>J</given-names></name><name><surname>Smith</surname> <given-names>J</given-names></name><name><surname>Zaren</surname> <given-names>H</given-names></name><name><surname>Park</surname> <given-names>J-W</given-names></name><name><surname>Hung</surname> <given-names>NP</given-names></name><name><surname>Kebebew</surname> <given-names>E</given-names></name><name><surname>Linehan</surname> <given-names>WM</given-names></name><name><surname>Metwalli</surname> <given-names>AR</given-names></name><name><surname>Pacak</surname> <given-names>K</given-names></name><name><surname>Pinto</surname> <given-names>PA</given-names></name><name><surname>Schiffman</surname> <given-names>M</given-names></name><name><surname>Schmidt</surname> <given-names>LS</given-names></name><name><surname>Vocke</surname> <given-names>CD</given-names></name><name><surname>Wentzensen</surname> <given-names>N</given-names></name><name><surname>Worrell</surname> <given-names>R</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Moncrieff</surname> <given-names>M</given-names></name><name><surname>Goparaju</surname> <given-names>C</given-names></name><name><surname>Melamed</surname> <given-names>J</given-names></name><name><surname>Pass</surname> <given-names>H</given-names></name><name><surname>Botnariuc</surname> <given-names>N</given-names></name><name><surname>Caraman</surname> <given-names>I</given-names></name><name><surname>Cernat</surname> <given-names>M</given-names></name><name><surname>Chemencedji</surname> <given-names>I</given-names></name><name><surname>Clipca</surname> <given-names>A</given-names></name><name><surname>Doruc</surname> <given-names>S</given-names></name><name><surname>Gorincioi</surname> <given-names>G</given-names></name><name><surname>Mura</surname> <given-names>S</given-names></name><name><surname>Pirtac</surname> <given-names>M</given-names></name><name><surname>Stancul</surname> <given-names>I</given-names></name><name><surname>Tcaciuc</surname> <given-names>D</given-names></name><name><surname>Albert</surname> <given-names>M</given-names></name><name><surname>Alexopoulou</surname> <given-names>I</given-names></name><name><surname>Arnaout</surname> <given-names>A</given-names></name><name><surname>Bartlett</surname> <given-names>J</given-names></name><name><surname>Engel</surname> <given-names>J</given-names></name><name><surname>Gilbert</surname> <given-names>S</given-names></name><name><surname>Parfitt</surname> <given-names>J</given-names></name><name><surname>Sekhon</surname> <given-names>H</given-names></name><name><surname>Thomas</surname> <given-names>G</given-names></name><name><surname>Rassl</surname> <given-names>DM</given-names></name><name><surname>Rintoul</surname> <given-names>RC</given-names></name><name><surname>Bifulco</surname> <given-names>C</given-names></name><name><surname>Tamakawa</surname> <given-names>R</given-names></name><name><surname>Urba</surname> <given-names>W</given-names></name><name><surname>Hayward</surname> <given-names>N</given-names></name><name><surname>Timmers</surname> <given-names>H</given-names></name><name><surname>Antenucci</surname> <given-names>A</given-names></name><name><surname>Facciolo</surname> <given-names>F</given-names></name><name><surname>Grazi</surname> <given-names>G</given-names></name><name><surname>Marino</surname> <given-names>M</given-names></name><name><surname>Merola</surname> <given-names>R</given-names></name><name><surname>de Krijger</surname> <given-names>R</given-names></name><name><surname>Gimenez-Roqueplo</surname> <given-names>A-P</given-names></name><name><surname>Piché</surname> <given-names>A</given-names></name><name><surname>Chevalier</surname> <given-names>S</given-names></name><name><surname>McKercher</surname> <given-names>G</given-names></name><name><surname>Birsoy</surname> <given-names>K</given-names></name><name><surname>Barnett</surname> <given-names>G</given-names></name><name><surname>Brewer</surname> <given-names>C</given-names></name><name><surname>Farver</surname> <given-names>C</given-names></name><name><surname>Naska</surname> <given-names>T</given-names></name><name><surname>Pennell</surname> <given-names>NA</given-names></name><name><surname>Raymond</surname> <given-names>D</given-names></name><name><surname>Schilero</surname> <given-names>C</given-names></name><name><surname>Smolenski</surname> <given-names>K</given-names></name><name><surname>Williams</surname> <given-names>F</given-names></name><name><surname>Morrison</surname> <given-names>C</given-names></name><name><surname>Borgia</surname> <given-names>JA</given-names></name><name><surname>Liptay</surname> <given-names>MJ</given-names></name><name><surname>Pool</surname> <given-names>M</given-names></name><name><surname>Seder</surname> <given-names>CW</given-names></name><name><surname>Junker</surname> <given-names>K</given-names></name><name><surname>Omberg</surname> <given-names>L</given-names></name><name><surname>Dinkin</surname> <given-names>M</given-names></name><name><surname>Manikhas</surname> <given-names>G</given-names></name><name><surname>Alvaro</surname> <given-names>D</given-names></name><name><surname>Bragazzi</surname> <given-names>MC</given-names></name><name><surname>Cardinale</surname> <given-names>V</given-names></name><name><surname>Carpino</surname> <given-names>G</given-names></name><name><surname>Gaudio</surname> <given-names>E</given-names></name><name><surname>Chesla</surname> <given-names>D</given-names></name><name><surname>Cottingham</surname> <given-names>S</given-names></name><name><surname>Dubina</surname> <given-names>M</given-names></name><name><surname>Moiseenko</surname> <given-names>F</given-names></name><name><surname>Dhanasekaran</surname> <given-names>R</given-names></name><name><surname>Becker</surname> <given-names>K-F</given-names></name><name><surname>Janssen</surname> <given-names>K-P</given-names></name><name><surname>Slotta-Huspenina</surname> <given-names>J</given-names></name><name><surname>Abdel-Rahman</surname> <given-names>MH</given-names></name><name><surname>Aziz</surname> <given-names>D</given-names></name><name><surname>Bell</surname> <given-names>S</given-names></name><name><surname>Cebulla</surname> <given-names>CM</given-names></name><name><surname>Davis</surname> <given-names>A</given-names></name><name><surname>Duell</surname> <given-names>R</given-names></name><name><surname>Elder</surname> <given-names>JB</given-names></name><name><surname>Hilty</surname> <given-names>J</given-names></name><name><surname>Kumar</surname> <given-names>B</given-names></name><name><surname>Lang</surname> <given-names>J</given-names></name><name><surname>Lehman</surname> <given-names>NL</given-names></name><name><surname>Mandt</surname> <given-names>R</given-names></name><name><surname>Nguyen</surname> <given-names>P</given-names></name><name><surname>Pilarski</surname> <given-names>R</given-names></name><name><surname>Rai</surname> <given-names>K</given-names></name><name><surname>Schoenfield</surname> <given-names>L</given-names></name><name><surname>Senecal</surname> <given-names>K</given-names></name><name><surname>Wakely</surname> <given-names>P</given-names></name><name><surname>Hansen</surname> <given-names>P</given-names></name><name><surname>Lechan</surname> <given-names>R</given-names></name><name><surname>Powers</surname> <given-names>J</given-names></name><name><surname>Tischler</surname> <given-names>A</given-names></name><name><surname>Grizzle</surname> <given-names>WE</given-names></name><name><surname>Sexton</surname> <given-names>KC</given-names></name><name><surname>Kastl</surname> <given-names>A</given-names></name><name><surname>Henderson</surname> <given-names>J</given-names></name><name><surname>Porten</surname> <given-names>S</given-names></name><name><surname>Waldmann</surname> <given-names>J</given-names></name><name><surname>Fassnacht</surname> <given-names>M</given-names></name><name><surname>Asa</surname> <given-names>SL</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><name><surname>Couce</surname> <given-names>M</given-names></name><name><surname>Graefen</surname> <given-names>M</given-names></name><name><surname>Huland</surname> <given-names>H</given-names></name><name><surname>Sauter</surname> <given-names>G</given-names></name><name><surname>Schlomm</surname> <given-names>T</given-names></name><name><surname>Simon</surname> <given-names>R</given-names></name><name><surname>Tennstedt</surname> <given-names>P</given-names></name><name><surname>Olabode</surname> <given-names>O</given-names></name><name><surname>Nelson</surname> <given-names>M</given-names></name><name><surname>Bathe</surname> <given-names>O</given-names></name><name><surname>Carroll</surname> <given-names>PR</given-names></name><name><surname>Chan</surname> <given-names>JM</given-names></name><name><surname>Disaia</surname> <given-names>P</given-names></name><name><surname>Glenn</surname> <given-names>P</given-names></name><name><surname>Kelley</surname> <given-names>RK</given-names></name><name><surname>Landen</surname> <given-names>CN</given-names></name><name><surname>Phillips</surname> <given-names>J</given-names></name><name><surname>Prados</surname> <given-names>M</given-names></name><name><surname>Simko</surname> <given-names>J</given-names></name><name><surname>Smith-McCune</surname> <given-names>K</given-names></name><name><surname>VandenBerg</surname> <given-names>S</given-names></name><name><surname>Roggin</surname> <given-names>K</given-names></name><name><surname>Fehrenbach</surname> <given-names>A</given-names></name><name><surname>Kendler</surname> <given-names>A</given-names></name><name><surname>Sifri</surname> <given-names>S</given-names></name><name><surname>Steele</surname> <given-names>R</given-names></name><name><surname>Jimeno</surname> <given-names>A</given-names></name><name><surname>Carey</surname> <given-names>F</given-names></name><name><surname>Forgie</surname> <given-names>I</given-names></name><name><surname>Mannelli</surname> <given-names>M</given-names></name><name><surname>Carney</surname> <given-names>M</given-names></name><name><surname>Hernandez</surname> <given-names>B</given-names></name><name><surname>Campos</surname> <given-names>B</given-names></name><name><surname>Herold-Mende</surname> <given-names>C</given-names></name><name><surname>Jungk</surname> <given-names>C</given-names></name><name><surname>Unterberg</surname> <given-names>A</given-names></name><name><surname>von Deimling</surname> <given-names>A</given-names></name><name><surname>Bossler</surname> <given-names>A</given-names></name><name><surname>Galbraith</surname> <given-names>J</given-names></name><name><surname>Jacobus</surname> <given-names>L</given-names></name><name><surname>Knudson</surname> <given-names>M</given-names></name><name><surname>Knutson</surname> <given-names>T</given-names></name><name><surname>Ma</surname> <given-names>D</given-names></name><name><surname>Milhem</surname> <given-names>M</given-names></name><name><surname>Sigmund</surname> <given-names>R</given-names></name><name><surname>Godwin</surname> <given-names>AK</given-names></name><name><surname>Madan</surname> <given-names>R</given-names></name><name><surname>Rosenthal</surname> <given-names>HG</given-names></name><name><surname>Adebamowo</surname> <given-names>C</given-names></name><name><surname>Adebamowo</surname> <given-names>SN</given-names></name><name><surname>Boussioutas</surname> <given-names>A</given-names></name><name><surname>Beer</surname> <given-names>D</given-names></name><name><surname>Giordano</surname> <given-names>T</given-names></name><name><surname>Mes-Masson</surname> <given-names>A-M</given-names></name><name><surname>Saad</surname> <given-names>F</given-names></name><name><surname>Bocklage</surname> <given-names>T</given-names></name><name><surname>Landrum</surname> <given-names>L</given-names></name><name><surname>Mannel</surname> <given-names>R</given-names></name><name><surname>Moore</surname> <given-names>K</given-names></name><name><surname>Moxley</surname> <given-names>K</given-names></name><name><surname>Postier</surname> <given-names>R</given-names></name><name><surname>Walker</surname> <given-names>J</given-names></name><name><surname>Zuna</surname> <given-names>R</given-names></name><name><surname>Feldman</surname> <given-names>M</given-names></name><name><surname>Valdivieso</surname> <given-names>F</given-names></name><name><surname>Dhir</surname> <given-names>R</given-names></name><name><surname>Luketich</surname> <given-names>J</given-names></name><name><surname>Pinero</surname> <given-names>EMM</given-names></name><name><surname>Quintero-Aguilo</surname> <given-names>M</given-names></name><name><surname>Carlotti</surname> <given-names>CG</given-names></name><name><surname>Dos Santos</surname> <given-names>JS</given-names></name><name><surname>Kemp</surname> <given-names>R</given-names></name><name><surname>Sankarankuty</surname> <given-names>A</given-names></name><name><surname>Tirapelli</surname> <given-names>D</given-names></name><name><surname>Catto</surname> <given-names>J</given-names></name><name><surname>Agnew</surname> <given-names>K</given-names></name><name><surname>Swisher</surname> <given-names>E</given-names></name><name><surname>Creaney</surname> <given-names>J</given-names></name><name><surname>Robinson</surname> <given-names>B</given-names></name><name><surname>Shelley</surname> <given-names>CS</given-names></name><name><surname>Godwin</surname> <given-names>EM</given-names></name><name><surname>Kendall</surname> <given-names>S</given-names></name><name><surname>Shipman</surname> <given-names>C</given-names></name><name><surname>Bradford</surname> <given-names>C</given-names></name><name><surname>Carey</surname> <given-names>T</given-names></name><name><surname>Haddad</surname> <given-names>A</given-names></name><name><surname>Moyer</surname> <given-names>J</given-names></name><name><surname>Peterson</surname> <given-names>L</given-names></name><name><surname>Prince</surname> <given-names>M</given-names></name><name><surname>Rozek</surname> <given-names>L</given-names></name><name><surname>Wolf</surname> <given-names>G</given-names></name><name><surname>Bowman</surname> <given-names>R</given-names></name><name><surname>Fong</surname> <given-names>KM</given-names></name><name><surname>Yang</surname> <given-names>I</given-names></name><name><surname>Korst</surname> <given-names>R</given-names></name><name><surname>Rathmell</surname> <given-names>WK</given-names></name><name><surname>Fantacone-Campbell</surname> <given-names>JL</given-names></name><name><surname>Hooke</surname> <given-names>JA</given-names></name><name><surname>Kovatich</surname> <given-names>AJ</given-names></name><name><surname>Shriver</surname> <given-names>CD</given-names></name><name><surname>DiPersio</surname> <given-names>J</given-names></name><name><surname>Drake</surname> <given-names>B</given-names></name><name><surname>Govindan</surname> <given-names>R</given-names></name><name><surname>Heath</surname> <given-names>S</given-names></name><name><surname>Ley</surname> <given-names>T</given-names></name><name><surname>Van Tine</surname> <given-names>B</given-names></name><name><surname>Westervelt</surname> <given-names>P</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Lee</surname> <given-names>JI</given-names></name><name><surname>Aredes</surname> <given-names>ND</given-names></name><name><surname>Mariamidze</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Comprehensive molecular characterization of the hippo signaling pathway in Cancer</article-title><source>Cell Reports</source><volume>25</volume><fpage>1304</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.10.001</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname> <given-names>IB</given-names></name><name><surname>Joe</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Oncogene addiction</article-title><source>Cancer Research</source><volume>68</volume><fpage>3077</fpage><lpage>3080</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-3293</pub-id><pub-id pub-id-type="pmid">18451130</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname> <given-names>S</given-names></name><name><surname>Eom</surname> <given-names>GH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>HDAC and HDAC inhibitor: from Cancer to cardiovascular diseases</article-title><source>Chonnam Medical Journal</source><volume>52</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.4068/cmj.2016.52.1.1</pub-id><pub-id pub-id-type="pmid">26865995</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshihara</surname> <given-names>K</given-names></name><name><surname>Shahmoradgoli</surname> <given-names>M</given-names></name><name><surname>Martínez</surname> <given-names>E</given-names></name><name><surname>Vegesna</surname> <given-names>R</given-names></name><name><surname>Kim</surname> <given-names>H</given-names></name><name><surname>Torres-Garcia</surname> <given-names>W</given-names></name><name><surname>Treviño</surname> <given-names>V</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Levine</surname> <given-names>DA</given-names></name><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Stemke-Hale</surname> <given-names>K</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Verhaak</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inferring tumour purity and stromal and immune cell admixture from expression data</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>2612</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3612</pub-id><pub-id pub-id-type="pmid">24113773</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanaruddin</surname> <given-names>SN</given-names></name><name><surname>Yee</surname> <given-names>PS</given-names></name><name><surname>Hor</surname> <given-names>SY</given-names></name><name><surname>Kong</surname> <given-names>YH</given-names></name><name><surname>Ghani</surname> <given-names>WM</given-names></name><name><surname>Mustafa</surname> <given-names>WM</given-names></name><name><surname>Zain</surname> <given-names>RB</given-names></name><name><surname>Prime</surname> <given-names>SS</given-names></name><name><surname>Rahman</surname> <given-names>ZA</given-names></name><name><surname>Cheong</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Common oncogenic mutations are infrequent in oral squamous cell carcinoma of asian origin</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e80229</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0080229</pub-id><pub-id pub-id-type="pmid">24224046</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanconato</surname> <given-names>F</given-names></name><name><surname>Battilana</surname> <given-names>G</given-names></name><name><surname>Cordenonsi</surname> <given-names>M</given-names></name><name><surname>Piccolo</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>YAP/TAZ as therapeutic targets in Cancer</article-title><source>Current Opinion in Pharmacology</source><volume>29</volume><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2016.05.002</pub-id><pub-id pub-id-type="pmid">27262779</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Ramakrishnan</surname> <given-names>SK</given-names></name><name><surname>Triner</surname> <given-names>D</given-names></name><name><surname>Centofanti</surname> <given-names>B</given-names></name><name><surname>Maitra</surname> <given-names>D</given-names></name><name><surname>Győrffy</surname> <given-names>B</given-names></name><name><surname>Sebolt-Leopold</surname> <given-names>JS</given-names></name><name><surname>Dame</surname> <given-names>MK</given-names></name><name><surname>Varani</surname> <given-names>J</given-names></name><name><surname>Brenner</surname> <given-names>DE</given-names></name><name><surname>Fearon</surname> <given-names>ER</given-names></name><name><surname>Omary</surname> <given-names>MB</given-names></name><name><surname>Shah</surname> <given-names>YM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tumor-selective proteotoxicity of verteporfin inhibits Colon cancer progression independently of YAP1</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra98</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aac5418</pub-id><pub-id pub-id-type="pmid">26443705</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Montminy</surname> <given-names>T</given-names></name><name><surname>Azad</surname> <given-names>T</given-names></name><name><surname>Lightbody</surname> <given-names>E</given-names></name><name><surname>Hao</surname> <given-names>Y</given-names></name><name><surname>SenGupta</surname> <given-names>S</given-names></name><name><surname>Asselin</surname> <given-names>E</given-names></name><name><surname>Nicol</surname> <given-names>C</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>PI3K positively regulates YAP and TAZ in mammary tumorigenesis through multiple signaling pathways</article-title><source>Molecular Cancer Research</source><volume>16</volume><fpage>1046</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-17-0593</pub-id><pub-id pub-id-type="pmid">29545474</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec id="s8" sec-type="appendix"><title>Key Resources Table</title><boxed-text><table-wrap id="keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">Human Improved Genome-wide Knockout CRISPR Library v1 <break/>(pooled library)</td><td valign="top">Addgene</td><td valign="top">#67989</td><td valign="top">Containing 90,709 gRNAs, selectable with puromycin</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pKLV2-EF1α-Cas9Bsd-W (plasmid)</td><td valign="top">Addgene</td><td valign="top">#68343</td><td valign="top">To express Cas9 constitutively, selectable with blasticidin</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pKLV2-U6gRNA5 (gGFP)-PGKmCherry2AGFP-W <break/>(plasmid)</td><td valign="top">Addgene</td><td valign="top">#67982</td><td valign="top">Reporter plasmid</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pKLV2- <break/>U6gRNA5(BbsI)-PGKpuro2ABFP-W (plasmid)</td><td valign="top">Addgene</td><td valign="top">#67974</td><td valign="top">For cloning of single sgRNAs, tag with blue fluorescence protein (BFP)</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pKLV2-U6gRNA5(BbsI)-PGKpuro2AmCherry-W (plasmid)</td><td valign="top">Addgene</td><td valign="top">#67977</td><td valign="top">For cloning of single sgRNAs, tag with mcherry</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pMD2.G (plasmid)</td><td valign="top">Addgene</td><td valign="top">#12259</td><td valign="top">For lentivirus generation</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">psPAX2 (plasmid)</td><td valign="top">Addgene</td><td valign="top">#12260</td><td valign="top">For lentivirus generation</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">jetPRIME reagent and buffer</td><td valign="top">Polyplus transfection</td><td valign="top">114–75</td><td valign="top">For transfection</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-48</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-115</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-136</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-150</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-153</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-156</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-166</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-174</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-188</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-195</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-204</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-207</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-214</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Cancer Research Malaysia <xref ref-type="bibr" rid="bib21">Fadlullah et al., 2016</xref>, PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27050151">27050151</ext-link></td><td valign="top">ORL-215</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Wellcome Sanger Institute</td><td valign="top">BICR10</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Wellcome Sanger Institute</td><td valign="top">HO-1-u-1</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Wellcome Sanger Institute</td><td valign="top">HSC-2</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Wellcome Sanger Institute</td><td valign="top">HSC-4</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Wellcome Sanger Institute</td><td valign="top">PE/CA-PJ15</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Wellcome Sanger Institute</td><td valign="top">SAS</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Cells derived from oral squamous cell carcinoma</td><td valign="top">Wellcome Sanger Institute</td><td valign="top">SCC-9</td><td valign="top">Maintained in DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Human embryonic kidney cells</td><td valign="top">Wellcome Sanger Institute</td><td valign="top">HEK293</td><td valign="top">Maintained in DMEM (high glucose) supplemented with 10% FBS, 1% penicillin/streptomycin</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-human YAP (D8H1X), Rabbit monoclonal</td><td valign="top">Cell Signaling Technology</td><td valign="top">#14074</td><td valign="top">WB - (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-human TAZ (D361D), Rabbit monoclonal</td><td valign="top">Cell Signaling Technology</td><td valign="top">#70148</td><td valign="top">WB - (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-human actin (clone C4), Mouse monoclonal</td><td valign="top">Merck Milipore</td><td valign="top">MAB1501</td><td valign="top">WB – (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-rabbit IgG-HRP</td><td valign="top">Southern Biotec</td><td valign="top">SB4010-05</td><td valign="top">Secondary antibody; WB – (1:10000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-mouse IgG-HRP</td><td valign="top">Southern Biotec</td><td valign="top">SB1010-05</td><td valign="top">Secondary antibody; WB – (1:10000)</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Q5 Hot Start High-Fidelity 2X Master Mix <break/></td><td valign="top">New England Biolabs</td><td valign="top">M0494S</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">QIAquick PCR purification kit</td><td valign="top">Qiagen</td><td valign="top">28104</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Qubit dsDNA broad-range (BR) assay kit</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Q32850</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">KAPA HotStart ReadyMix</td><td valign="top">Roche</td><td valign="top">KK2601</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Agilent High Sensitivity DNA kit</td><td valign="top">Agilent technologies</td><td valign="top">5067–4626</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">QIAprep Spin Miniprep Kit</td><td valign="top">Qiagen</td><td valign="top">27104</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">cDNA reverse transcription kit</td><td valign="top">Applied Biosystems, Thermo Fisher Scientific</td><td valign="top">4368813</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">PowerUp SYBR Green Master Mix</td><td valign="top">Applied Biosystems, Thermo Fisher Scientific</td><td valign="top">A25742</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">FITC Annexin V Apoptosis Detection Kit I</td><td valign="top">BD Bioscience</td><td valign="top">556547</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">BbsI enzyme</td><td valign="top">New England Biolabs</td><td valign="top">R0539S</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">T4 Polynucleotide kinase enzyme</td><td valign="top">New England Biolabs</td><td valign="top">M0201</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">T4 ligase and 10x ligase buffer</td><td valign="top">New England Biolabs</td><td valign="top">M0202S</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">WesternBright Quantum HRP substrate</td><td valign="top">Advansta</td><td valign="top">K-12042-D20</td><td valign="top">Substrate for Western Blot</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">TRIzol Reagent</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">15596026</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">CRISPRcleanR (version 0.5)</td><td valign="top"><xref ref-type="bibr" rid="bib42">Iorio et al., 2018</xref> PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/30103702">30103702</ext-link></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">MAGeCK (version 0.5.7)</td><td valign="top"><xref ref-type="bibr" rid="bib51">Li et al., 2014</xref> PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/25476604">25476604</ext-link></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Rstudio (version 1.2.1335)</td><td valign="top">Rstudio Inc</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GraphPad Prism (version 8)</td><td valign="top">GraphPad Software Inc</td><td valign="top"/><td valign="top"/></tr></tbody></table></table-wrap></boxed-text></sec></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.57761.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Reviewing Editor</role><aff><institution>Fox Chase Cancer Center</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Sudol</surname><given-names>Marius</given-names> </name><role>Reviewer</role><aff><institution/></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This work defines genes required for survival and robust growth by oral squamous cell carcinoma (OSCC) cells in Western and Asian populations. Following a genome-wide CRISPR screen, the authors identified components of the Hippo/Yap pathway as important for growth of multiple OSCC cell lines. In dissecting the pathway, the authors determined that some OSCC cell lines depend more on YAP1, some more on WWTR1/TAZ, while some depend on both, suggesting more heterogeneity in response than was previously appreciated. Importantly, the work also suggests some specific features of transcriptional pathways, including activation of the NF-κB pathway, in OSCC derived from Asians with a habit of betel quid chewing. These different dependencies may have clinical consequences, as the data suggests that OSCC cells specifically dependent on WWTR1 are associated with a distinct transcriptome and immune signature associated with response to immunotherapy.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Päivi Ojala as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Marius Sudol (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>This manuscript by Annie Chai and colleagues from the laboratory of Sok Ching Cheong reports in the CRISPR/Cas9-based screen of cells derived from oral squamous cell carcinoma (OSCC), which were predominantly of Asian, Malaysian origin. The screen was aimed at the identification of &quot;fitness genes&quot;. Several of these genes, some known and some new, were given non-essential status and a new set of essential genes was identified as worthwhile targets of a potential therapy. The authors identified components of the Hippo/Yap pathway as important for growth of multiple OSCC cell lines. For more than a decade, the two main pro-oncogene effectors of the Hippo pathway, namely YAP and TAZ, have been considered acting in unison in cancers. The current report indicates that YAP and TAZ may play specific roles in cancer. In dissecting the pathway, the authors determined that some OSCC cell lines depend more on YAP1, some more on WWTR1/TAZ, and in some either protein can complement the function of the other, suggesting more heterogeneity in response than was previously appreciated. The copy number amplification of WWTR1/TAZ was shown as likely to constitute a functional oncogenic role of this gene and its protein in OSCC. However, non-genomic mechanisms (with some exceptions) could likely activate YAP. These different dependencies may have clinical consequences, as the data suggests that OSCC cells specifically dependent on WWTR1 appear to be associated with a distinct transcriptome and immune signature associated with response to immunotherapy. Given the considerable interest in therapeutically targeting immune pathways, these findings could provide a valuable response biomarker, as indicating that two Hippo pathway endpoints that are often grouped together have quite distinct roles. The results also could guide the use of therapies under development for targeting YAP1 or WWTR1/TAZ. For example, another of the important conclusions of this study is that TAZ-dependent cell lines may represent fiduciaries of their original tumors, which could be primary candidates for checkpoint inhibitors treatment via modern immunotherapy.</p><p>There are some points that should be addressed by the authors to solidify the conclusions and improve the study.</p><p>Essential revisions:</p><p>(1) The authors emphasize that a rationale for their study is the use of cell materials developed from Asian populations with different risk factors, such as use of betel. They hypothesize that these features of the OSCC cell set may result in different dependency profiles than those already published for OSCC from the DepMap project (Behan et al. 2019, Meyers et al., 2017). However, they do not explicitly compare results with those from the DepMap project. This analysis should be added, to determine if the hypothesized difference exists.</p><p>(2) A lot of the analysis pathway appears to be derivative of approaches from Behan et al., 2019. This includes data exclusion for core fitness genes, assignment of tractability groups, and other points. The authors need to make clear the novelty of the current work.</p><p>(3) From data shown in Figure 1C, most of the cell lines have a limited number of non-core fitness genes (40 or less), whereas 4 lines have a very large number of dependencies. What genomic features characterize those with large numbers of dependencies? If these are excluded, how does this affect the statistical analysis present in Figure 2? Similarly, 10 of the 21 cell lines appeared to have &lt;10 core dependencies. Do these models specifically have unique genomic features, and YAP1 or WWTR1 dependency?</p><p>(4) In Figure 3—figure supplement 3, the authors note correlation between WWTR1 gene essentiality and expression across 273 cell models. What are the cancer types that are most dependent on WWTR1 (the point being, how specific is the observation of dependency to OSCC, versus being a general feature of squamous cancers)?</p><p>(5) In Figure 6, the authors analyze the YAP1 and WWTR1 gene signatures across a large group of OSCCs in the TCGA. Earlier in the study, the authors note that WWTR1 is often amplified as part of an amplicon including PIK3CA, TP63, and SOX2. To what extent is the transcriptional signature associated with amplification of these other genes, and dependent on their transcriptional activity, rather than that of WWTR1? Using their cell line models, they should complement TCGA analysis by using shRNA or drug inhibition to deplete WWTR1 versus other key genes in the amplicon, to determine which causes a specific loss of the immune-associated transcriptional signature. This is a really important data point for interpretation of the results.</p><p>(6) Besides papers cited by the authors, work relevant to the topic of this study includes Omori et al., 2020, for YAP1 as a driver, Saloura et al., 2019, showing YAP1 mutation is associated with a low CD8<sup>+</sup> T cell inflamed phenotype, Martin et al., 2018, dissecting the Hippo pathway and demonstrating the targetability of YAP1 in head and neck cancer in a detailed Nat Comm paper, and an extensive review of the pathway at the end of 2019 by Santos-de-Frutos and colleagues. This work should be cited and discussed by the authors. It is important that the Discussion addresses more about how the generated data relate to previously published reports. For example, the fact that YAP, TAZ, PI3K, TP63, and SOX2 are amplified in OSCC is curious as all these genes are part of the extended signaling network of the Hippo pathway. Please see the examples of relevant references and consider a short paragraph discussing this point. [Huang et al., 2017; Fan , Kim and Gumbiner, 2013. And Li et al., 2019] Also when the role of TA in eliciting the immune response is mentioned, it would be important to reference one of the first publications (as far as the reviewer is aware of) that indicated the role of TAZ (and YAP, perhaps) via LATS1 KO in mice. The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Moroishi T, (many authors) Guan KL. Cell. 2016 Dec 1;167(6):1525-1539.</p><p>(7) The authors should specifically state how many of their cell lines were highly dependent on WWTR1, how many on YAP1, and how many on both, out of the group of 21.</p><p>(8) The cell lines used in the screen are critical for the study. Therefore, it is suggested to provide in the Materials and methods and/or in the Results more information about how these lines were derived. It would help the readers a lot without referring to a previous publication (Fadlullah et al., 2016) and various commercial data for cell repositories. Please address if these cell lines were derived spontaneously (ala HeLa cells) or were engineered by transfections of immortalizing genes (ala HEK293 cell line, for example). If the latter was the case, please comment if the process of immortalization did not affect the actual transcriptional profile of the lines.</p><p>(9) As stated above, one of the critical conclusions this study is that TAZ-dependent OSCC lines may represent fiduciary (direct references) of their original tumors, and therefore patients with tumors driven by TAZ could be primary candidates for checkpoint inhibitors treatment via immunotherapy. Please address directly in the Discussion the fact that most of the tumors are quite heterogeneous in terms of oncogenic drivers and either the tumor biopsy or the cell lines derived from the tumor might not represent the &quot;main&quot; oncogenic drivers of the entire tumor.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.57761.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>(1) The authors emphasize that a rationale for their study is the use of cell materials developed from Asian populations with different risk factors, such as use of betel. They hypothesize that these features of the OSCC cell set may result in different dependency profiles than those already published for OSCC from the DepMap project (Behan et al., 2019, Meyers et al., 2017). However, they do not explicitly compare results with those from the DepMap project. This analysis should be added, to determine if the hypothesized difference exists.</p></disp-quote><p>We thank the reviewers for the suggestion. We have added the analysis of enriched dependencies seen among betel quid-associated OSCC in the revised manuscript and discussed the results accordingly. In particular, by comparing the gene dependencies identified from betel quid-associated OSCC lines with those non-betel quid associated OSCCs, we found that the NF-κB pathway is significantly enriched in the betel-quid associated lines. When cross checking the fitness genes in this pathway with those from the DepMap project, where models not known to be associated with betel quid were used, all except one were not identified as fitness genes (CSNK2A1 being marginally depleted in one of the cell lines included in DepMap; SCC-4). Notably, the literature that reported on betel quid as a risk factor in OSCC have demonstrated that aberrant NF-κB pathway activation is common in these cancers. Furthermore, extracts from betel quid have been shown to directly activate NF-κB signaling in OSCC as reported in previous studies. By contrast, this is rarely reported among the OSCC studies from the Western countries, where betel quid is uncommon.</p><p>We have added the results of this analysis to Figure 2 (Figure 2D), and explained this in the Results section (subsection “Identification of unique dependencies in betel-quid associated OSCC”). We also discussed our findings in the Discussion section (third paragraph). The description of the analysis has been added to the Materials and methods section of the revised manuscript (subsection “Differential fitness genes analysis for betel quid associated OSCCs”). Figure legends and figure source data have also been included accordingly.</p><disp-quote content-type="editor-comment"><p>2) A lot of the analysis pathway appears to be derivative of approaches from Behan et al., 2019. This includes data exclusion for core fitness genes, assignment of tractability groups, and other points. The authors need to make clear the novelty of the current work.</p></disp-quote><p>The publication from Behan et al. is one of the most comprehensive essential screens that was conducted across many types of cancers (pan-cancer) and in their project, they have developed comprehensive and robust methods in filtering and analyzing data from such screens particularly in identifying tractable genes for further therapeutic development. As one of our aims in conducting the essential screens for OSCC was to identify gene targets that could be translated to clinical benefit through the development or identification of new therapies, we applied similar filtering criteria to our data including removing the core-fitness genes (as described by Hart et al. Cell. 2015 Dec 3;163(6):1515-26. doi: 10.1016/j.cell.2015.11.015), and assigning tractability groups as described by Behan et al. Whilst we may have adopted a similar approach, our work is novel in that (i) our study focuses on OSCC and it would be the first to describe non-core fitness genes for OSCC and it is also the largest dataset of dependencies in OSCC models; (ii) we included models derived from Asians (particularly those with betel-quid chewing habit) where the disease is most prevalent and describe possible distinctiveness in the non-core fitness genes in models that are representative of OSCC in Asians; (iii) we looked specifically at known oncogenes and recurrently amplified regions to interrogate the function of OSCC cancer genes, and (iv) we report distinct dependencies on YAP1 and WWTR1 among the different subsets of OSCC where these dependencies could have implications in cancer therapies including immunotherapy.</p><disp-quote content-type="editor-comment"><p>3) From data shown in Figure 1C, most of the cell lines have a limited number of non-core fitness genes (40 or less), whereas 4 lines have a very large number of dependencies. What genomic features characterize those with large numbers of dependencies? If these are excluded, how does this affect the statistical analysis present in Figure 2? Similarly, 10 of the 21 cell lines appeared to have &lt;10 core dependencies. Do these models specifically have unique genomic features, and YAP1 or WWTR1 dependency?</p></disp-quote><p>We would like to clarify that the y-axis on Figure 1C refers to the number of dependent cell lines; while x-axis refers to the number of non-core fitness genes. For example, there are 366 genes that are essential in one out of 21 cell line (bottom most bar) – indicating fitness genes unique to a single cell line. In other words, we found 366 unique genes that is essential in only one cell line. On the other hand, only one gene (<italic>NELFCD</italic>) is a fitness gene for all the 21 cell lines (top most bar). This demonstrates the heterogeneity of the essentiality across the cell lines. To make this clearer, we have changed the y-axis label to “Number of dependent cell lines” and added more description in the figure legend.</p><disp-quote content-type="editor-comment"><p>4) In Figure 3—figure supplement 3, the authors note correlation between WWTR1 gene essentiality and expression across 273 cell models. What are the cancer types that are most dependent on WWTR1 (the point being, how specific is the observation of dependency to OSCC, versus being a general feature of squamous cancers)?</p></disp-quote><p>We observed the correlation of WWTR1 gene dependency with its gene expression in several cancer types including squamous cell lung carcinoma, breast carcinoma, glioblastoma, ovarian carcinoma and low-grade glioma in addition to OSCC. Therefore, this observation is not entirely unique to OSCC or squamous cell carcinoma. We have added this information on other cancers in Figure 3—figure supplement 3D and included the results in the fourth paragraph of the subsection “Differential dependency pattern on YAP1 and WWTR1”.</p><disp-quote content-type="editor-comment"><p>5) In Figure 6, the authors analyze the YAP1 and WWTR1 gene signatures across a large group of OSCCs in the TCGA. Earlier in the study, the authors note that WWTR1 is often amplified as part of an amplicon including PIK3CA, TP63, and SOX2. To what extent is the transcriptional signature associated with amplification of these other genes, and dependent on their transcriptional activity, rather than that of WWTR1? Using their cell line models, they should complement TCGA analysis by using shRNA or drug inhibition to deplete WWTR1 versus other key genes in the amplicon, to determine which causes a specific loss of the immune-associated transcriptional signature. This is a really important data point for interpretation of the results.</p></disp-quote><p>We thank the reviewer for the suggestion. We agree that it would be important to show that the correlation between WWTR1-dependency gene signatures with the immune signatures are indeed specific to WWTR1, and not due to other co-amplified genes such as PIK3CA, TP63 and SOX2. We did not previously include this analysis as using cell line model, most of the immune-associated transcriptional signature might not be directly measurable. Nevertheless, we have now taken two approaches to address this question as best as we could. First, we used a WWTR1-dependent model, ORL-214 to knockout WWTR1, PIK3CA, TP63 and SOX2 using two individual sgRNAs for each gene, and examined the down-regulation effect on PD-L1 gene expression. As we anticipated, only WWTR1-knock-out (KO) cells showed significant down-regulation of PD-L1 expression, but not in PIK3CA-, TP63-, nor SOX2-KO cells. These results are now reported in the subsection “ OSCC with WWTR1 dependency signature and immune biomarkers” and Figure 6—figure supplement 3A.</p><p>In addition, we also examined the correlation between the expression of PIK3CA, TP63 and SOX2 with PD-L1 expression, using an OSCC microarray dataset from Hiemer et al., 2015. Consistently, only WWTR1 gene expression showed significant correlation with PD-L1 gene expression. This correlation was not observed between PIK3CA, TP63, or SOX2 with PD-L1. These results are now reported in the aforementioned subsection and Figure 6—figure supplement 3B.</p><disp-quote content-type="editor-comment"><p>6) Besides papers cited by the authors, work relevant to the topic of this study includes Omori et al., 2020, for YAP1 as a driver, Saloura et al., 2019, showing YAP1 mutation is associated with a low CD8<sup>+</sup> T cell inflamed phenotype, Martin et al., 2018, dissecting the Hippo pathway and demonstrating the targetability of YAP1 in head and neck cancer in a detailed Nat Comm paper, and an extensive review of the pathway at the end of 2019 by Santos-de-Frutos and colleagues. This work should be cited and discussed by the authors. It is important that the Discussion addresses more about how the generated data relate to previously published reports. For example, the fact that YAP, TAZ, PI3K, TP63, and SOX2 are amplified in OSCC is curious as all these genes are part of the extended signaling network of the Hippo pathway. Please see the examples of relevant references and consider a short paragraph discussing this point. [Huang et al., 2017; Fan, Kim and Gumbiner, 2013. And Li et al., 2019] Also when the role of TA in eliciting the immune response is mentioned, it would be important to reference one of the first publications (as far as the reviewer is aware of) that indicated the role of TAZ (and YAP, perhaps) via LATS1 KO in mice. The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Moroishi T, (many authors) Guan KL. Cell. 2016 Dec 1;167(6):1525-1539.</p></disp-quote><p>We thank the reviewer for the suggestion to discuss our findings in the context of the highlighted literature. We have now elaborated on the relatedness of our findings with these literature and proposed opportunities for further studies that will address current knowledge gaps. These are now included in the Discussion of the revised manuscript. In addition to the suggested literature, we have also discussed and cited two additional papers that are relevant including Saladi et al., 2017, and Garcia-Escudero et al., 2018.</p><disp-quote content-type="editor-comment"><p>7) The authors should specifically state how many of their cell lines were highly dependent on WWTR1, how many on YAP1, and how many on both, out of the group of 21.</p></disp-quote><p>We thank the reviewer for this suggestion. Seven of the lines are highly dependent on YAP1, four are highly dependent on WWTR1, two are dependent on both YAP1 and WWTR1, while the rest did not show dependency on either YAP1 or WWTR1. This information is depicted in the bottom color-coded bar of the Figure 3A, where the dependency of the cell line on YAP1, WWTR1 and PIK3CA were determined from the extent of the genes depletion in the CRISPR screen, at a false-discovery rate of 5%, as defined using MAGECK analysis pipeline. We have now added this information in the second paragraph of the subsection “Differential dependency pattern on YAP1 and WWTR1”. We have also revised the figure legend to add clarity.</p><disp-quote content-type="editor-comment"><p>8) The cell lines used in the screen are critical for the study. Therefore, it is suggested to provide in the Materials and methods and/or in the Results more information about how these lines were derived. It would help the readers a lot without referring to a previous publication (Fadlullah et al., 2016) and various commercial data for cell repositories. Please address if these cell lines were derived spontaneously (ala HeLa cells) or were engineered by transfections of immortalizing genes (ala HEK293 cell line, for example). If the latter was the case, please comment if the process of immortalization did not affect the actual transcriptional profile of the lines.</p></disp-quote><p>As requested by the reviewer, we have now included information on how the lines were derived under the heading “Cell lines” in the Materials and methods section.</p><disp-quote content-type="editor-comment"><p>9) As stated above, one of the critical conclusions this study is that TAZ-dependent OSCC lines may represent fiduciary (direct references) of their original tumors, and therefore patients with tumors driven by TAZ could be primary candidates for checkpoint inhibitors treatment via immunotherapy. Please address directly in the Discussion the fact that most of the tumors are quite heterogeneous in terms of oncogenic drivers and either the tumor biopsy or the cell lines derived from the tumor might not represent the &quot;main&quot; oncogenic drivers of the entire tumor.</p></disp-quote><p>We agree with the reviewer and understand the importance of highlighting the assumption and limitation in our claims. We have now addressed in the Discussion section (seventh paragraph).</p></body></sub-article></article>